



Government of Pakistan  
Ministry of National Health Services, Regulations & Coordination  
Drug Regulatory Authority Of Pakistan  
Health & OTC Products Division (Non-Drugs)  
\*\*\*\*\*

Islamabad, the 18<sup>th</sup> September, 2023

“SAY NO TO CORRUPTION”

**SUBJECT: SUBMISSION OF DEFICIENT INFORMATION / DOCUMENTS**

The applications of following applicants were placed before the Enlistment Evaluation Committee (EEC) in its 115<sup>th</sup> meeting held on 23<sup>rd</sup> February, 2023 and the same have been deferred being deficient of the information / documents as specified in column (3) of the Table below which may be furnished within 20 days of uploading of this letter on official website of DRAP along with soft data as per **Annexed Format** at the end of this letter/document. Replies received after given time will not be entertained:-

<b>FOR EXPORT PURPOSE ONLY</b>		
<b>M/s Nugen (E. No. 000043), 28-KM, Ferozepur Road, Lahore</b>		
	<b>Nugen's Proplix Capsules</b>	Deferred for source of bee propolis ,monograph and testing method of finished product is required
	<b>Nugen's Propicitra Capsules</b>	Deferred for source of bee propolis ,monograph and testing method of finished product is required
	<b>Nugen's Cropwell Capsules</b>	Deferred for source of bee propolis ,monograph and testing method of finished product is required
<b>FOR EXPORT PURPOSE ONLY</b>		
<b>M/s Bio Life Enterprises Nutraceuticals (000061)</b> 14-KM, Adyala Road, Rawalpindi		
	<b>Vira-Plus Sachet</b>	Deferred for verification of testing facility of minerals are required
<b>FOR EXPORT PURPOSE ONLY</b>		
<b>M/s Salbion Health Sciences (Pvt) Ltd., (E. No. 000647)</b> 23-Km, Sheikhpura Road, Lahore-Pakistan		
	<b>SALKUF LOZENGE</b>	Deferred for confirmation of lozenges section
	<b>ALTUSSIN ORAL SPRAY</b>	Deferred for justification and clarification regarding applied formulation as heath product along facility of manufacturing of Spray
	<b>AMINO - L DROPS</b>	Deferred for method of testing of finished product along facility of testing amino acid
	<b>AMINOPANTEN BABY SYRUP</b>	Deferred for change of brand name , specifications of active ingredients and verification of testing facility of minerals are required
	<b>AQNUS CAPSULE</b>	Deferred for verification of testing facility of minerals are required
	<b>ASTRAQAVIT SYRUP</b>	Deferred for specification of active ingredients are required
	<b>COLENZIM PLUS SYRUP</b>	Deferred for specification of active ingredients are required
	<b>FERROFOL CAPSULE</b>	Deferred for change of brand name , specifications of active ingredients and verification of testing facility of minerals are required
	<b>LIVEREX CAPSULE</b>	Deferred for change of brand name and specifications of active ingredients are required
	<b>LOROBOTIK CAPSULE</b>	Deferred for method of testing of finished product is required
	<b>MEMORIN CAPSULE</b>	Deferred for change of brand name and specifications of active ingredients are required
	<b>MIQRAFEN CAPSULE</b>	Deferred for specification of active ingredients are required
	<b>NONSTRESS CAPSULE</b>	Deferred for change of brand name and specifications of active ingredients are required
	<b>PANENZIM CAPSULE</b>	Deferred for change of brand name and specifications of active ingredients are required
	<b>PROSTATIN CAPSULE</b>	Deferred for change of brand name and specifications of active ingredients along with justification of use of propolis in the formulation
	<b>PULMOLIZIN SYRUP</b>	Deferred for change of brand name and specifications of active ingredients are required
	<b>SEDAMAXS SYRUP</b>	Deferred for specification of active ingredients are required
	<b>UROLIZIN CAPSULE</b>	Deferred for clarification and rationality of applied formulation as firm uses herbs with nutraceutical ingredients

*[Signature]*

	<b>LINTUSS LOZENGE</b>	Deferred for change of brand name
	<b>LEUKORIX FORTE SACHET</b>	Deferred for change of brand name
	<b>APPETAL SYRUP</b>	Deferred for change of brand name and specifications of active ingredients are required
	<b>CALBON - D SYRUP</b>	Deferred for change of brand name , specifications of active ingredients and verification of testing facility of minerals are required
	<b>CALBON - D TABLET</b>	Deferred for change of brand name , specifications of active ingredients and verification of testing facility of minerals are required
	<b>ENZYTAL SYRUP</b>	Deferred for change of brand name and specifications of active ingredients are required
	<b>INFERTAL - M CAPSULE</b>	Deferred for change of brand name , specifications of active ingredients and verification of testing facility of minerals are required
	<b>LANCID SUSPENSION</b>	Deferred for change of brand name and specifications of active ingredients are required
	<b>MAYECRAN SACHET</b>	Deferred for change of brand name and specifications of active ingredients are required
	<b>MAYFOL SYRUP</b>	Deferred for change of brand name and specifications of active ingredients are required
	<b>MYOPREG CAPSULE</b>	Deferred for change of brand name , specifications of active ingredients and verification of testing facility of minerals are required
	<b>NEUROGIN PLUS SYRUP</b>	Deferred for change of brand name
	<b>OMIGAN 3 CAPSULE</b>	Deferred for specification of active ingredients are required
	<b>OVITAL CAPSULE</b>	Deferred for change of brand name
	<b>PHARVITAL SYRUP</b>	Deferred for change of brand name , specifications of active ingredients and verification of testing facility of minerals are required
<b>M/s Bless Laboratories (Pvt.) Ltd. (E.No. 000063)</b> Factory No.179, 1.5-KM, Kattar Band Road, Off Multan Road, Thokar Niaz Baig, Lahore		
	<b>Exit Drops</b>	Defererd for verification of testing facility of lactase enzyme is required
	<b>Exit Capsule</b>	Defererd for clarification regarding strength of lactase enzyme in formulation is required
	<b>VOL-D Drops</b>	Defererd for clarification regarding dose of Vitamin D
	<b>Volbex Syrup</b>	Deferred for monograph of Echinacea purpurea Extract along with meyhod of testing of finished product is required
	<b>Epifol Tablet</b>	Defererd for verification of testing facility of minerals are required
	<b>Arthrobex Tablet</b>	Deferred for change of brand name
<b>M/s Selco Research Laboratories, (E. No. 001189)</b> Plot No 50/3-A, Phase – 1 & 2, Industrial Estate, Hattar		
	<b>Fertifact Women Capsule</b>	Deferred for verification of testing facility of minerals are required
	<b>GLOWFACT Capsule</b>	Deferred for verification of testing facility of minerals are required
<b>M/s Davis Pharmaceuticals Lab (Consumer Division) (E. No. 000370)</b> 1st floor, 121-Industrial Triangle Area, Kahuta Road, Islamabad		
	<b>Davis's I-Care Syrup</b>	Deferred for change of brand name
	<b>Davis's Vitasole Syrup</b>	Defererd for verification of testing facility of minerals are required
	<b>Davis's Kalm Tablets</b>	Deferred for change of brand name
	<b>Davis's Oral Gel</b>	Deferred for justification of applied formulation as health product
	<b>Davis's Lean Tablets</b>	Deferred for change of brand name
	<b>Davis's Ease Tablets</b>	Deferred for change of brand name
	<b>Bone Health plus Tablets</b>	Defererd for verification of testing facility of minerals are required along with alternative brand names are required
	<b>Davis's Callithrix Tablets for Women</b>	Defererd for verification of testing facility of minerals are required
	<b>Davis's Callithrix Tablets for Man</b>	Defererd for verification of testing facility of minerals are required
	<b>Davis's Kállos Tablets</b>	Defererd for verification of testing facility of minerals are required

	<b>Davis's Healthmate-Z Tablet</b>	Deferred for verification of testing facility of minerals are required along with alternative brand names are required
	<b>Kostril Cough Syrup</b>	Deferred for change of brand name
	<b>Neurovit Tablets</b>	Deferred for change of brand name
	<b>Vitazinc Syrup</b>	Deferred for change of brand name
	<b>Davis's Cran-C Sachet</b>	Deferred for change of brand name
	<b>Davis's PS-Care Sachet</b>	Deferred for change of brand name
	<b>Davis's Slim Trim Tablets</b>	Deferred for change of brand name
	<b>Davis's Irotonic Syrup</b>	Deferred for verification of testing facility of minerals are required along with alternative brand names are required
<b>M/s. Nutrifactor Laboratories (Pvt) Ltd (E. No. 000324)</b> Plot No 4-B, Value Addition City, Khurrianwala, Faisalabad		
	<b>TRIFOLIC MEN TABLET</b>	Deferred for verification of testing facility of minerals are required
	<b>TRIFOLIC WOMEN TABLET</b>	Deferred for verification of testing facility of minerals are required
<b>M/s Herbion Pakistan Pvt Ltd., (E. No. 000001)</b> Plot No. 30, Sector 28, Korangi Industrial Area, Karachi		
	<b>Linkus Throat Spray</b>	Deferred for justification of applied product as a health product
<b>M/s Herbion Pakistan Pvt Ltd., (E. No. 000001)</b> Plot No. 30, Sector 28, Korangi Industrial Area, Karachi		
	<b>Active Z Tablet</b>	Deferred for specification of active ingredients are required
	<b>Bonjigar Syrup</b>	Deferred for specification of active ingredients are required
	<b>Cilavit D Chewable Tablet 2000 IU</b>	Deferred for specification of active ingredients are required
	<b>Relenza Capsule</b>	Deferred for specification of active ingredients are required
	<b>Bonjigar Capsule</b>	Deferred for specification of active ingredients are required
	<b>Flexigen Sachet – Sugar Free</b>	Deferred for specification of active ingredients are required
	<b>Paineez Ointment</b>	Deferred for change of brand name
<b>M/s Al-Noor Medica, (E.No. 000464)</b> Plot No. 3-C, Value Addition City, Khurrianwala, Faisalabad		
	<b>Super egg master (Powder):</b>	Deferred for change of brand name
	<b>Agreen (Granules)</b>	Deferred for clarification is required of applied formulation and approved section
	<b>Haemostin (Granules)</b>	Deferred for clarification is required of applied formulation and approved section
	<b>Injural (Granules)</b>	Deferred for clarification is required of applied formulation and approved section
	<b>Diarronil (Granules)</b>	Deferred for clarification is required of applied formulation and approved section
	<b>Dermolax (Granules)</b>	Deferred for clarification is required of applied formulation and approved section
	<b>Fibrosil (Granules)</b>	Deferred for clarification is required of applied formulation and approved section
	<b>Demasta (Granules)</b>	Deferred for clarification is required of applied formulation and approved section
	<b>Vety Super spray</b>	Deferred for confirmation of spary manufacturing facility
	<b>Al-Noor Diskettes White</b>	Deferred for justification of applied formulation as Homeopathic product as formulation contains only sugar diskettes

	<b>Al-Noor Diskettes Yellow</b>	Defererd for justification of applied formulation as Homeopathic product as formulation contains only sugar diskettes
	<b>Al-Noor Diskettes orange</b>	Defererd for justification of applied formulation as Homeopathic product as formulation contains only sugar diskettes
	<b>Al-Noor Diskettes Green</b>	Defererd for justification of applied formulation as Homeopathic product as formulation contains only sugar diskettes
	<b>Al-Noor Diskettes Red</b>	Defererd for justification of applied formulation as Homeopathic product as formulation contains only sugar diskettes
	<b>Al-Noor Globules</b>	Defererd for justification of applied formulation as Homeopathic product as formulation contains only sugar diskettes
	<b>Dephos (Granules)</b>	Deferred for clarification is required of applied formulation and approved section
	<b>Vety Fibro Gold D.S</b>	Deferred for clarification regarding Oral powder Veterniary section
	<b>Moutholin (Granules)</b>	Deferred for clarification is required of applied formulation and approved section
	<b>Cure All (Granules)</b>	Deferred for clarification is required of applied formulation and approved section
	<b>Milk Care (Granules)</b>	Deferred for clarification is required of applied formulation and approved section
	<b>Sorinil (Granules)</b>	Deferred for clarification is required of applied formulation and approved section
	<b>Dento gum (Lotion)</b>	Deferred for clarification regarding applied formulation.
	<b>Al-Noor Colic far drops</b>	Deferred for change of brand name
	<b>U-lapsi (Granules)</b>	Deferred for clarification is required of applied formulation and approved section

**M/s Dr. Masood Homoeopathic Pharmaceuticals (E. No. 000016)**

56-Quaid-e-Azam Industrial Estate, Kot Lakhpat, Lahore

	<b>Dr.Masood's Alloxan Dilutions</b>	Deferred for homeopathic monograph of alloxan and justification of use as homeopathic product
	<b>Dr.Masood's Bismuth Carbonicum Dilutions</b>	Deferred for clarification regarding applied dilution as trituration of bismuth carbonicum with lactose is made first till its 6x potency is insoluble in water and alcohol as per procedure in EHPI, while the firm applied potency in liquid form.
	<b>Dr.Masood's Cortisone Dilutions</b>	Deferred for Homeopathic monograph of <b>Cortisone</b> and evidene of testing that source is free from TSE,BSE and salmonella
	<b>Dr.Masood's Cydonia Vulgaris Dilutions</b>	Defererd for sigend and stamped form 3 is required
	<b>Dr.Masood's Folliculinum Dilutions</b>	Deferred for Homeopathic monograph of Oestrone and evidene of testing that source is free from TSE,BSE and salmonella
	<b>Dr.Masood's Magnet Polus Australis Dilutions</b>	Deferred for Homeopathic monograph of Magnet Polus Australis along competitors availbilty of applied formulation in local or international market
	<b>Dr.Masood's Orchitinum Dilutions</b>	Deferred for Homeopathic monograph of Orchitinum and evidene of testing that source is free from TSE,BSE and salmonella
	<b>Dr.Masood's Oxygenum Dilutions</b>	Deferred for facility of manufacturing of oxygenium dilution as caution is required for avoiding smoking,lighting any fire,electric spark because of explosion hazards
	<b>Dr.Masood's Placenta Humana Dilutions</b>	Deferred for Homeopathic monograph of Human Placenta and evidene of testing that source is free from TSE,BSE and salmonella
	<b>Dr.Masood's Rosmarinus Officinalis Dilutions</b>	Deferred for Homeopathic monograph of Garden rosemary is required
	<b>Dr.Masood's SOL Dilutions</b>	Deferred for Homeopathic monograph of sol(sunlight) along competitors availbilty of applied formulation in local or international market

	<b>Dr.Masood's Sulphanilamide Dilutions</b>	Deferred for homeopathic monograph of P-amino benzenesulphonamide and justification of use as homeopathic product
	<b>Dr.Masood's Testosterone Dilutions</b>	Deferred for Homeopathic monograph of Testosterone and evidence of testing that source is free from TSE,BSE and salmonella
	<b>Dr.Masood's Trinitrotoluene (T.N.T) Dilutions</b>	Deferred for confirmation of facility of handling storage and facility of preparation of said dilution as material is highly explosive
	<b>Dr.Masood's Typhoidinum Dilutions</b>	Deferred for Homeopathic monograph of Testosterone and evidence of testing that source is free from TSE,BSE and salmonella
	<b>Dr.Masood's Her Rose Eye Drops</b>	Deferred for competitors availability of applied formulation along with confirmation of sterile Eye Drop section with sterile testing facility

**CureNix Healthcare Pharma. E.No. 01355**  
**lot#. E99/B . S.I.T.E, Phase II, Superhighway. Karachi**

	<b>VITAMNIX Syrup</b>	Deferred for verification of testing facilities for minerals are required
	<b>FERTIXEED M Sachet</b>	Deferred for verification of testing facilities for minerals are required
	<b>FERTIXEED W Sachet</b>	Deferred for verification of testing facilities for minerals are required
	<b>KOSEIN-D Sachet</b>	Deferred for verification of testing facilities for minerals are required
	<b>VITO-MAX SOFTGEL</b>	Deferred for verification of testing facilities for minerals are required
	<b>HSN-CURE Tablet</b>	Deferred for verification of testing facilities for minerals are required

**MS Laboratories (Homoeo Division), (E. No. 000551)**

St.No.28, Nisar Colony Industrial Area, Samanabad, Faisalabad (Homeopathic)

	<b>MS Bella Nat Dry Powder</b>	Deferred for following reasons: ➤ Clarification regarding applied formulation and approved section ➤ The nature of Active ingredients used in formulation either triturates or in liquid potency/Dilution along with official homeopathic method of preparation
	<b>MS Dyro Sed Dry Powder</b>	Deferred for following reasons: ➤ Clarification regarding applied formulation and approved section ➤ The nature of Active ingredients used in formulation either triturates or in liquid potency/Dilution along with official homeopathic method of preparation
	<b>MS Tino Gel Dry Powder</b>	Deferred for following reasons: ➤ Clarification regarding applied formulation and approved section ➤ The nature of Active ingredients used in formulation either triturates or in liquid potency/Dilution along with official homeopathic method of preparation
	<b>MS Bryo Mag Dry Powder</b>	Deferred for following reasons: ➤ Clarification regarding applied formulation and approved section ➤ The nature of Active ingredients used in formulation either triturates or in liquid potency/Dilution along with official homeopathic method of preparation
	<b>MS Mega Mass 5000 Powder</b>	Deferred for following reasons: ➤ Clarification regarding applied formulation and approved section ➤ The nature of Active ingredients used in formulation either triturates or in liquid potency/Dilution along with official homeopathic method of preparation
	<b>MS Furbaleen Dry Powder</b>	Deferred for following reasons: ➤ Clarification regarding applied formulation and approved section ➤ The nature of Active ingredients used in formulation either triturates or in liquid potency/Dilution along with official homeopathic method of preparation
	<b>Aizal Magun Dry Powder</b>	Deferred for following reasons: ➤ Clarification regarding applied formulation and approved

		section ➤ The nature of Active ingredients used in ormlulation either trituartes or in liquid potency/Dilution along with offical homeopathic method of preparartion
	<b>MS Khandani Bawaseeri Dry Powder</b>	Defererd for following reasons: ➤ Calrification regarding applied formulation and approved section ➤ The nature of Active ingredients used in ormlulation either trituartes or in liquid potency/Dilution along with offical homeopathic method of preparartion
	<b>MS Natural Slimming Tea</b>	Defererd for following reasons: ➤ Calrification regarding applied formulation and approved section ➤ The nature of Active ingredients used in ormlulation either trituartes or in liquid potency/Dilution along with offical homeopathic method of preparartion
	<b>MS Body Made Capsules</b>	Defererd for change of brand name
	<b>MS Rheuma Guard Capsule</b>	Defererd for change of brand name
	<b>MS Ultra Made Capsule</b>	Defererd for change of brand name
	<b>MS Cheston Capsule</b>	Defererd for change of brand name
	<b>MS Golden Sehatmand Capsule</b>	Defererd for change of brand name
	<b>MS Arnica Hair Oil</b>	Defererd for change of brand name
	<b>Mk Mercline</b>	Deferred for clarification regarding applied formulation as oral or topical
	<b>MS Super Hard Tilla</b>	Defererd for change of brand name
	<b>Aizal Dental Lotion</b>	Rjected since the firm applied lotion formulation in Oil Section
	<b>MS Acnex Cream</b>	Defererd for change of brand name
	<b>MS Breast Up Cream</b>	Defererd for change of brand name
	<b>MS StomiGel Oral Gel</b>	Defererd for clarification /justification regarding applied formulation as topical or oral use
	<b>MS Sulphur Cream</b>	Deffererd for Homeopathic pharmacopoaia of Sulphur is required
	<b>MS V-Care Cream</b>	Defererd for change of brand name
	<b>MS Vigor Max Cream</b>	Defererd for change of brand name
	<b>Khandani Bawaseeri Ointment</b>	Defererd for change of brand name
	<b>MS Diabex Tablet</b>	Defererd for change of brand name
	<b>MS Inflamic Tablets</b>	Defererd for change of brand name
	<b>MS Bio-21 Syrup</b>	Defererd for clarification regarding potency/dilution of Atropa belladonna in the formulation
	<b>MS Tonsilex Syrup</b>	Defererd for change of brand name
<b>M/s EN Laboratories (E. No. 001099)</b> Chak No. 109 RB, Tehsil Jaranwala, District Faisalabad		
1.	<b>R.B Alfalfa Syrup</b>	Deferred for following reasons: ➤ Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). ➤ Company /Firm establishment documents are not provided
2.	<b>R.B Jigri Syrup</b>	Deferred for following reasons: ➤ Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).



		<ul style="list-style-type: none"> <li>➤ Company /Firm establishment documents are not provided</li> <li>➤ Alternative brand names are required</li> </ul>
3.	<b>R.B Mensturation Syrup</b>	Deferred for following reasons: <ul style="list-style-type: none"> <li>➤ Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> <li>➤ Company /Firm establishment documents are not provided</li> <li>➤ Alternative brand names are required</li> </ul>
4.	<b>R.B Nerve Plus Syrup</b>	Deferred for following reasons: <ul style="list-style-type: none"> <li>➤ Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> <li>➤ Company /Firm establishment documents are not provided</li> <li>➤ Alternative brand names are required</li> </ul>
5.	<b>Rb Feverreb Syrup</b>	Deferred for following reasons: <ul style="list-style-type: none"> <li>➤ Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> <li>➤ Company /Firm establishment documents are not provided</li> <li>➤ Alternative brand names are required</li> </ul>
6.	<b>Anmol Grace Gold Syrup</b>	Deferred for following reasons: <ul style="list-style-type: none"> <li>➤ Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> <li>➤ Company /Firm establishment documents are not provided</li> <li>➤ Alternative brand names are required</li> </ul>
	<b>Anmol Jam E Qalb Syrup</b>	Deferred for following reasons: <ul style="list-style-type: none"> <li>➤ Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> <li>➤ Company /Firm establishment documents are not provided</li> <li>➤ Alternative brand names are required</li> </ul>
<b>M/s Nutrevo Health Care (E. No. 001124)</b> Khewat No. 438, Khatauni No.452, Khasra No. 819, 14 – Km Adyala Road, Rawalpindi		
7.	<b>Salwa gel</b>	Deffered for clarification regarding unit dose preapartion of cream along with alternative brand anmes are required
8.	<b>Heel up cream</b>	Defererd for Monograph of Quath processed oil and alternative brand names are required
9.	<b>Paincure gel</b>	Deferred for change of brand anme
10.	<b>Caplain gel</b>	Deferred for justification of use of bromelain in topical formulation.
11.	<b>Piloff ointment</b>	Deferred for change of brand anme
<b>M/s Citi Pharma Pvt Ltd., (E. No. 001333)</b> located at 3-Km Head Balloki Road, Phool Nagar, Distt: Kasur		
12.	<b>Redcal Sachet</b>	Deferred for change of brand anme
13.	<b>Flucit Sachet</b>	Deferred for change of brand anme
14.	<b>Immuno Sachet</b>	Deferred for change of brand anme
15.	<b>Fer Fit Sachet</b>	Deferred for change of brand anme
<b>M/s Mian Unani Pharma, (E. No. 001301)</b> Khewat No.619, Khatauni No.986 – 994, Mouza Chak No. 73-JB, Japal – Jhang Road, Faisalabad		
16.	<b>MUP HEMOPLEX SYRUP</b>	Deferred for provision of undertaking regarding content and brand name is required
17.	<b>MUP ZAMBO VIT SYRUP</b>	Deferred for monograph of Sisymbrium irio and Lime water along with competitors availability of applied formulation
	<b>MUP FIGSUR CREAM</b>	Deferred for justification of applied formulation as alternative medicines
<b>M/s Vet Pride Pharmaceutical, (E. No. 001316)</b> Plot No. 77, Street No. 02, RCCI Industrial Estate, Rawat		
18.	<b>Vet Pride's Dermax Lotion</b>	Deferred for change of brand name
<b>M/s Qazi Unani Pharma, (E. No. 001209)</b>		

73-JB, Japal – Jhang Road, Faisalabad		
	Qazi's Q Vicks Balm	Defererd for change of brand name
	Qazi's <b>Vaselline +Chanbaili</b>	Defererd for justification of applied formulation as alternative medicines
	Qazi's Burn Care Cream	Deferred for change of brand name
	Qazi's Fair & Fresh Cream	Deferred for change of brand name
	Qazi's Q Kracker Cream	Defererd for justification of applied formulation as alternative medicines
	Qazi's Acne Care Cream	Deferred for change of brand name
	Qazi's Happy Life Cream	Deferred for change of brand name
	Qazi's Sandal White Cream	Deferred for change of brand name
	Qazi's KushtaQali	Deferred for Justification of applied formulation as alternative medicines(Herbal/Unani) along with monograph of active ingredients and safety profile of product
	Qazi's KushtaMarjan	Deferred for Justification of applied formulation as alternative medicines(Herbal/Unani) along with monograph of active ingredients and safety profile of product
	Qazi's KushtaFaulad	Deferred for Justification of applied formulation as alternative medicines(Herbal/Unani) along with monograph of active ingredients and safety profile of product
	Qazi's KushtaSadaf	Deferred for Justification of applied formulation as alternative medicines(Herbal/Unani) along with monograph of active ingredients and safety profile of product
	Qazi's KushtaQasharBiazaMurgh	Deferred for Justification of applied formulation as alternative medicines(Herbal/Unani) along with monograph of active ingredients and safety profile of product
	Qazi's KushtaAqeeq	Deferred for Justification of applied formulation as alternative medicines(Herbal/Unani) along with monograph of active ingredients and safety profile of product
	Qazi's KushtaNuqra	Deferred for Justification of applied formulation as alternative medicines(Herbal/Unani) along with monograph of active ingredients and safety profile of product
	Qazi's KushtaJawaharMohraKhas	Deferred for Justification of applied formulation as alternative medicines(Herbal/Unani) along with monograph of active ingredients and safety profile of product
	Qazi's KushtaAbraksufaid	Deferred for Justification of applied formulation as alternative medicines(Herbal/Unani) along with monograph of active ingredients and safety profile of product
	Qazi's KushtaAbrakSiyah	Deferred for Justification of applied formulation as alternative medicines(Herbal/Unani) along with monograph of active ingredients and safety profile of product
	Qazi's KushtaZamurd	Deferred for Justification of applied formulation as alternative medicines(Herbal/Unani) along with monograph of active ingredients and safety profile of product
	Qazi's KushtaQaran –al Eil	Deferred for Justification of applied formulation as alternative medicines(Herbal/Unani) along with monograph of active ingredients and safety profile of product
	Qazi's KushtaMurwareed	Deferred for Justification of applied formulation as alternative medicines(Herbal/Unani) along with monograph of active ingredients and safety profile of product
	Qazi's KushtaYaqoot	Deferred for Justification of applied formulation as alternative medicines(Herbal/Unani) along with monograph of active ingredients and safety profile of product



	Qazi's KushtaShangrif	Deferred for Justification of applied formulation as alternative medicines(Herbal/Unani) along with monograph of active ingredients and safety profile of product
<b>M/s ISIS Pharmaceuticals and Chemical Works (Natural Division), (E. No. 000783)</b> 25/4, Sector 12-C, North Karachi Industrial Area,		
	<b>LIV-CURE Capsule</b>	Deferred for change of brand name
	<b>Gyni-Care Capsule</b>	Deferred for change of brand name
<b>M/s. Trends Pharmaceuticals (Nutraceuticals &amp; Cam Division), Plot 546/ 547, Sundar Industrial Estate, Lahore</b>		
	<b>Achnis Capsule.</b>	Defererd for method of testing of finished product is required
	<b>Biotren Capsule.</b>	Deferred for verification of testing facility of minerals are required
	<b>Coptren Capsule.</b>	Deferred for verification of testing facility of minerals are required
	<b>Jontren Capsule.</b>	Deferred for method of testing of finished product is required
	<b>Trenglo Capsule.</b>	Deferred for method of testing of finished product is required along with competitors avaiability in local or international market
	<b>Montmo Capsule.</b>	Deferred for method of testing of finished product is required along with competitors avaiability in local or international market
	<b>Terbo Capsule.</b>	Deferred for method of testing of finished product is required
<b>Vet Tec</b>		
	<b>VET TEC-CPHOS ORAL LIQUID</b>	Defererd for verification of testing facility of minerals are required
	<b>VET TEC-COPPER POWDER</b>	Deferred for provision of strength of active ingredients in mg/gm along with content undertaking of dossier is required
	<b>VET TEC-SPARK POWDER</b>	Defererd for verification of testing facility of minerals are required
	<b>VET TEC-DIGESTA POWDER</b>	Defererd for verification of testing facility of minerals are required
	<b>VET TEC-GROW-L POWDER</b>	Deferred for provision of strength of active ingredients in mg/gm along with clarification regarding type of crude protein,fat and fiber used in the formulation Also method of testing of finished product is required
<b>M/s Vital Mark Laboratories (Pvt) Ltd., (Veterinary Nutritional Division) (E. No. 000459)</b> <b>Chak No.108, G.B. Industrial Estate, Jaranwala, Faisalabad</b>		
19.	<b>VITA CYM T MINERAL</b>	Deferred for specification and salt of minerals along with quantities of active ingredients in mg or ml.
20.	<b>VITAL CYM MINERAL</b>	Deferred for specification and salt of minerals along with quantities of active ingredients in mg or ml.
21.	<b>VITAL AD3E MINERAL</b>	Deferred for specification and salt of minerals along with quantities of active ingredients in mg or ml. Brand name needs to be changed
22.	<b>TRUST ADEH MINERAL</b>	Deferred for specification and salt of minerals along with quantities of active ingredients in mg or ml. Brand name needs to be changed
23.	<b>VITA Trust Powder</b>	Deferred for specification and salt of minerals along with quantities of active ingredients in mg or ml. Brand name needs to be changed
24.	<b>VITAL UDDER GOLD</b>	Deferred for specification of active ingredinetes are required Brand name needs to be changed
25.	<b>VITA MAX MINERAL</b>	Deferred for specification and salt of minerals along with quantities of active ingredients in mg or ml. Brand name needs to be changed Justification of toxin binder in the formulation is required
26.	<b>VITA AVITRIL T</b>	Deferred for specification and salt of minerals along with quantities of active ingredients in mg or ml. Brand name needs to be changed
27.	<b>VITAL MILK GROW</b>	Deferred for specification and salt of minerals along with quantities of active ingredients in mg or ml. Brand name needs to be changed clarify Type of Byfass fat used in the formulation
28.	<b>Vital Feedolene</b>	Deferred for herbal monographs of Alfalfa

		Galegaoffi Lycopodium Jodium Abratinium
29.	<b>Vita Respobromex</b>	Defererd for monograph of Vasicine and alternative brand name are required
30.	<b>Vital Bromex</b>	Defererd for monograph of Vasicine and alternative brand name are required
31.	<b>Vital Broncomenth</b>	Deferred for specification and salt of minerals along with quantities of active ingredients in mg or ml. Brand name needs to be changed
32.	<b>Vita Mastivexyem</b>	Deferred for specification along with method of testing of finished product is required
33.	<b>VITA ENERGY T</b>	Deferred for specification along with method of testing of finished product is required

<b>M/s ACE Biotics.,</b> <b>28-KM Multan Road, Lahore (E. No. 00852)</b>		
1.	Primal Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
2.	Exlax Sachet	Deferred for following reasons: Signed and stamped form 3 ,Evidence of R and I receiving and fee submission is required
3.	Citroace Sachet	Deferred for undertaking regarding content and brand name is required
<b>M/s. Adcok Pharmaceuticals (Pvt) Ltd</b> <b>Plot No 3-3-km, Defence off Raiwind Road ,Near Lahore Univerisity Lahore (E. No. 00326)</b>		
4.	Avo.Cran Sachet	Deferred till verification of CAPA by the panel and decision by the EEC. EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
5.	Polyton 120ml Syrup	Deferred till verification of CAPA by the panel and decision by the EEC. EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
6.	Bonage 120ml Liquid	Deferred till verification of CAPA by the panel and decision by the EEC.

		EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
7.	Actozin Syrup	Deferred till verification of CAPA by the panel and decision by the EEC. EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
8.	Lekzi Drops	Deferred till verification of CAPA by the panel and decision by the EEC. EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
9.	Gut. Well Syrup	Deferred till verification of CAPA by the panel and decision by the EEC. EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
10.	A.Grow Drops	Deferred till verification of CAPA by the panel and decision by the EEC. EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
11.	D.Grow Drops	Deferred till verification of CAPA by the panel and decision by the EEC. EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division

		of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
12.	Mytacid Syrup	Deferred till verification of CAPA by the panel and decision by the EEC. EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
13.	Myo.Nostal Tablet	Deferred till verification of CAPA by the panel and decision by the EEC. EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
14.	Myo.Nostal Sachet	Deferred till verification of CAPA by the panel and decision by the EEC. EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
15.	Ultravit.Z Syrup	Deferred till verification of CAPA by the panel and decision by the EEC. EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
16.	Linzative Syrup	Deferred till verification of CAPA by the panel and decision by the EEC. EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.

17.	Ultravit.Z Tablet	<p>Deferred till verification of CAPA by the panel and decision by the EEC.</p> <p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
18.	Cafnest Syrup	<p>Deferred till verification of CAPA by the panel and decision by the EEC.</p> <p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
19.	Qingkou Syrup	<p>Deferred till verification of CAPA by the panel and decision by the EEC.</p> <p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
20.	Qingkou Tablet	<p>Deferred till verification of CAPA by the panel and decision by the EEC.</p> <p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
21.	Appezar Syrup	<p>Deferred till verification of CAPA by the panel and decision by the EEC.</p> <p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>

22.	Tribooster Tablet	<p>Deferred till verification of CAPA by the panel and decision by the EEC.</p> <p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
23.	Cavofer.F Tablet	<p>Deferred till verification of CAPA by the panel and decision by the EEC.</p> <p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
24.	Caveo.H Syrup	<p>Deferred till verification of CAPA by the panel and decision by the EEC.</p> <p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
25.	Cavofer.F Syrup	<p>Deferred till verification of CAPA by the panel and decision by the EEC.</p> <p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
26.	Caveocal Tablet	<p>Deferred till verification of CAPA by the panel and decision by the EEC.</p> <p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>



27.	Caveo.8 Syrup	<p>Deferred till verification of CAPA by the panel and decision by the EEC.</p> <p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
28.	Coveo.Cid Syrup	<p>Deferred till verification of CAPA by the panel and decision by the EEC.</p> <p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
29.	Afcal Tablet	<p>Deferred till verification of CAPA by the panel and decision by the EEC.</p> <p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
30.	Afri Tablet	<p>Deferred till verification of CAPA by the panel and decision by the EEC.</p> <p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
31.	Fair Way Plus Tablet	<p>Deferred till verification of CAPA by the panel and decision by the EEC.</p> <p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>

32.	Zee.Q Tablet	<p>Deferred till verification of CAPA by the panel and decision by the EEC.</p> <p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
33.	Re.Mine Tablet	<p>Deferred till verification of CAPA by the panel and decision by the EEC.</p> <p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
34.	GMS Powder	<p>Deferred till verification of CAPA by the panel and decision by the EEC.</p> <p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
35.	GMS.Anta Syrup	<p>Deferred till verification of CAPA by the panel and decision by the EEC.</p> <p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
36.	GMS.Senna Syrup	<p>Deferred till verification of CAPA by the panel and decision by the EEC.</p> <p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>

37.	GMS.D3	<p>Deferred till verification of CAPA by the panel and decision by the EEC.</p> <p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
38.	Trilex Tablet	<p>Deferred till verification of CAPA by the panel and decision by the EEC.</p> <p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
39.	Myolex Tablet	<p>Deferred till verification of CAPA by the panel and decision by the EEC.</p> <p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
40.	Appilex Syrup	<p>Deferred till verification of CAPA by the panel and decision by the EEC.</p> <p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
41.	Zif.Vita Tablet	<p>Deferred till verification of CAPA by the panel and decision by the EEC.</p> <p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>

42.	Z.Sil Tablet	<p>Deferred till verification of CAPA by the panel and decision by the EEC.</p> <p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
43.	Albafolic Tablet	<p>Deferred till verification of CAPA by the panel and decision by the EEC.</p> <p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
44.	C.Bext Sachet	<p>Deferred till verification of CAPA by the panel and decision by the EEC.</p> <p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
45.	Biloba Syrup	<p>Deferred till verification of CAPA by the panel and decision by the EEC.</p> <p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
46.	Calvay Tablet	<p>Deferred till verification of CAPA by the panel and decision by the EEC.</p> <p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>

47.	Ikarin Tablet	<p>Deferred till verification of CAPA by the panel and decision by the EEC.</p> <p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
48.	Provic Drops	<p>Deferred till verification of CAPA by the panel and decision by the EEC.</p> <p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
49.	Cuftic Syrup	<p>Deferred till verification of CAPA by the panel and decision by the EEC.</p> <p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
50.	Duyen Drops	<p>Deferred till verification of CAPA by the panel and decision by the EEC.</p> <p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
51.	Duyen Syrup	<p>Deferred till verification of CAPA by the panel and decision by the EEC.</p> <p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>

52.	Lensure Supplement	<p>Deferred till verification of CAPA by the panel and decision by the EEC.</p> <p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
53.	Cranstar Syrup	<p>Deferred till verification of CAPA by the panel and decision by the EEC.</p> <p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
54.	Cranstar Sachet	<p>Deferred till verification of CAPA by the panel and decision by the EEC.</p> <p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
55.	Lacion Syrup	<p>Deferred till verification of CAPA by the panel and decision by the EEC.</p> <p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
56.	Bincuf Syrup	<p>Deferred till verification of CAPA by the panel and decision by the EEC.</p> <p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>



57.	Best GB Drops	<p>Deferred till verification of CAPA by the panel and decision by the EEC.</p> <p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
58.	Lofric Syrup	<p>Deferred till verification of CAPA by the panel and decision by the EEC.</p> <p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
59.	Lofric Tablet	<p>Deferred till verification of CAPA by the panel and decision by the EEC.</p> <p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
60.	Peptol Syrup	<p>Deferred till verification of CAPA by the panel and decision by the EEC.</p> <p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
61.	Teralix Syrup	<p>Deferred till verification of CAPA by the panel and decision by the EEC.</p> <p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p>
<b>M/s Al-Sehat Laboratories,</b>		

Plot No. K-229, Phase-II, Super Highway Industrial Area, Karachi (E. No. 01088)		
62.	Ginkolin Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise
63.	Calbon One Syrup	Deferred for change of brand name
64.	Macvin Syrup	Deferred for evidence of fee submission is required
65.	Ginrex G Syrup	Deferred for following reasons: Signed and stamped form 3 ,Evidence of R and I receiving and fee submission is required
66.	Nutridol Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
67.	Mac Vita Syrup	Deferred for following reasons: Signed and stamped form 3 ,Evidence of R and I receiving and fee submission is required
68.	Gastorid Syrup	Deferred for undertaking regarding content and brand name is required
M/s Ali's Pakistan, Plot No. 10 Street No1, Al-Ghani Estate, Dullu Khurd Industrial Area, Ferozepur Road, Lahore (E. No. 00778)		
69.	Foli.Z Tablet	Deferred for change of brand name
M/s. Alpha Nutraceutical Research Laboratories, 21/S, Quaid-e-Azam, Industrial Estate, Kot Lakhpat, Lahore (E. No. 00230)		
70.	Hepa.Med Syrup	Deferred for change of brand name
71.	Bevomin.M Syrup	Deferred for signed and stamped form 3 is required
72.	Gastin Syrup	Deferred for submission of signed and stamped form 3 and content undertaking of dossiers is required
M/s Angel Human Health Nutraceutical, Salam Square # 7, Madina Industrial City, 12Km, Samundri Road, Faisalabad (E. No. 00460)		
73.	Aminocare Oral Sachet	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
74.	Belzyme Syrup	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
75.	Hepasil Syrup	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
76.	Vitall Tablet	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required

77.	Cloud Tablet	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
78.	Bio.progest Tablet	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
79.	IRES.V Supplement	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
80.	Prejux Syrup	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
81.	K.Line Tablet	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
82.	Ezicran Sachet	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
83.	Progestisafe Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
84.	Qufosafe Tablet	Deferred for Undertaking regarding content and brand name is required
85.	Crampi Syrup	Deferred for Evidence of fee submission is required
86.	QOL Syrup	Deferred for signed and stamped form 3 is required
87.	Crampi Drops	Deferred for signed and stamped form 3 is required
88.	Nutribon Syrup	Deferred for stability studies undertaking along with alternative brand name are required
89.	Nutrimal Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
90.	Orisan Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
91.	Orisan Drops	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent

		preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
92.	Prujex Syrup	Deferred for R and I receiving of dossier along evidence of fee submission is required
<b>M/s. ARK Laboratories</b> <b>Plot 36, Phase 1 &amp; 2, Industrial Area, Hattar, KPK (E. No. 00309)</b>		
93.	Irocare.F Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
<b>M/s. Arshzik (Veterinary),</b> <b>23 Km Near Al-Ghani CNG, G.T. Road, Rawat, Rawalpindi (E. No. 00302)</b>		
94.	Gumbozix Oral Powder	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving, Undertaking regarding content and brand name is required
95.	Vitarsh Poultry Powder	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving, Undertaking regarding content and brand name is required
96.	West Gold 1000ml Oral Liquid	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving, Undertaking regarding content and brand name is required
97.	Selvet E Oral Liquid	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving, Undertaking regarding content and brand name is required
98.	Coxifar Oral Liquid	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving, Undertaking regarding content and brand name is required
99.	Dekvet Oral Liquid	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving, Undertaking regarding content and brand name is required
100.	Mintovet Oral Liquid	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving, Undertaking regarding content and brand name is required
101.	Respofin Oral Liquid	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving, Undertaking regarding content and brand name is required
102.	Hepvet Oral Liquid	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving, Undertaking regarding content and brand name is required
103.	Bio Toxi Tech Oral Liquid	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving, Undertaking regarding content and brand name is required
104.	Uri Tech Powder	Deferred for following reasons:

		Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
105.	Hydrovet Oral Liquid	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
106.	Amin & Vit Oral Liquid	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
107.	Livowest Oral Liquid	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
108.	Bromowest Oral Liquid	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
<b>M/s Arzik Laboratories, 146-C, Punjab Small Industrial Estate, Sargodha Road, Faisalabad-Pakistan (E. No. 00501)</b>		
109.	Miret.T Tablet	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
110.	<b>Femula Syrup</b>	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , required
111.	<b>Ecion Drops</b>	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
112.	<b>HD-3 Tablet</b>	Deferred for following reasons: Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
113.	<b>Nuramin Syrup</b>	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
114.	<b>Brain-T Drops</b>	Deferred for change of brand name
115.	<b>Max-E Tablet</b>	Deferred for verification of testing facility of minerals are required
116.	LC FER Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
117.	Gripp Syrup	Deferred for Evidence of fee submission and R and I receiving is required
118.	Nervella Tablet	Deferred for Evidence of fee submission and R and I receiving is required
119.	Focus D Drops	Deferred for Evidence of fee submission and R and I receiving is required
120.	Neo Fit Syrup	Deferred for Evidence of fee submission and R and I receiving is required
121.	Neo Fit Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in



		the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
122.	Macid Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
<b>M/s. Asfar Health Care, 34-A, Punjab Small Industrial Area, Kasur (E. No. 00811)</b>		
123.	Pregline Tablet	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
124.	Care Q10 Tablet	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
125.	Myocyst Tablet	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
126.	Stevia Active Drops	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
127.	Melafer Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
128.	Senolex Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
129.	Grow.X Syrup	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
130.	Lutefer Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant



		product application to check its status whether it has been disposed of or otherwise.
131.	Stefcal Tablet	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
<b>M/s Atco Healthcare (Pvt) Ltd., [Nutraceutical] B-3/A, S.I.T.E., Karachi-Pakistan (E. No. 00705)</b>		
132.	My.D 5,000IU Chewable Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
133.	Caullacid Capsule	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
134.	My.D 10,000IU Chewable Tablet	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
135.	CB.250 Syrup	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
136.	CB.250 Plus Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
137.	Omegafull Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
<b>M/s Aurum Health Care, .5-KM, Thokar Niaz Baig Kattar Band Road, Lahore-Pakistan [Nutraceutical] (E. No. 00622)</b>		
138.	Aptain Syrup	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
139.	Furanate Syrup	Deferred for following reasons: Evidence of fee submission along with R&I receiving ,
140.	Furacal Suspension	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving ,
141.	Furadek Drops	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
142.	Furavit.Z Tablet	Deferred for following reasons:

		Undertaking regarding content and brand name is required
143.	Q Folic Plus Tablet	Deferred for following reasons: Properly Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required Alternative brand names are also required
144.	Furanate Tablet	Deferred for following reasons: Properly filled signed and stamped form 3 is required
145.	Furavit Z Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
146.	Furacal Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
<b>M/s Awacs Laboratories, 6KM Pindi Road Chakwal, District Chakwal (E. No. 00393)</b>		
147.	Benerv.B Tablet	Deferred for following reasons: Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required Alternative brand name are require d
148.	Hicogent.X Capsule	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
149.	Hyper.Ease Capsule	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
150.	Mannomax Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
151.	Dexfol Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
152.	Myro Sachet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division

		of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
153.	Asemia Capsule	Deferred for following reasons: Undertaking regarding content and brand name is required
154.	Immune Plus Sachet	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving is not provided Alternative brand name are required
<b>M/s Bio Life Enterprises Nutraceuticals</b> <b>14-KM, Adyala Road, Rawalpindi (E. No. 00061)</b>		
155.	Pro.Gut Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
156.	Ovasit Sachet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
157.	Exafer.F Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
158.	Merofol Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
159.	Calrex Tablet	Deferred for change of brand name and evidence of R and I receiving is required
160.	Calrex Drops	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
161.	Apilon Syrup	Deferred for provision of evidence of fee submission
162.	Peltron Syrup	Deferred for R and I receiving is not provided Alternative brand name are also required
163.	Peltron Tablet	Deferred for R and I receiving is not provided Alternative brand name are also required

164.	Fericid+ Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
<b>M/s. BIONS (Bio Natural Solution)</b> <b>Plot No. 15, 1 Km Bhangreel Road, T-Chowk, Rawat, Islamabad (E. No. 00261)</b>		
165.	Arch Liv liquid	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
166.	Keyphos liquid	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving, Undertaking regarding content and brand name is required
167.	HI.Ease liquid	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving, Undertaking regarding content and brand name is required
168.	Feed Line Cleaner liquid	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
169.	Se Vac liquid	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
170.	Solo Se liquid	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
171.	Bions Minerals Premix liquid	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant

		product application to check its status whether it has been disposed of or otherwise.
172.	Bions Vitamins Premix liquid	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
<b>M/s Bio Serve Pharma, Plot No. 165, 1st Floor, S.I.T.E. Super Highway, Phase-II, Karachi (Nutraceuticals) (E. No. 00466)</b>		
173.	<b>Cof King Syrup</b>	Defererd for change of brand name
174.	<b>Bio C Tablet</b>	Defererd for verification of testing facility of minerlas are required
<b>M/s Bio-Med Pharma, Plot No.DP-28/1, Sector 12 C, North Karachi Industrial Area, Karachi-Pakistan [Nutraceutical] (E. No. 00623)</b>		
175.	PC.Cure Sachet	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
176.	MH.Collagen Sachet	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
177.	Amino.Whey Sachet	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
178.	Erectifert Sachet	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
179.	Usicure Sachet	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
180.	Bio.Cal Sachet	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
181.	Irrotone Sachet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
182.	Witsol Sachet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
183.	Witsol Plus Sachet	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
184.	Kid.Med Sachet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division



		of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
185.	Silimed Sachet	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
186.	Silimed Plus Sachet	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
187.	Win Plus Sachet	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
188.	Bio Sure Sachet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
189.	Biocid Sachet	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
<b>M/s. BIONS (Bio Natural Solution) Plot No. 15, 1 Km Bhangreel Road, T-Chowk, Rawat, Islamabad (E. No. 00261)</b>		
190.	MD Kill Oral Liquid	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
191.	Metanex Oral Liquid	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
192.	Vitafast Oral Liquid	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
193.	Morjex Oral Liquid	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
194.	Dr. Calco Oral Liquid	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
195.	Dr. Fibro Oral Liquid	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
196.	Dr. Spray Oral Liquid	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
197.	Fibroplus Oral Liquid	Deferred for following reasons:



		Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
198.	Wondup Oral Liquid	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
199.	Orgacid Oral Liquid	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
200.	Silver.Liquid Plus Oral Liquid	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
201.	Hepo Sel Oral Liquid	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
202.	Super Heat Powder	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
203.	Bursa.Med Powder	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
204.	Se Cool Plus Powder	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
205.	Arch Mint Oral Liquid	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
206.	Duxo Vit E Oral Liquid	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
207.	SE.SEL.E Oral Liquid	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
208.	SE.Immune Oral Liquid	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
209.	Immuno DX Oral Liquid	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
210.	Marko Liver Oral Liquid	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
211.	Tune Live Oral Liquid	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
212.	Cippo GP Oral Liquid	Deferred for following reasons:

		Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
213.	E Plus C Oral Liquid	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
214.	Mentovit Plus Oral Liquid	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
215.	Calphos.E Liquid	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
216.	Vit.Extra Liquid	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
217.	Milky Way Liquid	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
218.	Respithol Liquid	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
219.	Duxo Acid Liquid	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
220.	Spirit.50 Liquid	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
221.	Lysomix Liquid	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
222.	Fam.Vita Liquid	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
223.	Immune High.8 Liquid	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
224.	Gumbo Four Liquid	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
225.	Supreme Lytamin Powder	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.

226.	Dog Apathic Liquid	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
227.	Calco Nill Cobalt Liquid	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
228.	Bone Phosphate Powder	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
229.	Eczema Care Liquid	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
230.	Poly NS Liquid	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
231.	SE . Diarow Powder	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
232.	SE Fibgen Liquid	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant

		product application to check its status whether it has been disposed of or otherwise.
233.	SE.Gold Yeast Liquid	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
234.	SE Sulphates Powder	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
235.	Liso Gold Powder	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
236.	SE Sulphates Powder	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
237.	SE.Gold Yeast Liquid	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
238.	Liso Gold Powder	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
239.	Mintovill Liquid	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
240.	SPR Supreme Pain Relief Powder	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
241.	Multivill Liquid	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
242.	Organovill Liquid	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
243.	Dekavill Liquid	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
<b>M/s Biozone International Plot No. 8, Bhengrail Road, Rawat, Islamabad (E. No. 00094)</b>		
244.	Neurofol Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent

		preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
245.	Neurofol Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
<b>M/s. Blossom Laboratories (Pvt.) Ltd., 30-KM, Badian Road, ½ K.M Off Roda Bohgal Road, Lahore Cant (E. No. 00181)</b>		
1.	<b>Blossom B.Flox Capsule</b>	Defererd for change of brand name
246.	<b>Blossom Painaway Capsule</b>	Deferred for change of brand name
247.	<b>Blossom Pilesaway Capsule</b>	Deferred for change of brand name
248.	<b>Blossom Pilezee Capsule</b>	Deferred for change of brand name
249.	<b>Blossom B.Fit Slimming</b>	Defererd for change of brand name
<b>M/s Capex Cosmetic &amp; Pharmaceuticals Experts Plot No. 119, Kahuta Industrial Triangle, Islamabad (E. No. 00080)</b>		
250.	Capex Capsicum Cream	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
<b>M/s. Cidex Laboratories, 84-B S.I.E Kohat Road, Peshawar (E. No. 00160)</b>		
251.	Diabovit Plus Tablet	Defererd for provision of evidence of fee submission and alternative brand names are required
252.	Gat.Cid Suspension	Deferred or provision of content undertaking and undertaking for brand name is require d
253.	MegaSure Powder	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
254.	Myo.Fem Sachet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise
255.	Neuropan Plus Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent



		preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise
	<b>Imunx Tablet</b>	
257.	Noscon-Z Suspension	Defererd for provision of evidence of fee submission and alternative brand names are required
258.	Prime-Vit Syrup	Defererd for provison of sigend and stamped form 3 is require d
259.	Prime-Vit Tablet	Defererd for provision of evidence of fee submission and alternative brand names are required
260.	Vita-Min Syrup	Defererd for provision of evidence of fee submission and alternative brand names are required
261.	Weltomin Syrup	Defererd for provision of evidence of fee submission, sigend and stamped form 3 ,evidence of R and I receiving
262.	Cough-Set Syrup	Defererd for provision of evidence of fee submission, sigend and stamped form 3 ,evidence of R and I receiving
263.	Pepcid Suspension	Defererd for provision of evidence of fee submission, sigend and stamped form 3 ,evidence of R and I receiving
264.	G.Care Tablet	Defererd for provision of evidence of fee submission, sigend and stamped form 3 ,evidence of R and I receiving
265.	Corsafe Capsule	Defererd for provision of evidence of fee submission, sigend and stamped form 3 ,evidence of R and I receiving
266.	Triloba Plus Syrup	Defererd for provision of evidence of fee submission, sigend and stamped form 3 ,evidence of R and I receiving
267.	Triloba Plus Capsule	Defererd for provision of evidence of fee submission, sigend and stamped form 3 ,evidence of R and I receiving
268.	Gascon Suspension	Defererd for provision of evidence of fee submission, sigend and stamped form 3 ,evidence of R and I receiving
269.	Obeset Capsule	Defererd for provision of evidence of fee submission, sigend and stamped form 3 ,evidence of R and I receiving
270.	Myocyst Plus Sachet	Defererd for provision of evidence of fee submission, sigend and stamped form 3 ,evidence of R and I receiving
271.	Caltop Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
272.	Kal.Bo Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
273.	Lexodex 120ml Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
274.	Mecofolic Tablet	Deferred or provision of content undertaking and undertaking for brand name is require d



275.	Vita.8 120ml Syrup	Defererd for provision of evidence of fee submission,sigend and stamped form 3 ,evidence of R and I receiving
276.	Vita.8 Tablet	Defererd for provision of evidence of fee submission,sigend and stamped form 3 ,evidence of R and I receiving
277.	Funtizer 120ml Syrup	Defererd for provision of evidence of fee submission and alternative brand names are required
278.	Hi.Vit Tablet	Defererd for provision of evidence of fee submission and alternative brand names are required
279.	Lexodex Drops	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
<b>M/s Classic Nutraceutical Labs (Veterinary) Plot No.89, 15km, Hangu Road, Kohat-Pakistan (Veterinary) (E. No. 00390)</b>		
280.	Carmisel Liquid	Defererd for provision of evidence of fee submission,sigend and stamped form 3 ,evidence of R and I receiving
281.	Colic Green Liquid	Defererd for provision of evidence of fee submission,sigend and stamped form 3 ,evidence of R and I receiving
282.	Tempcure Liquid	Defererd for provision of evidence of fee submission,sigend and stamped form 3 ,evidence of R and I receiving
283.	Garlisel Liquid	Defererd for provision of evidence of fee submission,sigend and stamped form 3 ,evidence of R and I receiving
284.	Stomach Oral Powder	Defererd for provision of evidence of fee submission,sigend and stamped form 3 ,evidence of R and I receiving
285.	Saline Electuary Oral Powder	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
<b>M/s Claudia Health Care, Plot No.32 – 33, Industrial Triangle, Kahuta Road, Islamabad (E. No. 01113)</b>		
286.	Plairex Cream	Defererd for provision of evidence of fee submission,sigend and stamped form 3 ,evidence of R and I receiving
287.	La Toux Syrup	Defererd for provision of evidence of fee submission,sigend and stamped form 3 ,evidence of R and I receiving
288.	Koha Ivy Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
289.	Tosnil Plus Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
290.	Trum Orange Tablet	Defererd for provision of evidence of fee submission,sigend and stamped form 3 ,evidence of R and I receiving

291.	Dia Z Tablet	Defererd for provision of evidence of fee submission,sigend and stamped form 3 ,evidence of R and I receiving
292.	Clafol Plus Tablet	Defererd for provision of evidence of fee submission,sigend and stamped form 3 ,evidence of R and I receiving
293.	Claudia C Max Tablet	Defererd for provision of evidence of fee submission,sigend and stamped form 3 ,evidence of R and I receiving
294.	Clafol Tablet	Defererd for provision of evidence of fee submission,sigend and stamped form 3 ,evidence of R and I receiving
295.	Inci.S Lotion	Defererd for provision of evidence of fee submission,sigend and stamped form 3 ,evidence of R and I receiving
296.	HBf Capsule	Defererd for provision of evidence of fee submission,sigend and stamped form 3 ,evidence of R and I receiving
297.	Zinocal Syrup	Defererd for provision of evidence of fee submission,sigend and stamped form 3 ,evidence of R and I receiving
298.	Dialin Drops	Defererd for provision of evidence of fee submission,sigend and stamped form 3 ,evidence of R and I receiving
299.	Mincarvidol Capsule	Defererd for provision of evidence of fee submission,sigend and stamped form 3 ,evidence of R and I receiving
300.	Baariz Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
301.	Minskelaxin Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
<b>M/s. Cosmo Pharma International (Pvt) Ltd,</b> <b>Plot No. 883, Block- 2, Azizabad, Bangoria Town, Industrial Area FB Area, Karachi (E. No. 00259)</b>		
302.	Moringano Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
303.	CP.Glow Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
<b>M/s Cure Inn Phytoceuticals (Pvt)Ltd.,</b> <b>Plot No. 10,11-C ,Punjab Small Industrial Estate,44-Km from Lahore,Ferozepur Road, Kasur (E. No. 00351)</b>		
304.	Cure Inn's	Deferred for change of brand name
305.	Cure Inn's Kidz Cof Drops	Deferred for change of brand name
<b>M/s Dolphin Labs.,</b>		

18-km, Sheikhpura Road, Lahore (Nutraceutical/Herbal) (E. No. 00542)		
306.	<b>Finical-D Tablet</b>	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
307.	<b>ENZYQ 500 Tablet</b>	Deferred for change of brand name and verification of testing facility of minerals are required
308.	Caldol.D Tablet	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving, Undertaking regarding content and brand name is required
309.	Flexy Joint Tablet	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving, Undertaking regarding content and brand name is required
310.	Cutimore.H Tablet	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving, Undertaking regarding content and brand name is required
311.	Fertimore.F Tablet	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving, Undertaking regarding content and brand name is required
312.	Myfem Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
313.	LQ.10 Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
314.	Cran.D Tablet	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving, Undertaking regarding content and brand name is required
315.	L.Minocid Tablet	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving, Undertaking regarding content and brand name is required
316.	Hemobalamin Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.

317.	Urocrane Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
318.	Glucosagen Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
319.	Inosifol Tablet	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
320.	L.Folate Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
321.	Algea Nor Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
322.	Glutavin Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
323.	<b>Ossein Sachet</b>	Defererd for clarification regarding Joshanda section
324.	Memoboost Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
325.	Neofolad Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent

		preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
326.	Irofer.B Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
327.	Ossofin Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
328.	Calcit.D3 Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
329.	D.Ferro Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
330.	Ostopar.K2 Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
331.	Ossovit.D Suspension	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.



332.	Ferrocid.B12 Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
333.	Vitamedgold Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
334.	UB.Run Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
335.	Oricum Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
336.	Calpro.D Suspension	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
337.	Livamino.S Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
338.	Noxis Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant



		product application to check its status whether it has been disposed of or otherwise.
339.	Serritase Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
340.	Cyprocit Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
341.	Vitmore Tablet	
342.	Ipocal Tablet	Defererd for provison of undertaking regarding content and brand name is require d
343.	Adenosine Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
344.	Tetrafolate 800 Tablet	Defererd for provison of undertaking regarding content and brand name is require d
345.	Effervit.C Effervescent Tablet	Defererd for provison of undertaking regarding content and brand name is require d
346.	Ferofol.Z Tablet	Defererd for provison of undertaking regarding content and brand name is require d
347.	Laxafin Tablet	Defererd for provison of undertaking regarding content and brand name is require d
348.	Cacit Effervescent Tablet	
<b>M/s Eco Life Pharma (Pvt) Ltd., 1-Km New Gulyana Road, Gujar Khan, District Rawalpindi (E. No. 00926)</b>		
349.	Safa Gel Gel	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
350.	Heri Gel Gel	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
351.	Sharbat Arusa Shehed Sharbat	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
352.	Ammarball Oil	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
353.	Chakora Slim Capsule	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
354.	Arq Hepadoz Arq	Deferred for following reasons:

		Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving, Undertaking regarding content and brand name is required
355.	Johar Chakotra	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving, Undertaking regarding content and brand name is required
356.	Kawargandal Capsule	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving, Undertaking regarding content and brand name is required
357.	Podeen Bhara	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving, Undertaking regarding content and brand name is required
358.	Rasonteen Capsule	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving, Undertaking regarding content and brand name is required
359.	Sharbat Thandak Sharbat	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving, Undertaking regarding content and brand name is required
360.	Ummal Shifaf Syrup	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving, Undertaking regarding content and brand name is required
<b>M/s Elate Pharma, Plot No. H. 165-A, S.I.T.E, Super Highway, Phase-II, Karachi (E. No. 00809)</b>		
361.	<b>Progain softgel</b>	Defererd for verification of testing facility of minerals are required
362.	<b>Bloat free softgel</b>	Defererd for change of brand name
363.	<b>Day.D3 softgel</b>	Deferred for following reasons: Evidence of fee submission along with R&I receiving, Undertaking regarding content and brand name is required
364.	<b>Selzeam softgel</b>	Defererd for verification of testing facility of minerals are required
365.	<b>Botsel softgel</b>	Defererd for verification of testing facility of minerals are required
<b>M/s EmmEss Neutraceuticals 227-Kararwala, 10-Km, Jaranwala Road, Faisalabad (E. No. 00072)</b>		
366.	Deez.D Drops	Defererd for provision of evidence of R and I receiving and fee submission
367.	Luvit.I Tablet	Defererd for provision of evidence of R and I receiving and fee submission
368.	Emmfol Drops	Defererd for provision of evidence of R and I receiving and fee submission
369.	EZ Col Drops	Defererd for provision of evidence of R and I receiving and fee submission
370.	Emmcof Syrup	Defererd for provision of undertaking regarding content and brand name is require d
371.	<b>Fizz C.500 Tablet</b>	
372.	<b>Emmtizer Syrup</b>	
<b>M/s Fablous Pharma Al Ashar Industrial Estate, 20-Km Ferozepur Road, Lahore (E. No. 01065)</b>		
373.	Numeros Z+ Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
374.	Frutavit.M Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent

		preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
375.	Nutracol Drops	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
376.	Dora Drops	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
377.	Kids Heal Drops	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
378.	Solam IP Tablet	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
379.	Solam MV Tablet	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
380.	D.Star Capsule	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
381.	Odeno Plus Tablet	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
382.	Skel.Heal Tablet	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
383.	Ortho Health Tablet	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
384.	Synofol Tablet	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
385.	Vital Antioxidant Complex Tablet	Deferred for following reasons:

		Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
386.	Recin Tablet	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
387.	Optimum Iron.Vitamin Complex Tablet	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
388.	Oricit.C Tablet	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
389.	Calcium Heal Capsule	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
390.	Kids Cal Chewable Tablet	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
391.	Ciliren Tablet	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
392.	Solam VD Tablet	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
393.	Smika.F Tablet	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
394.	Whitening Heal Capsule	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
395.	Vitalize Tablet	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
396.	Colic Heal Drops	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
397.	Max & Max Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
398.	Rabimalt Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product

		applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
399.	Opti.M Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
400.	Befol Plus 6 Tablet	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
401.	Befol Tablet	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
402.	Optimum Synergy Tablet	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
403.	Namra.D Drops	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
404.	Essential Vitamins & Minerals Tablet	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
405.	Ayuvit Tablet	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
406.	Colic Drops	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
407.	Optivital Tablet	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
408.	Ayucal Plus Tablet	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
409.	Ginko Health Syrup	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
410.	A.Kids Drops	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
411.	D.Kids Drops	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
412.	Calgaeum Tablet	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
413.	Fertis Tablet	Deferred for following reasons:



		Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
414.	Irozone Tablet	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
415.	My Cough Drops	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
416.	Brailin Tablet	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
417.	D Star Drops	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
418.	Irolin.F Tablet	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
419.	Bone Heal Tablet	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
420.	Vivitale Tablet	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
421.	Ginko Heal Plus Syrup	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
422.	Ram Cold Syrup	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
423.	Neoflex Tablet	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
424.	Melnia Tablet	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
425.	Solate Capsule	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
426.	Ferrovitale Tablet	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
427.	Bonic Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
428.	Slimex Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent



		preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
429.	Agfa.D Drops	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
430.	Iron Heal Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
431.	CranHeall Syrup	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
432.	Fabzink Drops	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
433.	Fabzink Syrup	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
434.	J Malti Syrup	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
<b>M/s. Filix Pharmaceuticals (Pvt) Ltd. (Dedicated Section) Plot No. 4-B, Main Road, RCCI, Rawat, Rawalpindi (E. No. 00120)</b>		
435.	Vivisid Sachet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
<b>M/s. Focus &amp; Rulz Healthcare Division, Plot No. 44, Industrial Triangle Kahuta Road, Islamabad (E. No. 00183)</b>		
436.	<b>P -CURE 400mg Capsules</b>	Defererd for justification regarding applied formulation as health product along competitors availability in local or international market
437.	<b>MINVIT PLUS TABLET</b>	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product

		applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
<b>M/s Genetics Health Care, Plot No.537-A, Sunder Industrial Estate, Lahore-Pakistan [Nutraceutical] (E. No. 00626)</b>		
438.	Luxan Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
439.	Aptolant Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
440.	Braxis Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
<b>M/s Glorious Laboratories, Plot No. 238, Industrial Triangle, Kahuta Road, Islamabad (E. No. 01059)</b>		
441.	<b>Oad Men Tablet</b>	Defererd for change of brand name
442.	<b>Oad Women Tablet</b>	Defererd for change of brand name
443.	<b>Tuff.Mount Tablet</b>	Defererd for provision of fee submission and R ans I receiving is required
444.	<b>Mag.Cofac Capsule</b>	Defererd for provision of fee submission and R ans I receiving is required
445.	<b>Eldercra Sachet</b>	Defererd for provision of fee submission and R ans I receiving is required
446.	<b>Eva Tablet</b>	Defererd for provision of fee submission and R ans I receiving is required
447.	<b>Orostat Sachet</b>	Defererd for provision of fee submission and R ans I receiving is required
448.	<b>Nutrich Tablet</b>	Defererd for provision of fee submission and R ans I receiving is required
449.	<b>Methyco Chewable Tablet</b>	Defirred for evidence of fee submission and R and I receiving is required
450.	<b>Vita-nue Tablet</b>	Defirred for evidence of fee submission and R and I receiving is required
451.	<b>Brain in Drops</b>	Defirred for evidence of fee submission and R and I receiving is require d
452.	<b>Brrainee Drops</b>	Defirred for evidence of fee submission and R and I receiving is required verification of testing facility of minerals are required
453.	<b>Tribzosaf Capsule</b>	Defirred for evidence of fee submission and R and I receiving is require d verification of testing facility of minerals are required

454.	<b>Domegasaf Syrup</b>	Deferred for evidence of fee submission and R and I receiving is required
455.	<b>Snofersaf tablet</b>	Deferred for evidence of fee submission and R and I receiving is required
456.	<b>Snofersaf Syrup</b>	Deferred for evidence of fee submission and R and I receiving is required
457.	<b>Marshnol Syrup</b>	Deferred for evidence of fee submission and R and I receiving is required
458.	<b>Bonex Tablet</b>	Deferred for change of brand name and verification of testing facility of minerals are required
459.	<b>Glomega Syrup</b>	Deferred for evidence of fee submission and R and I receiving is required
460.	<b>Glorious.C+Z Tablet</b>	Deferred for evidence of fee submission and R and I receiving is required
461.	<b>Glorious.C 500 Tablet</b>	Deferred for evidence of fee submission and R and I receiving is required
462.	<b>Glorious.C+Z Tablet</b>	Deferred for monograph of DIM (di indole methane) and Indole 3 carbinol along with competitors availability of applied formulation
<b>M/s. Gold Sheff International Nutraceutical, 537-F, Sunder Industrial Estate (PIE), Raiwind Road, Lahore (E. No. 00353)</b>		
463.	Bodyfuel Junior Nutritional Supplement	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
464.	Bodyfuel Nutritional Supplement	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
465.	Bodyfule Diet Nutritional Supplement	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
466.	Mamamil Gold Nutritional Supplement	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
<b>M/s Greektect (Pvt) Ltd Plot No. D-30/A (First Floor), S.I.T.E.-II, Phase-I, Super Highway, Karachi (E. No. 00091)</b>		
467.	Coliriz Syrup	Deferred for following reasons:

		Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
468.	Shorical.D Tablet	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
469.	Shorimalt Syrup	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
470.	Shorivit.M Tablet	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
471.	Shorimalt.F Tablet	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
472.	Transheal (Skin Revitalizing System) Cream	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
473.	Transheal (Skin Revitalizing System) Tablet	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
474.	Transheal (Slimfit System) Capsule	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
475.	Transheal (Joint & Pain System) Cream	
476.	Transheal (Joint & Pain System) Tablet	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
477.	Transheal (Female Health System) Tablet	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
478.	Transheal (Memory & Neuro System) Tablet	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
479.	Transheal (Male Health System) Capsule	
480.	Transheal (Complete Health System) Tablet	
481.	Transheal (Gastro & Liver System) Tablet	
482.	Transheal (Sleep & Calm System) Tablet	
<b>M/s Green Which Natural Pharma Pvt. Ltd., [Herbal Unani] 9.5 KM, Sheikhpura Road, Lahore-Pakistan (E. No. 00724</b>		
483.	Green's Alhayat Surfe Cough Syrup	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
484.	Green's Alhayat Hayat.e.Jigar Syrup	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
485.	Green's Alhayat Sharbat Toot Siah Syrup	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving , Undertaking regarding content and brand name is required
486.	Green's Alhayat Samry Sharbat Foulad Syrup	Deferred for following reasons:

		Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving, Undertaking regarding content and brand name is required
487.	Green's Alhayat Shabab Hi Shabab Syrup	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving, Undertaking regarding content and brand name is required
488.	Green's Alhayat Gastric Syrup	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving, Undertaking regarding content and brand name is required
489.	Green's Alhayat Madri Tonic Syrup	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving, Undertaking regarding content and brand name is required
490.	Green's Alhayat Laal Sharbat Syrup	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving, Undertaking regarding content and brand name is required
491.	Green's Alhayat Sharbat.e.Foulad Syrup	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving, Undertaking regarding content and brand name is required
492.	Green's Alhayat Mulathi Cough Syrup	Deferred for following reasons: Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving, Undertaking regarding content and brand name is required
493.	<b>K-ZYME SYRUP</b>	Deferred for specification of active ingredients are required
494.	<b>Sr. Kuf syrup</b>	Deferred for specification of active ingredients are required
495.	<b>Urimex Syrup</b>	Deferred for provision of herbal monographs of Sabal Ser Epigea Repens Stigmata Cantharis Equisetum Pereira Brava Hydrangea Sarkanda Lycopodium Terebinthina
496.	<b>Vito M Syrup</b>	Deferred for specification of active ingredients are required
497.	<b>Gas-O-Care Suspension</b>	Deferred for specification of active ingredients are required
498.	<b>Gas-O-Care Suspension (Mint Flavor )</b>	Deferred for evidence of fee submission and R and I receiving is required
499.	<b>Peppermint syrup</b>	Deferred for specification of active ingredients are required
500.	<b>K-Cid Suspension</b>	Deferred for specification of active ingredients are required
501.	<b>SanSim Forte Syrup (Orange Flavor)</b>	Deferred for evidence of fee submission and R and I receiving is required
502.	<b>SanSim Forte Syrup (Lemon Flavor)</b>	Deferred for evidence of fee submission and R and I receiving is required
503.	<b>Super Ghutti Syrup</b>	Deferred for evidence of fee submission and R and I receiving is required
504.	<b>SanSim Forte Syrup (Strawberry Flavor)</b>	Deferred for evidence of fee submission and R and I receiving is required
505.	<b>SanSim Forte Syrup (Banana Flavor)</b>	Deferred for evidence of fee submission and R and I receiving is required
506.	<b>PROGINK Syrup</b>	Deferred for specification of active ingredients are required
507.	<b>PEN LOT Syrup</b>	Deferred for specification of active ingredients are required
508.	<b>HIBRO-G Syrup</b>	Deferred for specification of active ingredients are required



509.	<b>GYNO-ZONE Syrup</b>	Defererd for specification of active ingerdients are required
510.	<b>GINKGO FLAV Syrup</b>	Defererd for specification of active ingerdients are required
511.	<b>GINKGO BEX Syrup</b>	Defererd for specification of active ingerdients are required
512.	<b>NEURO TONIC SYRUP</b>	Defererd for evidence of fee submission and R and I receiving is require d
513.	<b>KUFSONEX SYRUP</b>	Defererd for specification of active ingerdients are required
514.	<b>IROKUF-T syrup</b>	Defererd for evidence of fee submission and R and I receiving is require d
515.	<b>Cough Stop Syrup</b>	Defererd for specification of active ingerdients are required
516.	<b>Anir Vit Syrup</b>	Defererd for specification of active ingerdients are required
517.	<b>Pipzin Syrup</b>	Defererd for specification of active ingerdients are required
518.	<b>Green's Dizin + suspension</b>	Defererd for specification of active ingerdients are required
519.	<b>Cvit-D Drops</b>	Defererd for provison jstification of applied formulation in drops and competitors availability
520.	<b>Maxol Suspension</b>	Defererd for provision of fee submission and R and I receiving is required
521.	<b>Noxid Plus Suspension</b>	Defererd for specification of active ingerdients are required
522.	<b>Colic Syrup</b>	Defererd for specification of active ingerdients are required
523.	<b>Colic Drops</b>	Defererd for specification of active ingerdients are required
524.	<b>Baby Cough Syrup</b>	Defererd for specification of active ingerdients are required
525.	<b>Live.52 Fort</b>	Defererd for specification of active ingerdients are required
526.	<b>Sharbat-E-Podina</b>	Defererd for specification of active ingerdients are required
527.	<b>Gastro-G Suspension</b>	Defererd for specification of active ingerdients are required
<b>M/s Green Natural Care, 22-KM off Ferozepur Road, Lahore (Herbal/Unani) (E. No. 00547)</b>		
528.	Splash Sachet	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
<b>Haaks Vethum (Private) Limited. Plot No. 60-B (II), Phase No. 1A, M-3 Industrial Estate, Sahianwala, Faisalabad (E. No. 00974)</b>		
529.	Lysovit Plus Powder	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
530.	FT Hepa Liquid	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
531.	FT Mint Liquid	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
532.	FT Gumbo Powder	Deferred for following reasons:

		Properly filled signed and stamped form 3, Evidence of fee submission along with R&I receiving, Undertaking regarding content and brand name is required
<b>M/s Harbasian Laboratories Pakistan (Pvt) Ltd., 290-Jail Road, Opp. Bilal Masjid, Kot Lakhpat, Industrial Area, Lahore (E. No. 00396)</b>		
533.	Tricard Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
<b>M/s Haven Pharmaceuticals Pvt. Ltd., located at the address, Plot No. 65-A, M-3, Industrial Estate, Sahianwala, Faisalabad (E. No. 00985)</b>		
534.	Dilatin Sachet	Deferred for Undertaking regarding content and brand name is required
535.	Gloven Capsule	Deferred for Signed and stamped form 3 along with alternative brand names are required
536.	Havocran Sachet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
537.	Renovia Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
<b>M/s Herbion Pakistan Pvt, Ltd. Plot No. 30, Sector 28, Korangi Industrial Area, Karachi (E. No. 00001)</b>		
538.	Glufair Oral Solution	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
539.	Glufair Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
540.	Cilvit D (10,000IU) Strawberry Flavor Chewable Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since

		computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
541.	Cilavit D (5000IU) Chocolate Flavor Chewable Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
542.	Vigor Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
543.	Vigor Plus Capsule	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
544.	Linkus Orvi Kids Granules	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
545.	Linkus Kids Syrup	Deferred for following reasons: Properly filled signed and stamped form 3,Evidence of fee submission along with R&I receiving ,Undertaking regarding content and brand name is required
546.	Entocid Syrup	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files.Hence,there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly,EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.
<b>M/s. Cynosure Pvt. Ltd., Plot No. 21-A, Tawakkal Town, Old Shuja Abad Road, Multan (E. No. 00159)</b>		
547.	Cynosure OXIM Syrup	Deferred for verification of testing facility of minerals are required
548.	Cynosure ENERGI PLUS Tablet	Deferred for verification of testing facility of minerals are required
549.	Cynosure ALMIN Tablet	Deferred for verification of testing facility of minerals are required

550.	Cynosure B-NATE SYRUP	Defererd for verification of testing facility of minerals are required
551.	Cynosure's CYNOCAL C (Effervescent Tablet)	Deferred for change of brand name verification of testing facility of minerals are required
552.	Cynosure GLO-PLUS capsule	Deferred for change of brand name
553.	Cynosure MULTIPEAK Tablet	Deferred for change of brand name
554.	CYNOSURE Provita-M Tablet	Defererd for verification of testing facility of minerals are required
555.	PYRAVIT PLUS SYRUP	Defererd for verification of testing facility of minerals are required
556.	PYRAVIT PLUS Tablet	Defererd for verification of testing facility of minerals are required

<b>M/s Herbiotics Health Care, Plot No. 1-B, Street No. S-4, RCCI Industrial Estate, Rawat (E. No. 00394)</b>		
1.	<b>Antef Cream</b>	
2.	<b>Wintol Cream</b>	
3.	<b>Annem Cream</b>	
4.	<b>Ram.P Lotion</b>	Deferred for change of brand name
5.	<b>Remesol Oil</b>	
6.	<b>Ezeol Cream</b>	
7.	<b>Herbin Lotion</b>	
8.	<b>Herbin Plus Lotion</b>	
9.	<b>Curiq Balm</b>	
10.	<b>Zinko Syrup</b>	Deferred for change of brand name
11.	<b>Zinko Tablet</b>	Deferred for change of brand name
12.	<b>Insignia Drops</b>	
13.	<b>Mec.12 Tablet</b>	Deferred for change of brand name and verification of testing facility of minerals
14.	<b>Magno Tablet</b>	Deferred for change of brand name
15.	<b>Totsip Syrup</b>	Deferred for change of brand name
16.	<b>Abolic Syrup</b>	Deferred for change of brand name
17.	<b>Vitamin.C Plus 250mg Tablet</b>	Deferred for change of brand name
18.	<b>Comfotil Balm</b>	
19.	<b>Kulim Ointment</b>	
20.	<b>GCM.Plus Cream</b>	
21.	<b>Remesol Cream</b>	
22.	<b>Winfor Cream</b>	
23.	<b>Anti.sub Syrup</b>	Deferred for change of brand name
24.	<b>Irosub Syrup</b>	Deferred for change of brand name
25.	<b>Baxferon Drops</b>	Deferred for strength and rationality of dose calculation of vitamin A per unit drop formulation

26.	<b>DU.400 Drops</b>	Deferred for strength and rationality of dose calculation of vitamin A per unit drop formulation
27.	<b>Neodix.D Drops</b>	Deferred for change of brand name
28.	<b>Ivyrol Drops</b>	
29.	<b>Irosub Tablet</b>	Deferred for change of brand name
30.	<b>Round.C Tablet</b>	Deferred for change of brand name
31.	<b>Round.Z Tablet</b>	Deferred for verification of testing facility of minerals
<b>M/s. Himont Laboratories (Pvt) Ltd., 17-Km, Ferozepur Road, Lahore (E. No. 00122)</b>		
32.	<b>Hicap SS Tablet</b>	
33.	<b>Pregnovit P Tablet</b>	
34.	<b>Ferplex Plus Tablet</b>	
35.	<b>Ferplex Syrup</b>	
36.	<b>Hicap T Tablet</b>	
<b>M/s Hinucon, Plot No. 12/1, Sector 15, Korangi Industrial Area, Karachi (E. No. 00062)</b>		
37.	<b>Coxnil 150mg Tablet</b>	Deferred for Justification/Clarification regarding applied formulation as health product
38.	<b>Coxnil 150mg Sachet</b>	Deferred for Justification/Clarification regarding applied formulation as health product
39.	<b>Coxnil 160mg Effervescent Tablet Flavor Mint</b>	Deferred for Justification/Clarification regarding applied formulation as health product
40.	<b>Coxnil 160mg Effervescent Tablet Flavor Orange Tablet</b>	Deferred for Justification/Clarification regarding applied formulation as health product
41.	<b>Coxnil 160mg Effervescent Tablet Mango Flavor Tablet</b>	Deferred for Justification/Clarification regarding applied formulation as health product
42.	<b>Coxnil 160mg Effervescent Tablet Flavor Pineapple Tablet</b>	Deferred for Justification/Clarification regarding applied formulation as health product
43.	<b>Coxnil 300mg Effervescent Tablet Flavor Mint Lemonade Tablet</b>	Deferred for Justification/Clarification regarding applied formulation as health product
44.	<b>Coxnil 300mg Effervescent Tablet Flavor Orange Tablet</b>	Deferred for Justification/Clarification regarding applied formulation as health product
45.	<b>Coxnil 300mg Effervescent Tablet Flavor Mango Tablet</b>	Deferred for Justification/Clarification regarding applied formulation as health product
46.	<b>Coxnil 300mg Effervescent Tablet Flavor Pineapple</b>	Deferred for Justification/Clarification regarding applied formulation as health product
47.	<b>Coxnil 600mg Sachet</b>	Deferred for Justification/Clarification regarding applied formulation as health product
48.	<b>Coxnil 300mg Sachet</b>	Deferred for Justification/Clarification regarding applied formulation as health product
49.	<b>Coxnil 600mg Tablet</b>	Deferred for Justification/Clarification regarding applied formulation as health product
50.	<b>Coxnil 300mg Capsule</b>	Deferred for Justification/Clarification regarding applied formulation as health product



51.	Coxnil 300mg Tablet	Deferred for Justification/Clarification regarding applied formulation as health product
<b>M/s Hi-Nutrition</b> <b>Hashim Park, 9.5-KM, Sheikhpura Road, Lahore (E. No. 00077)</b>		
52.	Nucee Sachet	Deferred for provision of Specifications of ingredients and change of brand name
53.	Venynol Gold Tablet	Deferred for provision of Specifications of ingredients and change of brand name
54.	Creatine Monohydrate Powder	Deferred for provision of Specifications of ingredients and change of brand name
55.	Whey Proein Isolate Powder	Deferred for provision of Specifications of ingredients and change of brand name along with verification of testing facility of minerals
56.	BCAA Big 6 Powder	Deferred for provision of Specifications of ingredients and change of brand name and verification of testing facility of amino acids
57.	Beta Alanine Powder	Deferred for provision of Specifications of ingredients and change of brand name verification of testing facility of amino acids
<b>M/s. Hiranis Pharmaceuticals (Pvt.) Ltd.</b> <b>E-145-149, North Western Industrial Zone, Port Qasim, Karachi 75020 (E. No. 00174)</b>		
58.	Pumanol Syrup	
59.	XGen Calcium, Magnesium & Zinc with Vitamin D3 Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
60.	XGen Multivitamin for Women (Prenatal and Postpartum) Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
61.	Xgen Serratiopeptidase Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
62.	Xgen Multivitamin (One a Day.Daily Vitamin) Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
63.	Xgen Iron with Folic Acid, Vitamin B12 & Vitmain C Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
64.	Xgen Calcium and Vitamin D3 with Vitamin K2 Tablet	
65.	Xgen Biotin Tablet	
66.	Xgen Vitamin D3 Tablet	
67.	Imunilone 25mg Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
68.	Imunilone 100mg Capsule	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
69.	Vit&Min Heart Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
70.	Relokuf Syrup	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing

71.	Vitotal.W Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
72.	NeoMag Forte D3 Tablet	
73.	NeoMag Plus Tablet	
74.	Artrosamin Capsule	
75.	Sesja Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
76.	Calone.K Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
77.	Calone.K Sachet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
<b>M/s. Hisun Pharmaceutical Industries (Natural Division)</b> <b>Plot No 37-A, R-02, Industrial Estate Gadoon District, Swabi KPK (E. No. 00325)</b>		
78.	Ntasid Suspension	
79.	Elbrit Syrup	Deferred for Evidence of R and I receiving along with copy of fee submission is required
80.	Conex.D Suspension	Deferred for Evidence of R and I receiving along with copy of fee submission is required
81.	Conex.D Tablet	Deferred for Evidence of R and I receiving along with copy of fee submission is required
<b>M/s Inovics Healthcare [Nutraceutical]</b> <b>P-819, 14-km, Adyala Road, Rawalpindi-Pakistan (E. No. 00737)</b>		
82.	Dentavit Tablet	
<b>M/s Izfaar Pharmaceuticals (Pvt) Limited,</b> <b>located at the address 542- A&amp;B, Sunder Industrial Estate, Lahore (E. No. 00928)</b>		
83.	Mamozone Capsule	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
84.	Mouthon.DS (Vet) Liquid	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
85.	Liv.Heal (Vet) Liquid	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
86.	Fibro Hit DS Plus Liquid	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
87.	Colco.X (Vet) Liquid	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
88.	Mouthan.DS (Vet) Liquid	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing

89.	Scor.S Suspension	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
90.	Calf Boost (Vet) Liquid	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
91.	Vitamin (Vet) Powder	Deferred for Evidence of R and I receiving along with copy of fee submission is required
92.	Vitex Syrup	Deferred for Evidence of R and I receiving along with copy of fee submission is required
93.	Vitmin (Vet) Liquid Vet	Deferred for Evidence of R and I receiving along with copy of fee submission is required
<b>M/s. Kaap Pharmaceuticals, 18-Km Ferozepur Road, Lahore-Pakistan (E. No. 00204)</b>		
94.	<b>SlimKap Capsule</b>	Deferred for provision of strength of formulation each one capsule and verification of testing facility of minerals
95.	<b>AntaKap Chewable Tablet</b>	Deferred for verification of testing facility of minerals
96.	<b>Be.Men Capsule</b>	Deferred for verification of testing facility of minerals
97.	<b>Xankap Tablet</b>	Deferred for verification of testing facility of minerals
98.	<b>Xankap Plus Tablet</b>	Deferred for verification of testing facility of minerals
99.	<b>Theravit.Z Tablet</b>	Deferred for verification of testing facility of minerals
100.	<b>HB.Plus Tablet</b>	Deferred for verification of testing facility of minerals
101.	<b>Ferlatum.F Capsule</b>	Deferred for verification of testing facility of minerals
102.	<b>Ferlatum.F Syrup</b>	Deferred for verification of testing facility of minerals
103.	<b>Ferlatum.F Drops</b>	Deferred for verification of testing facility of minerals
<b>M/s Kint Laboratories, 4KM North Kallar Sayedan Road, Rawat Rawalpindi (E. No. 00360)</b>		
104.	<b>ECOCID Oral Liquid</b>	Deferred for verification of testing facility of minerals
105.	<b>C.Fresh 20 Powder</b>	Deferred for verification of testing facility of minerals
106.	<b>Turmax Tablet</b>	
107.	<b>Canxi Tablet</b>	
108.	<b>Arbutus Tablet</b>	
109.	<b>Purea Tablet</b>	
110.	<b>Mobilita Tablet</b>	
111.	<b>Hydromel Cream</b>	Deferred for justification of applied formulation as health product
112.	<b>Bergin Syrup</b>	Deferred for verification of testing facility of minerals
<b>M/s Medicom Superior, 122-A, Muzammal Town, Chung, Multan Road, Lahore (E. No. 00361)</b>		

113.	Bexfol Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
114.	Irofol V Tablet	Deferred for Evidence of R and I receiving along with copy of fee submission is required
115.	Meprez Syrup	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
116.	Mizl Syrup	Deferred for Evidence of R and I receiving along with copy of fee submission is required
<b>M/s. Modherbs, Plot No. C-596, Sector 2, Ahsanabad, Scheme-33, Opp SITE, Super Highway, Karachi (E. No. 00125)</b>		
117.	<b>Weltrum Gold Tablet</b>	Deferred for verification of testing facility of minerals
118.	<b>Mestil Syrup</b>	Deferred for verification of testing facility of minerals
119.	<b>Furica tablet</b>	Deferred for verification of testing facility of minerals
120.	<b>Lactancia Tablet</b>	Deferred for verification of testing facility of minerals
<b>M/s MRG Laboratories (Pvt) Ltd., Plot No. C-68, S.I.T.E. Phase-I, Super Highway, Karachi-Pakistan (E. No. 00381)</b>		
121.	Neodart Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
122.	Gratis Syrup	Deferred for Evidence of R and I receiving along with copy of fee submission is required
123.	Mixto Syrup	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
124.	Teroy Tablet	
125.	Gyno Ease Plus Tablet	
126.	Q.Fanec Tablet	
127.	Teroy Tablet	
128.	Carisyp Syrup	
129.	Omploy Tablet	
130.	One Way Capsule	
131.	Iroterm Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
132.	Kelcel Vit Syrup	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
133.	Magzol.D Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
<b>M/s MSG Nutraceuticals</b>		

Plot No.34, Street S-1, RCCI Industrial Estate, Rawat (E. No. 01109)		
134.	Purge Sachet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
135.	Biolac Food Supplement	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
136.	Myosit Sachet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
137.	Genocal Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
138.	Lactocell Sachet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
139.	Ostimac Sachet	
140.	Lactocare Sachet	
141.	Trulac Food Supplement	
142.	Myosit Plus Sachet	
143.	Mensolec Syrup	
144.	Pro.Chain Sachet	
145.	Nitrogain Food Supplement	
146.	Biolac Diet Food Supplement	
147.	Sugno Food Supplement	
148.	Glucosure Food Supplement	
149.	Pro Milk Food Supplement	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
150.	Z.Flor Sachet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
151.	Calmax Food Supplement	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
152.	Fitmax Sachet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
153.	Mospro Lotion	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
154.	Progot Sachet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
155.	Align Sachet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
156.	Nutria.Food Supplement	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing.



		Fee receipt is missing
157.	B.Mom Food Supplement	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
158.	D.Flora Sachet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
159.	Eva.Pro Sachet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
160.	Immuno Up Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
161.	Kids Up Food Supplement	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
162.	Tusseon Cough Relief Syrup	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
163.	Ostiloft Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
164.	Zingvit Multivitamin Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
165.	3D3 Plus Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
166.	Baby Infant Drops	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
167.	Relcer Syrup	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
168.	Real Met Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
169.	Pink Iron Syrup	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
170.	Kufrel Cough Drops	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
171.	Real Berry Sachet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
172.	Lig.Cid Syrup	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing

173.	Sciro.Kal Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
174.	Gainer.M Multivitamin & Minerals Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
175.	Live.S Syrup	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
176.	Zydiron Syrup	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
177.	Zydiron Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
178.	UD3 Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
179.	Zyronex Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
180.	UD3 Syrup	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
181.	Uristone.K Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
182.	Uristone.K Syrup	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
183.	Zingvit Syrup	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
184.	UD3 Drops	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
185.	Hebifer Syrup	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
186.	Recal.D Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
<b>M/s MSK Cosmo &amp; Nutraceuticals.</b>		
<b>5-KM, Lahore Road, Near Sialkot Bypass, Gujranwala (E. No. 00975)</b>		
187.	Leco Fin Capsule	
188.	Myotal Sachet	
189.	Nutus Syrup	
190.	Oviset Sachet	

191.	Myo Pink Capsule	
192.	DU 50 Capsule	
193.	M. Olifer Capsule	
194.	BX Gel Syrup	
195.	Progen.S Capsule	
196.	D.Bio Capsule	
<b>M/s. Neutra Cure,</b>		
<b>SB-02 &amp; 15, Sector 6-G, Korangi Township, Karachi (E. No. 00119)</b>		
197.	Hiwin Plus Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
<b>M/s Nutrabiobiotics, Nutritional Life Science</b>		
<b>Plot No. 89-K3, Industrial Estate, Hayatabad, Peshawar (E. No. 00003)</b>		
198.	Diod Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
199.	Kaybone Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
200.	Kaybone Syrup	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
201.	Perfective Capsule	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
202.	Potencia Capsule	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
203.	Apti-Up Syrup	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
204.	Algrace Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
205.	Algrace Syrup	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
206.	Cidonil Syrup	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
207.	O2-Plex Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
208.	Pregnamin Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
209.	Nutragink Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
210.	Figura Capsule	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing.

		Fee receipt is missing
211.	Nutradol Capsule	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
212.	Spacid-D Syrup	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
213.	Semenator Capsule	
214.	Coen-10 Tablet	
215.	Cal-3 Tablet	
216.	Everslim Capsule	
217.	Nutrakuff Syrup	
<b>M/s Nutrevo Health Care</b>		
<b>Khewat No. 438, Khatauni No.452, Khasra No. 819, 14 – Km Adyala Road, Rawalpindi (E. No. 01124)</b>		
218.	Calevo Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
219.	Glim Gink Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
220.	Iron.N Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
221.	Osteo Revo Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
222.	Zuma.D Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
223.	Glimfo 400 Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
224.	Glim D Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
225.	Bone Vita Chewable Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
226.	Nutrimega Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
227.	Corbifer Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
228.	Reed Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
229.	Glim100 Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing.

		Fee receipt is missing
230.	Silbia Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
231.	Neurit Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
232.	Ascal 1000 Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
233.	Evoday Syrup	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
234.	Evotize Syrup	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
235.	Zuma.D Syrup	
236.	Hackrid Syrup	
237.	Zeptize Syrup	
238.	Silbia Syrup	
239.	Herbi Cid Syrup	
240.	Oste.Glim Syrup	
241.	Calevo Syrup	
242.	Zeest.7 Syrup	
243.	Gavacid Syrup	
244.	Zipcid Syrup	
245.	Iron.N Syrup	
246.	Reed Syrup	
247.	Glim Gink Syrup	
<b>M/s. Nutrifactor Laboratories (Pvt) Ltd</b> <b>Plot No 4-B, Value Addition City, Khurrianwala, Faisalabad (E. No. 00324)</b>		
248.	Enerzee Tablet	
249.	Nugen Tablet	
250.	Bzolve Chewable Tablet	
<b>M/s. Nutrix Health Care</b> <b>Plot No 44 Street No 3 Small Industrial Area 9KM Summandari Road Faisalabad (E. No. 00323)</b>		
251.	Osteorix Sachte	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
<b>M/s Oasis Pharma,</b> <b>23-Km Raiwind Road, Lahore (E. No. 00779)</b>		
252.	Karve Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
253.	Bio.H Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
254.	Spazib Capsule	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing.



		Fee receipt is missing
255.	Oslim Capsule	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
256.	Citoz Sachet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
257.	Lipoxy Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
258.	Lyso Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
259.	Osega.3 Syrup	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
260.	Laxon Drops	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
261.	Inoci Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
262.	Slip.C 1000 Effervescent Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
263.	Vitex.C Effervescent Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
264.	Sipgro.C Effervescent Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
265.	Utx Effervescent Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
266.	Piles.ex Sachet	
267.	Ferricon Tablet	
268.	Fervent Tablet	
269.	Ivycore Syrup	
270.	Diarend Syrup	
271.	Dairsly Syrup	
<b>M/s. Paragon Herbal Laboratories, Plot No. Kht 285, Ktn 570, Allah Hoo Industrial Area, Near Sabzi Mandi, Gujumatta, Ferozepur Road, Lahore (E. No</b>		
272.	C.Vital Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
273.	Zonic Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing.

		Fee receipt is missing
<b>M/s. Phytotia Laboratories, 27/28-C, Small Industrial Estate, Kohat Road, Peshawar (E. No. 00308)</b>		
274.	Phytotia Phytin Tablet	
275.	Phytotia Garcen Tablet	
276.	Phytotia Sil.E Tablet	
277.	Phytotia P.Boost Tablet	
278.	Phytotia Bor.X Tablet	
279.	Phytotia D.Meg Tablet	
280.	Phytotia B6 Tablet	
281.	Phyron Plus Tablet	
282.	Phytobion Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
283.	Phytotia K.Bon Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
284.	Phytotia K2 Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
285.	Serat.P Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
286.	Phytotia B12 Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
287.	Siara.DS Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
288.	Phytotia Teres Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
289.	Phytotia Foltin Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
290.	Phytotia Biotin Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
291.	Phytotia L.More Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
292.	Phytotia Pepzit Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
293.	Phytotia Ino.Boost Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
294.	PhyCin 750 Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing.

		Fee receipt is missing
295.	CiTin 500 Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
296.	FlexoVit Tablet	
297.	Cran.X Sachet	
298.	BasoPan Plus Tablet	
299.	BasoPan Tablet	
300.	KeVit Tablet	
301.	AsoNyl Tablet	
302.	Magni.Z Tablet	
<b>M/s Polyfine Nutra-Sciences</b>		
<b>Plot No. 39-40 D, Industrial Estate, Hayatabad, Peshawar (E. No. 00019)</b>		
303.	<b>Sogical syrup</b> Each 5ml contains: Vitamin D3 (USP)..... 1.9mcg Calcium as Calcium Carbonate (USP).... 150mg Magnesium as Magnesium sulphate (USP).... 75mg Zinc sulphate (USP)..... 3mg	Deferred for verification of testing facility of minerals
304.	<b>Sogical Tablet</b> Each Tablet contains: Vitamin D3 (USP)..... 200 IU Calcium Carbonate (USP)... 320mg Magnesium sulphate (USP)... 50mg Zinc sulphate (USP).... 10mg	Deferred for verification of testing facility of minerals
305.	<b>Alvityl Syrup</b> Each 5ml contains Vitamin C (USP)....16.66mg Niacinamide (USP).....6.66mg Calcium Pantothenate (USP).1.25mg Zinc Sulphate (USP).....1mg Magnesium Sulphate (USP)0.833mg Choline Chloride (USP)....0.833mg Vitamin B1 (USP)....0.5mg Vitamin B2 (USP)....0.56mg Vitamin B6 (USP)....0.5mg Vitamin B12 (USP).....0.33mcg Vitamin D3 (USP)....66.66IU Iodine (USP)....16.66mcg Biotin (USP)....10mcg Folic Acid (USP)....6.66mcg Vitamin A (USP)....833IU	Deferred for verification of testing facility of minerals
<b>M/s. Reign Nutro Pharma (Pvt.) Ltd.,</b>		
<b>Plot No. L-1-C/1, Federal "B" Industrial Area, Shaheed Rashid Minhas Road, Karachi (E. No. 00157)</b>		
306.	Genacid Syrup	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
307.	Gasvit Syrup	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing

308.	Koflite Syrup	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
<b>M/s RG Pharmaceuticals (Pvt) Ltd., Plot No. 217 Sunder Industrial Estate, Lahore (E. No. 00944)</b>		
309.	OneNatal Softgel Capsule	
310.	OneNatal Tablet	
<b>M/s Route2Health, Plot No. 229, Sunder Industrial Estate, Raiwind Road, Lahore, (E. No. 01317)</b>		
311.	Laxalix Syrup	Deferred for the Evidence of fee submission and R and I receiving is required
312.	Laxalix Tablet	Deferred for the Evidence of fee submission and R and I receiving is required
313.	Master Minds Capsule	Deferred for the Evidence of fee submission and R and I receiving is required
314.	EliQ10 Chrome Capsule	Deferred for the Evidence of fee submission and R and I receiving is required
315.	Elix.D3 2000 Tablet	Deferred for the Evidence of fee submission and R and I receiving is required
316.	EliQ10 Rapid Capsule	Deferred for the Evidence of fee submission and R and I receiving is required
317.	EliQ10 + Capsule	Deferred for the Evidence of fee submission and R and I receiving is required
318.	Elix.D3 5000 Tablet	Deferred for the Evidence of fee submission and R and I receiving is required
319.	Elix.D3 1000 Tablet	Deferred for the Evidence of fee submission and R and I receiving is required
320.	Zincare Syrup	Deferred for the Evidence of fee submission and R and I receiving is required
<b>M/s. Royal Laboratories, 22-24 Farooq Industrial Estate, 20 Km Ferozepur Road, Lahore (E. No. 00301)</b>		
321.	Mac.C 500mg Tablet	
322.	Mac.C 1000mg Tablet	
<b>M/s Salbion Health Sciences (Pvt) Ltd., 23-Km, Sheikhpura Road, Lahore-Pakistan (E. No. 00647)</b>		
323.	Lavex Capsule	Deferred for the Evidence of fee submission and R and I receiving is required
324.	Neurop Drops	Deferred for the Evidence of fee submission and R and I receiving is required
325.	Kubet Syrup	Deferred for the Evidence of fee submission and R and I receiving is required
326.	Salmeg Baby Drops	Deferred for the Evidence of fee submission and R and I receiving is required
327.	Kubet Tablet	Deferred for the Evidence of fee submission and R and I receiving is required
328.	Senoprin Drops	Deferred for the Evidence of fee submission and R and I receiving is required
329.	Neurop Syrup	Deferred for the Evidence of fee submission and R and I receiving is required
330.	Salbion's Chuarqa	Deferred for the Evidence of fee submission and R and I receiving is required
331.	Oris Sachet	
332.	essentra 16 Tablet	
333.	K.Tiser Syrup	
334.	Dana Plus Syrup	

335.	Salbion's Arq.e.Gulab Khalis Arq	
336.	Stevy Sweetener Tablet	
337.	B.Folate Tablet	
338.	Salbion's Ghutti Ghutti	
339.	Fibir Max Oral Powder	
340.	Fybrew Oral Powder	
341.	Nosex Inhaler Inhaler	
342.	Maxrice Sachet	
343.	Glone Tablet	
344.	Safi.Nol Syrup	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
345.	Salbion Ispaghul Oral Powder	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
346.	Kenody Sachet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
347.	Lavex Drops	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
348.	Salbion's Peppermint Syrup	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
349.	Neurop Capsule	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
<b>M/s Scotmann Pharmaceuticals (Health &amp; OTC Division), (Nutraceutical) 5-D, I-10/3 Industrial Area, Islamabad-Pakistan (E. No. 00639)</b>		
350.	<b>Radiance Pro Twist.Off Softgel Capsule</b> Each Softgel capsule Contains: L-Glutathione.... 1000mg Vitamin C.... 100mg Vitamin E.... 200mg Collagen.... 200mg	Deferred for provision of specifications of ingredients
<b>M/ Semos Pharmaceuticals (Pvt.) Ltd., (Healthcare Division), Plot No.8/18, Sector 12, Block C, North Karachi Industrial Area, Karachi (E. No. 01111)</b>		
351.	Melatin Tablet	
352.	Vitakid Tablet	
353.	Imucox Tablet	
354.	Mesentials Tablet	
355.	Relaxer Tablet	
356.	Vitakid Plus Tablet	
357.	Se Dyro Syrup	
358.	ZV Syrup	
359.	Oryc Syrup	
360.	Pead Care Syrup	
361.	Regulate Syrup	
362.	Haipil Capsule	
363.	Apitis Tablet	
364.	Dicoz Capsule	
365.	Dietfol Capsule	



366.	Dizin Capsule	
367.	Anol Drops	
368.	Antasen Syrup	
369.	NPH Syrup	
370.	Appitiz Syrup	
371.	Colid Syrup	
372.	Dentopain Syrup	
<b>M/s. SHMZ Labs &amp; Pharmaceuticals (Pvt.) Ltd.</b>		
<b>101-Sundar Industrial Estate, Lahore (E. No. 00231)</b>		
373.	<b>Caltig.D3 Soft Chew Lozenges</b>	
374.	<b>SHMZ's HEMOBIN SYRUP</b>	Deferred for change of brand name and verification of testing facility
375.	<b>SHMZ's MENSO KARE SYRUP</b>	Deferred for change of brand name
376.	<b>SHMZ's SHMZ ANTACID SUSPENSION</b>	Deferred for change of brand name
<b>M/s. Sidaz Health Foods.,</b>		
<b>Plot No. A-65, Sindh Small Industrial Extension Hyderabad (E. No. 00814)</b>		
377.	Si.Krantine Capsule	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
378.	Sitrate.K Capsule	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
379.	Si.Gest Plus Capsule	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
380.	Re.Viter Plus Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
<b>M/s Sigma Life Pharmaceuticals,</b>		
<b>8-KM, Rawalpindi Road, Rawat (E. No. 00344)</b>		
381.	Melatonin Drops	
382.	Appy Syrup	
383.	Namgin Syrup	
384.	Mycid Syrup	
385.	Cran.F Sachet	
386.	W.Cran Sachet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
<b>M/s. Sindhco Nutraceutical</b>		
<b>6-D, Small Industrial Estate, 8-km, from Kasur, Ferozepur Road, Kasur (E. No. 00330)</b>		
387.	Max.X Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
388.	Obesigal Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
389.	Gifto Cold Men's Capsule	Deferred for the following reason: Form-3 is unsigned.

		Brand name and contents undertakings are missing. Fee receipt is missing
390.	Cobalasin Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
391.	Liferon Ultra Syrup	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
392.	Liferon Ultra Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
393.	Multisin.Plus Syrup	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
394.	Laxati.Pro Tablet	Deferred for the Evidence of fee submission and R and I receiving is required
395.	Craan Mx Liquid	Deferred for the Evidence of fee submission and R and I receiving is required
396.	Multisin.Plus Tablet	Deferred for the Evidence of fee submission and R and I receiving is required
397.	Osteo Cal Tablet	Deferred for the Evidence of fee submission and R and I receiving is required
398.	Dr. Uri+ Capsule	Deferred for the Evidence of fee submission and R and I receiving is required
399.	Cale.D Tablet	Deferred for the Evidence of fee submission and R and I receiving is required
400.	Vitz.C Plus Tablet	Deferred for the Evidence of fee submission and R and I receiving is required
401.	Spascure	Deferred for the Evidence of fee submission and R and I receiving is required
402.	Spasin Tablet	Deferred for the Evidence of fee submission and R and I receiving is required
403.	Metofer.F Tablet	Deferred for the Evidence of fee submission and R and I receiving is required
404.	Cale.D	
405.	Coliget Ultra Drops	
<b>M/s Tabros Pharma Pvt Ltd., Essa House 32-1-C, Block 6, P.E.C.H.S., Karachi</b>		
406.	Zepro Tablet	Deferred for the Evidence of fee submission and R and I receiving is required
407.	Calyxo Syrup	Deferred for the Evidence of fee submission and R and I receiving is required
408.	Zetex Tablet	Deferred for the Evidence of fee submission and R and I receiving is required
409.	Rancor Capsule	Deferred for the Evidence of fee submission and R and I receiving is required
410.	Livizab Capsule	Deferred for the Evidence of fee submission and R and I receiving is required
<b>M/s Tehseen Industries, [Nutraceutical Division] Plot NO.54/55B Punjab Small Industrial Estate 8-km Kasur, 44-KM Ferozpur Road, Lahore (E. No. 00714)</b>		
411.	OBSE Cal Syrup	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
412.	OBSE Pep Syrup	Deferred for the Evidence of fee submission and R and I receiving is required
413.	OBSE Fer.F Syrup	Deferred for the following reason:

		Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
414.	Levecare Syrup	Deferred for the Evidence of fee submission and R and I receiving is required
415.	OBSE Vit Syrup	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
416.	OBSE Kuf Syrup	Deferred for the Evidence of fee submission and R and I receiving is required
417.	OBSE Appe Syrup	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
418.	Fero.Malt Tablet	Deferred for the Evidence of fee submission and R and I receiving is required
419.	Immune C Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
420.	Cal Bone Syrup	Deferred for the Evidence of fee submission and R and I receiving is required
421.	Ctc.500 Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
422.	Vitexa Syrup	
423.	Alkacid Syrup	
424.	Ginko T Tablet	
425.	Pregnex Tablet	
426.	Appetix Tablet	
427.	Asomic Tablet	

**M/s Theramed Healthcare****45-KM Natha Khalsa, Multan Road, Lahore-Pakistan [Nutraceutical & Herbal Unani] (E. No. 00729)**

428.	E Coby Sachet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
429.	Bluakar Sachet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
430.	Appti Syrup	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
431.	IroVit Syrup	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
432.	Cougy Syrup	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
433.	CZ Berry Sachet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
434.	Cranta Sachet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
435.	Calty Effervescent Tablet	Deferred for the following reason:

		Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
436.	Meytesol Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
437.	Epyma Syrup	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
438.	Diamed Syrup	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
439.	Diacure Syrup	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
440.	Utiny Sachet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
441.	Dinta Effervescent Tablet	
442.	EC Plus Sachet	
443.	TriCal Effervescent Tablet	
<b>M/s. Trends Pharmaceuticals (Nutraceuticals &amp; Cam Division), Plot 546/ 547, Sundar Industrial Estate, Lahore (E. No. 00305)</b>		
444.	Malvit.D Drops	
445.	Litocran Sachet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
446.	Trenfer Tablet	Deferred for change of brand name
<b>M/s Vernon Nutraceutical (Pvt) Ltd Saggian Bridge Water Land Park, Street No. L-4, R-2, Plot-2, Faizpur Khurd, Lahore (E. No. 00276)</b>		
447.	N.Tacid Syrup	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
448.	Hyzotized Syrup	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
449.	Hyzocid Syrup	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
450.	Hyzovit Syrup	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
451.	Cacvit Syrup	
452.	Poietin Syrup	Deferred for change of brand name
<b>M/s Vida Laboratories, Karachi Plot No. 225, Sector 23, Korangi Industrial Area, Karachi (E. No. 00021)</b>		
453.	<b>C Q10 (Coenzyme Q10) 50mg Chewable Tablet</b>	Deferred for verification of testing facility of minerals
<b>M/s. Viegen Pharma (Pvt) Ltd, Plot No. 74-G, Sundar Industrial Estate, Sundar Raiwind Road, Lahore (E. No. 00313)</b>		
454.	Selbon Suspension	Deferred for verification of testing facility of minerals

455.	<b>KS-Multi Plus Tablet</b>	Deferred for verification of testing facility of minerals
456.	<b>KS-Bone Tablet</b>	Deferred for verification of testing facility of minerals
457.	<b>KS-Fast Tablet</b>	Deferred for verification of testing facility of minerals
458.	<b>KS-Multibol Syrup</b>	Deferred for verification of testing facility
<b>M/s Vital Phyto Pharma (Pvt) Ltd., GT Road, Sohawa, Chakwal Road, Distt: Rawalpindi (E. No. 00355)</b>		
459.	<b>Hemlit.HB Tablet</b>	Deferred for change of brand name and verification of testing facility of minerals
460.	<b>Fortn.D Tablet</b>	Deferred for provision of salts of the ingredients and verification of testing facility of minerals
461.	<b>Hemlit.HB Syrup</b>	Deferred for change of brand name
462.	<b>Brace.T Tablet</b>	Deferred for change of brand name and provision of salts of the ingredients and verification of testing facility of minerals
463.	<b>Brace.T Syrup</b>	Deferred for change of brand name and provision of salts of the ingredients and verification of testing facility of minerals
464.	<b>Possible Syrup</b>	Deferred for the following reasons: Brand name is to be change Justification of formulation is required. Specifications of ingredients are missing
465.	<b>Inspire Tablet</b>	Deferred for change of brand name and verification of testing facility of minerals
466.	<b>GRO. Plus Powder</b>	Deferred for change of brand name and provision of salts of the ingredients and verification of testing facility of minerals
467.	<b>Preneed Tablet</b>	Deferred for and verification of testing facility of minerals
468.	<b>Adoxide Extra Syrup</b>	Deferred for change of brand name and verification of testing facility of minerals
469.	<b>Cough Care Syrup</b>	Deferred for change of brand name
470.	<b>Hep.Detox Capsule</b> acid (USP) .75 mg	Deferred for change of brand name

<b>M/s Weather Folds Health Care, 69/2, Phase-II, Industrial Area Hattar (Nutraceutical) (E. No. 00463)</b>		
471.	Fenazon 10mg Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
472.	Zon.Q 100mg Capsule	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
473.	Proxceed Plus Sachet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
474.	Best.D 2000IU Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
475.	Melzon 5mg Drops	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
476.	Neurozon Syrup	Deferred for the following reason: Form-3 is unsigned.



		Brand name and contents undertakings are missing. Fee receipt is missing
477.	Melzon 3mg Tablet	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
478.	Kidzon Drops	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
479.	Melzon 5mg Tablet	
480.	Melzon 10mg Tablet	
481.	Zarnit 500mg Tablet	
482.	A+D Drops	
483.	Melzon 10mg Drops	
<b>M/s. Wilshire Laboratory (Pvt.) Ltd., Plot No.5, Farooq Industrial Estate, 20-KM, Ferozepur Road, Lahore (E. No. 00155)</b>		
484.	D+C Tablet	
485.	Benfoxin Capsule	Deferred for the following reason: Form-3 is unsigned. Brand name and contents undertakings are missing. Fee receipt is missing
<b>M/s. Xecutive Pharma 171-S, Quaid-e-Azam Industrial Estate, Kot Lakhpat, Lahore (E. No. 00312)</b>		
486.	Selgina.M Tab	Deferred for verification of testing facility for minerals
487.	Selgina.F Tab	Deferred for verification of testing facility for minerals
488.	Kal.3 Drops	

<b>M/s. Zestech Sciences Plot No. 48, Sector 23, Korangi Industrial Area, Karachi (E. No. 00117)</b>		
489.	Mapbone Tablet	Deferred for change of brand name and provision of specifications of ingredients
490.	Mapbone Plus Tablet	Deferred for change of brand name and provision of specifications of ingredients
<b>M/s Zonex Pharma (Pvt) Ltd., Plot No.121, Sundar Industrial Estate, Raiwind Road, Lahore (Nutraceutical) (E. No. 00558)</b>		
491.	Glutax.9GS Tablet	Approved with general claim

<b>M/s Selmore Agencies Pvt Ltd., located at 500 Shadman-1, Lahore agent of M/s Samu Median Co. Ltd., 235-15, Chusa-Ro, Sinam-Myeon, Yesan-Gun, Chungcheongnam-Do, Korea (E.No.01278)</b>		
1.	NoHeat-SSolublePowder	Deferred for mentioning the specifications and Salt of copper being used in the formulation.
2. L	VibaZonePowder	Deferred to seek clarification regarding Triple salt (Potassium Peroxymonosulfate) being a disinfectant complex composition for livestock. Justify the formulation as nutraceutical Health product under SRO 412.  Mention specifications of ingredients.
3.	BiogenPowder	Deferred to seek clarification is required regarding protease (proteolytic enzyme) since there are several proteolytic enzymes like bromelain, chymotrypsin, ficin, papain, serrapeptase, and trypsin. What type of Protease(s) beign used in the formulation?  Mention specifications of ingredients.
4.	PhospholigoLiquid	Deferred for mentioning the salt & specification of each elemental ingredient also provide alternative brand name is not provided.
5.	LiversoleLiquid	Deferred for provision of alternate brand name.

	Mention specifications of ingredients.
--	--

<b>M/sSportsOneInternationalTradingCo.,locatedatShopNo.1-2CrownMarketSinghpura,138-GT RoadLahoreagentofM/sGalvanizeNutritionKft,Columbusu.27.29/BBudapest1145Hungary(PrincipalManufacturer:M/sTuttiElelmiszeripariKft.,Pinkeret1.,9142Rabapaton,Hungary),(E.No.01146)</b>		
6.	<b>GalvanizeChrome100Isolate(Vanillaflavor)</b>	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> <li>• Original Free sale certificate issued by regulatory body and countersigned by the Embassy of Pakistan in country of origin not provided.</li> <li>• Long term and accelerated stability studies data of 3 batches as per requirement of Zone IV-A not provided.</li> <li>• Clarification regarding type of protein and carbohydrate used in the formulation is required.</li> <li>• Mention specifications of ingredients.</li> </ul>
7.	<b>GalvanizeChrome100whey(Chocolate)</b>	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> <li>• Original Free sale certificate issued by regulatory body and countersigned by the Embassy of Pakistan in country of origin not provided.</li> <li>• Long term and accelerated stability studies data of 3 batches as per requirement of Zone IV-A not provided.</li> <li>• Clarification regarding type of protein, fats and carbohydrate used in the formulation is required.</li> <li>• Mention specifications of ingredients.</li> </ul>
8.	<b>Galvanize100IsoZero</b>	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> <li>• Original Free sale certificate issued by regulatory body and countersigned by the Embassy of Pakistan in country of origin not provided.</li> <li>• Long term and accelerated stability studies data of 3 batches as per requirement of Zone IV-A not provided.</li> <li>• Clarification regarding type of protein, fats and carbohydrate used in the formulation is required.</li> <li>• Mention specifications of ingredients.</li> </ul>
9.	<b>GalvanizeChromeDrN.O</b>	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> <li>• Original Free sale certificate issued by regulatory body and countersigned by the Embassy of Pakistan in country of origin not provided.</li> <li>• Long term and accelerated stability studies data of 3 batches as per requirement of Zone IV-A not provided.</li> <li>• Mention specifications of ingredients.</li> </ul>
10.	<b>GalvanizeNutritionMassGainer(Chocolateflavor)</b>	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> <li>• Original Free sale certificate issued by regulatory body and countersigned by the Embassy of Pakistan in country of origin not provided.</li> <li>• Long term and accelerated stability studies data of 3 batches as per requirement of Zone IV-A not provided.</li> <li>• Clarification regarding type of protein, fats and carbohydrate used in the formulation is required.</li> <li>• Mention specifications of ingredients.</li> </ul>
11.	<b>GalvanizeNutritionMassGainer(Vanillaflavor)</b>	Deferred with final opportunity for the provision of following documents: <ul style="list-style-type: none"> <li>• Original Free sale certificate issued by regulatory body and countersigned by the Embassy of Pakistan in country of origin not provided.</li> <li>• Long term and accelerated stability studies data of 3 batches as per requirement of Zone IV-A not provided.</li> <li>• Clarification regarding type of protein, fats and carbohydrate used in the formulation is required.</li> <li>• Mention specifications of ingredients.</li> </ul>
12.	<b>GalvanizeChromeT-Max(Capsules)</b>	Deferred with final opportunity for the provision of following documents:

		<ul style="list-style-type: none"> <li>• Original Free sale certificate issued by regulatory body and countersigned by the Embassy of Pakistan in country of origin not provided.</li> <li>• Long term and accelerated stability studies data of 3 batches as per requirement of Zone IV-A not provided.</li> <li>• Mention specifications of ingredients.</li> </ul>
13.	<b>Galvanize Nutrition ZMBP RO (Capsules)</b>	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> <li>• Original Free sale certificate issued by regulatory body and countersigned by the Embassy of Pakistan in country of origin not provided.</li> <li>• Long term and accelerated stability studies data of 3 batches as per requirement of Zone IV-A not provided.</li> <li>• Mention specifications of ingredients.</li> </ul>
14.	<b>Galvanize Nutrition Daily Vitamin (Capsules)</b>	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> <li>• Original Free sale certificate issued by regulatory body and countersigned by the Embassy of Pakistan in country of origin not provided.</li> <li>• Long term and accelerated stability studies data of 3 batches as per requirement of Zone IV-A not provided.</li> <li>• Mention specifications of ingredients.</li> </ul>
15.	<b>Galvanize Nutrition C1000 (Capsules)</b>	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> <li>• Original Free sale certificate issued by regulatory body and countersigned by the Embassy of Pakistan in country of origin not provided.</li> <li>• Long term and accelerated stability studies data of 3 batches as per requirement of Zone IV-A not provided.</li> <li>• Mention specifications of ingredients.</li> </ul>
16.	<b>Galvanize Nutrition CA-MG (Tablets)</b>	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> <li>• Original Free sale certificate issued by regulatory body and countersigned by the Embassy of Pakistan in country of origin not provided.</li> <li>• Long term and accelerated stability studies data of 3 batches as per requirement of Zone IV-A not provided.</li> <li>• Mention specifications of ingredients.</li> </ul>
17.	<b>Galvanize Nutrition CLA Pro (Capsules)</b>	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> <li>• Original Free sale certificate issued by regulatory body and countersigned by the Embassy of Pakistan in country of origin not provided.</li> <li>• Long term and accelerated stability studies data of 3 batches as per requirement of Zone IV-A not provided.</li> <li>• Mention specifications of ingredients.</li> </ul>
18.	<b>Galvanize Nutrition Omega 3 Fatty acids (Capsules)</b>	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> <li>• Original Free sale certificate issued by regulatory body and countersigned by the Embassy of Pakistan in country of origin not provided.</li> <li>• Long term and accelerated stability studies data of 3 batches as per requirement of Zone IV-A not provided.</li> <li>• Mention specifications of ingredients.</li> </ul>
19.	<b>Galvanize Nutrition Carni Pro (Capsules)</b>	<p>Deferred with final opportunity for the provision of following documents:</p> <ul style="list-style-type: none"> <li>• Original Free sale certificate issued by regulatory body and countersigned by the Embassy of Pakistan in country of origin not provided.</li> <li>• Long term and accelerated stability studies data of 3 batches as per requirement of Zone IV-A not provided.</li> <li>• Mention specifications of ingredients.</li> </ul>
<b>M/s DXN International Pakistan (Pvt) Limited, located at the address 2nd Floor, OPF Building, Plot # 20-A/II, Block 6, P.E.C.H.S Shahrah-e-Faisal, Karachi agent of M/s DXN Pharmaceutical SDN. BHD address Lot 1109, Mukim MA Lau, DAERAH, KUBANG Pssu 06000 Jitra Kedah Malaysia (E. No. 00839)</b>		
20.	<b>Roselle Tablet</b>	EEC decided to accede the request of firm for the extension of time for the submission of documents upto 31.03.2023.

21.	<b>Mycovita Sachet</b>	EEC decided to <b>accede</b> the request of firm for the extension of time for the submission of documents upto 31.03.2023.
22.	<b>DXN Ganocelium Capsule</b>	EEC decided to <b>accede</b> the request of firm for the extension of time for the submission of documents upto 31.03.2023.
23.	<b>DXN ReishiGano Capsule</b>	EEC decided to <b>accede</b> the request of firm for the extension of time for the submission of documents upto 31.03.2023.
<b>M/s Chemist International, located at the address, Alhamd Garden Phase-I, House No. 1, Main Street Near Alsaeed Chowk MozaBuddoo, Tehsil Feroz Wala District Shekhupura agent of M/s Labiana Life Sciences, C/Venus 26, Pol. Ind. Can Parellada, Tarrasa 08228, Barcelona, Spain (E. No. 01047)</b>		
24.	<b>Easy Breath Liquid</b>	Deferred due to following reasons: <ul style="list-style-type: none"> <li>• Brand name is inappropriate needs to be changed.</li> <li>• Mention specifications of ingredients.</li> </ul>
25.	<b>Easy Immune Liquid</b>	<ul style="list-style-type: none"> <li>• The applied formulation is a Liquid to be dispensed in Liters. However, strength of Vitamin E is given as 100mg per gram.</li> <li>• Brand name is inappropriate needs to be changed.</li> <li>• Mention specifications of ingredients.</li> </ul>
<b>M/s Leven Medical Care, located at Office No. 8-C, Street 3, Shah Jamal, Lahore, agent of M/s HC Clover Prductos Y Servicios S.L. C/ Alicante, 8-10, Arganda del Rey, 28500 Madrid Spain (E. No. 01227)</b>		
26.	<b>Fertybiotic Man Capsule</b>	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Provide original free sale certificate (copy is provided which is issued by Ministry of Health) and stability studies data as per requirement of zone IV A.</li> <li>• Mention of salt of zinc being used in the formulation.</li> <li>• Mention specifications of ingredients.</li> </ul>
27.	<b>Fertybiotic Women Plus Sachet</b>	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Provide original free sale certificate (copy is provided which is issued by Ministry of Health) and stability studies data as per requirement of zone IV A.</li> <li>• Furthermore the applied formulation contains Melatonin (1.8mg) which is registered as drug.</li> <li>• Mention specifications of ingredients.</li> </ul>
28.	<b>Fertybiotic Women Sachet</b>	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Provide original free sale certificate (copy is provided which is issued by Ministry of Health) and stability studies data as per requirement of zone IV A.</li> <li>• Furthermore the applied formulation contains Melatonin (1mg) which is registered as drug.</li> <li>• Mention specifications of ingredients.</li> </ul>
29.	<b>Fertybiotic Pregnancy Capsule</b>	Deferred for following reasons: <ul style="list-style-type: none"> <li>• Provide original free sale certificate (copy is provided which is issued by Ministry of Health) and stability studies data as per requirement of zone IV A.</li> <li>• Mention salt of each elemental ingredient.</li> <li>• Mention specifications of ingredients.</li> </ul>
<b>• M/s Ali Poultry Enterprises, located at Mughal Pura No.3, Road Kot Amin-ul-Din, Faisalabad, agent of M/s Toni Bio, 23 Rue Saint-Aubin, 22120 Yffiniac, France (Principal Manufacturer: M/s Deltavit, Zac Des Chatelets 2 Rue Jean Kerisel 22950 Tregueux, France)( E. No. 01255)</b>		
30.	<b>Toni Liver Liquid</b>	<ul style="list-style-type: none"> <li>• Deferred for provision of appropriate brand name and justification of use of sorbitol syrup as active ingredient.</li> <li>• Mention specifications of ingredients.</li> </ul>

31.	<b>Toni Hotlyte Liquid</b>	Deferred for mentioning of salt and specification of each elemental ingredient.
32.	<b>Star Phos Liquid</b>	EEC considered the alternative brand name as “ <b>Star PHos Plus Liquid</b> ” submitted by the firm. However, decided to defer the case for mentioning of salt and specification of each elemental ingredient.
33.	<b>Toni Fin Plus E Liquid</b>	Deferred for provision of specification of each ingredient being used in the formulation.
34.	<b>Toni Phose Plus Liquid</b>	Deferred for mentioning of salt and specification of each elemental ingredient.
35.	<b>Toni Myconil Plus Liquid</b>	<ul style="list-style-type: none"> <li>Deferred for mentioning of salt of potassium. Justify the use of Mono Propylene Glycol and Sorbitol as active ingredient.</li> <li>Mention specifications of ingredients.</li> </ul>
36.	<b>Toni Garlix Liquid</b>	<p>Deferred with <b>final opportunity</b> to submit following deficiency:</p> <ul style="list-style-type: none"> <li>Long term stability studies data of 3 batches for the period of 2 years according to the requirement of Zone IV-A not provided.</li> <li>Mention specifications of ingredients.</li> </ul>
37.	<b>Toni Vit E Sel 20% Liquid</b>	<ul style="list-style-type: none"> <li>Deferred for mentioning of salt of selenium being used in the formulation.</li> <li>Mention specifications of ingredients.</li> </ul>
<b>M/s Sattar Agro&amp; Livestock, located at Rana Nisar Road, Off Defense Road, Bohbtian Chowk, Lahore, an agent of M/s VetPlanet d.o.o. Vršac, Serbia Vojvodanskihbrigada 16, Vrsac, Tehnoloski park bb, Business Incubators 6-8, Versac, Serbia (E. No. 01175)</b>		
38.	<b>Hairball Free Gel</b>	<p>Deferred with final opportunity for fulfillment of following deficiencies:</p> <ul style="list-style-type: none"> <li>Brand name is not appropriate, needs to be changed.</li> <li>Justify the applied formulation as nutraceutical health product.</li> <li>Mention specifications of ingredients.</li> </ul>
<b>• M/s Thermion Pharmaceuticals &amp; Chemicals (Pvt.) Ltd., 147/5, Block B, Labour Colony, Off Defense Road, Lahore, an agent of M/s Jinan GSY Biotechnology Co. Ltd., 296 Km, 700 Meters, 220 State Highway, Xiaoli Town, Changqing District Jinan City, Shangdong Province, China (E. No. 01095)</b>		
39.	<b>Thermo Immune Oral Solution</b> Zinc ....1000 mg	<ul style="list-style-type: none"> <li>Deferred for mentioning of salt of selenium &amp; zinc. Justify the use of Propylene Glycol as active ingredient.</li> <li>Mention specifications of ingredients.</li> </ul>
40.	<b>Zincar-C 130 Oral Liquid</b>	Deferred for mentioning of specifications of ingredients and justify the use of fruit sugar as active ingredient.
41.	<b>Thermo Mix Powder</b>	<p>Deferred for mentioning of salt of each elemental ingredient. Clarification is required for by pass fat and live yeast as active ingredient.</p> <p>Mention specification of each ingredient.</p>
42.	<b>HiGrow 80 Oral Solution</b>	Deferred for provision of specifications of each ingredient being used in the formulation.
43.	<b>Vetmoin T Plus Powder</b>	<p>Deferred for mentioning of salt of each elemental ingredient.</p> <p>Mention specification of each ingredient.</p>
<b>• M/s. Jawad Impex International, located at 21-Iftikhar Building, Chouburji, Lahore is Agent of M/s. INTRACARE BV Voltaweg 4, 5466 AZ VEGHEL The Netherlands (E. No. 00116)</b>		
44.	<b>Intra Epidine Liquid</b>	<ul style="list-style-type: none"> <li>Deferred with <b>final opportunity</b> for fulfillment of following deficiency:</li> <li>CoPP provided by the firm is not notarized and countered signed by Embassy of Pakistan.</li> <li>Mention specification of each ingredient.</li> </ul>
45.	<b>Intra Hoof-Fit Gel</b>	<p>Deferred with <b>final opportunity</b> for fulfillment of following deficiency:</p> <ul style="list-style-type: none"> <li>CoPP provided by the firm is not notarized and countered signed by Embassy of Pakistan.</li> <li>Mention specification of each ingredient.</li> </ul>



M/s Daata Impex, H. No. 206, Imperial I, Paragon City, Burki Road, Lahore, an agent of M/s Wuhan Sunhy Biology Co., Ltd., No. 98, Guanggu 8 <sup>th</sup> Road, East Lake High-tech Development Zone, Wuhan City, Hubei Province, P.R. China (E. No. 01168)		
46.	<b>Sunphase HT 1000 Ultrafine Powder</b>	EEC decided to <b>accede</b> the request of firm for the extension of time for the submission of Free Sale Certificate and change of formulation upto 31.03.2023. Brand Name is not appropriate, needs to be changed
M/s New Global Enterprises, Suite 2-A, 2 <sup>nd</sup> floor, Block 10/3, Prince Cant, Bahadurabad, Karachi-Pakistan is an agent of Principal Manufacturer: M/s Seri MH Ummsdn. Bhd. Bt 2, Kawasan Perindustrian MARA Jalan Padang TembakPengkalanChepa 16100 Kota Bharu Kelantan Malaysia (M/s Intan Biotech Industries SDN BHD, LOT 2475, JLN 2/44 Kawasan PerindustriesPengkalanCehpa I I, 16100 Kota Bahru Kelantan, Malaysia (hereinafter called "The Supplier of SUSU UNTA") (E. No. 00513		
47.	<b>Wax Zat Ear Drops</b>	Deferred with <b>final opportunity</b> for the provision of following deficiencies: <ul style="list-style-type: none"> <li>Stability and accelerated stability studies data of 3 batches as per requirement of Zone IV-A is not provided.</li> <li>Registration/market authorization of the product in the country of origin not provided.</li> <li>GMP certificate not provided.</li> <li>Mention specification of each ingredient.</li> </ul>
48.	<b>NasozafInhation Drop</b>	Deferred with <b>final opportunity</b> for the provision of following deficiencies: <ul style="list-style-type: none"> <li>Stability and accelerated stability studies data of 3 batches as per requirement of Zone IV-A is not provided.</li> <li>Registration/market authorization of the product in the country of origin not provided.</li> <li>GMP certificate not provided.</li> <li>Mention specification of each ingredient.</li> </ul>
M/s Sports One International Trading Co., located at Shop No. 1-2 Crown Market Singhapura, 138-GT Road Lahore, agent of M/s Applied Nutrition Ltd., 17 Webber Estate, Webber Road, Knowsley, Industrial Park Knowsley L33 7SQ, United Kingdom (E. No. 01229)		
49.	<b>Applied Nutrition CLA Gold softgels</b>	Deferred with <b>final opportunity</b> for the provision of following deficiencies: <ul style="list-style-type: none"> <li>Original Notarized fee sale certificate, countersigned by the embassy of Pakistan in the country of Origin is not provided.</li> <li>Long Term and accelerated Stability Studies data of 3 batches as per the requirement of Zone IV-A not provided.</li> <li>Change of brand name.</li> <li>Mention specification of each ingredient.</li> </ul>
50.	<b>Applied Nutrition ISO-XP Powder</b>	Deferred with <b>final opportunity</b> for the provision of following deficiencies: <ul style="list-style-type: none"> <li>Original Notarized fee sale certificate, countersigned by the embassy of Pakistan in the country of Origin is not provided.</li> <li>Long Term and accelerated Stability Studies data of 3 batches as per the requirement of Zone IV-A not provided.</li> <li>Clarify the applied formulation as nutraceutical health product.</li> <li>Mention specification of each ingredient.</li> </ul>
51.	<b>Applied Nutrition L-Carnitine Capsules</b>	Deferred with <b>final opportunity</b> for the provision of following deficiencies: <ul style="list-style-type: none"> <li>Original Notarized fee sale certificate, countersigned by the embassy of Pakistan in the country of Origin is not provided.</li> <li>Long Term and accelerated Stability Studies data of 3 batches as per the requirement of Zone IV-A not provided.</li> <li>Mention specification of each ingredient.</li> </ul>

52.	Applied Nutrition Multivitamin Complex Capsules	Deferred with <b>final opportunity</b> for the provision of following deficiencies: <ul style="list-style-type: none"> <li>• Original Notarized fee sale certificate, countersigned by the embassy of Pakistan in the country of Origin is not provided.</li> <li>• Long Term and accelerated Stability Studies data of 3 batches as per the requirement of Zone IV-A not provided.</li> <li>• Mention salt of each elemental ingredient being used in formulation.</li> <li>• Mention specification of each ingredient.</li> </ul>
53.	<b>Applied Nutrition shred x capsules</b>	Deferred with <b>final opportunity</b> for the provision of following deficiencies: <ul style="list-style-type: none"> <li>• Original Notarized fee sale certificate, countersigned by the embassy of Pakistan in the country of Origin is not provided.</li> <li>• Long Term and accelerated Stability Studies data of 3 batches as per the requirement of Zone IV-A not provided.</li> <li>• Mention salt of chromium.</li> <li>• Mention specification of each ingredient.</li> </ul>
54.	<b>Applied Nutrition TRI-OMEGA Softgels</b>	Deferred with <b>final opportunity</b> for the provision of following deficiencies: <ul style="list-style-type: none"> <li>• Original Notarized fee sale certificate, countersigned by the embassy of Pakistan in the country of Origin is not provided.</li> <li>• Long Term and accelerated Stability Studies data of 3 batches as per the requirement of Zone IV-A not provided.</li> <li>• Mention specification of each ingredient.</li> </ul>
55.	<b>Applied Nutrition Vitamin B12 Tablets</b>	Deferred with <b>final opportunity</b> for the provision of following deficiencies: <ul style="list-style-type: none"> <li>• Original Notarized fee sale certificate, countersigned by the embassy of Pakistan in the country of Origin is not provided.</li> <li>• Long Term and accelerated Stability Studies data of 3 batches as per the requirement of Zone IV-A not provided.</li> <li>• Mention specification of each ingredient.</li> </ul>
56.	<b>Applied Nutrition Vitamin C Tablets</b>	Deferred with <b>final opportunity</b> for the provision of following deficiencies: <ul style="list-style-type: none"> <li>• Original Notarized fee sale certificate, countersigned by the embassy of Pakistan in the country of Origin is not provided.</li> <li>• Long Term and accelerated Stability Studies data of 3 batches as per the requirement of Zone IV-A not provided.</li> <li>• Mention specification of each ingredient.</li> </ul>
57.	<b>Applied Nutrition Vitamin D3 Tablets</b>	Deferred with <b>final opportunity</b> for the provision of following deficiencies: <ul style="list-style-type: none"> <li>• Original Notarized fee sale certificate, countersigned by the embassy of Pakistan in the country of Origin is not provided.</li> <li>• Long Term and accelerated Stability Studies data of 3 batches as per the requirement of Zone IV-A not provided.</li> <li>• Mention specification of each ingredient.</li> </ul>
58.	Applied Nutrition ZMA PRO CAPSULES	Deferred with <b>final opportunity</b> for the provision of following deficiencies: <ul style="list-style-type: none"> <li>• Original Notarized fee sale certificate, countersigned by the embassy of Pakistan in the country of Origin is not provided.</li> <li>• Long Term and accelerated Stability Studies data of 3 batches as per the requirement of Zone IV-A not provided.</li> <li>• Mention salt of zinc and magnesium being used in formulation.</li> <li>• Mention specification of each ingredient.</li> </ul>

<b>M/s BroMed Animal Health, 246-A, West Wood Colony Thokar Niaz Baig Lahore, an agent of M/s Eckel Animal Nutrition, GmbH &amp; Co., KG ImStiefelfeld 10 D-56651 Niederzissen, Germany (E. No. 00886)</b>		
59.	Anta Mix ME Powder	Deferred with <b>final opportunity</b> for the provision of following deficiencies: <ul style="list-style-type: none"> <li>• Application is not submitted on prescribed form 5.</li> <li>• Long term and accelerated stability studies data of 3 batches as per the condition of Zone IV-A not provided.</li> <li>• Formulation contains Microencapsulated acid clarification is required what type of acid being encapsulated and at what strength.</li> <li>• Original and notarized free sale certificate countersigned by the Embassy of Pakistan in the country of origin in not provided.</li> <li>• Strength of active ingredients is given in Percentage.</li> <li>• Mention specification of each ingredient.</li> </ul>
<b>M/s Faiz Ismail &amp; Sons, E-991/B, Nadirabad No.2, Bedian Road, Lahore, an agent of M/s Regilait SAS, 102 RD 906, Saint Martin Belle Roche, CS, 20309, 71009, Macon, France (E. No. 01157)</b>		
60.	France Lait 1 Powder	Deferred with <b>final opportunity</b> for the provision of following deficiencies: <ul style="list-style-type: none"> <li>• Needs clarification regarding the type of Vitamin K used in formulation.</li> <li>• Long term and accelerated stability studies data as per the requirement of Zone IV A not provided.</li> <li>• Provided exact strength of Fluoride used in formulation.</li> <li>• Mention salt of each elemental ingredient.</li> <li>• Mention specification of each ingredient.</li> </ul>
61.	France Lait 2 Powder	Deferred with <b>final opportunity</b> for the provision of following deficiencies: <ul style="list-style-type: none"> <li>• Needs clarification regarding the type of Vitamin K used in formulation.</li> <li>• Long term and accelerated stability studies data as per the requirement of Zone IV A not provided.</li> <li>• Provided exact strength of Fluoride used in formulation.</li> <li>• Mention salt of each elemental ingredient.</li> <li>• Mention specification of each ingredient.</li> </ul>
62.	France Lait LF Powder	Deferred with <b>final opportunity</b> for the provision of following deficiencies: <ul style="list-style-type: none"> <li>• Needs clarification regarding the type of Vitamin K used in formulation.</li> <li>• Long term and accelerated stability studies data as per the requirement of Zone IV A not provided.</li> <li>• Provided exact strength of Fluoride, chromium and Molybdenum used in formulation.</li> <li>• Mention salt of each elemental ingredient.</li> <li>• Mention specification of each ingredient.</li> </ul>
63.	France Lait 3 Powder	Deferred with <b>final opportunity</b> for the provision of following deficiencies: <ul style="list-style-type: none"> <li>• Needs clarification regarding the type of Vitamin K used in formulation.</li> <li>• Long term and accelerated stability studies data as per the requirement of Zone IV A not provided.</li> <li>• Provided exact strength of Fluoride used in formulation.</li> <li>• Mention salt of each elemental ingredient.</li> <li>• Mention specification of each ingredient.</li> </ul>
<b>M/s Brand Station, 89 A2, Wapda Town Extension, Lahore, agent of M/s Inner Mongolia Huatian Pharmaceutical Co. Ltd., Development and Experiment Zone for Economical Transformation of Resource Dependent City, Chifeng, Inner Mongolia, China (E. No. 01217)</b>		
64.	Anti-Virus Oral Solution	Deferred with <b>final opportunity</b> for the provision of following deficiencies: <ul style="list-style-type: none"> <li>• Original free sale certificate issued by the regulatory body and countersigned by the embassy of Pakistan is not provided.</li> <li>• Accelerated Stability Studies data of 3 batches according to the requirement of Zone IV-A not provided.</li> </ul>

		<ul style="list-style-type: none"> <li>• Clarification is required regarding use and role of APN in formulation.</li> <li>• Brand Name is not appropriate, needs to be changed.</li> <li>• Mention specification of each ingredient.</li> </ul>
65.	<b>Lysozyme Water Soluble Powder</b>	<p>Deferred with <b>final opportunity</b> for the provision of following deficiencies:</p> <ul style="list-style-type: none"> <li>• Original free sale certificate issued by the regulatory body and countersigned by the embassy of Pakistan is not provided.</li> <li>• Accelerated Stability Studies data of 3 batches according to the requirement of Zone IV-A not provided.</li> <li>• Mention specification of each ingredient.</li> <li>•</li> </ul>
<p align="center"><b>M/sProspectGroup(Pvt.)Ltd,125-UpperMall,LahoreagentofM/sNutraManufacturing,1050WoodruffRoad,Greenville,SC29607.Subsidiaryof GeneralNutritionCorporation(GNC),USA(E.No.00299</b></p>		
557.	<b>GNCIsomerECapsule</b>	<p>Deferred with <b>final opportunity</b> for the provision of following deficiencies:</p> <ul style="list-style-type: none"> <li>• Brand Name mentioned on Form 5 is GNC Isomer E Capsule</li> <li>• Capsule and brand name given on Exhibit A attached copy of Certificate of Free Sale is Isomer E Capsule, needs clarification.</li> <li>• Accelerated and long term stabilities data of three (03) batches is required according to requirement of Zone IV A.</li> <li>• Mention specification of each ingredient</li> </ul>
558.	<b>GNCKidsEyeHealthChewableTablet</b>	<p>Deferred with <b>final opportunity</b> for the provision of following deficiencies:</p> <ul style="list-style-type: none"> <li>• Brand Name mentioned on Form 5 is GNC Kids Eye Health Chewable Tablet</li> <li>• Capsule and brand name given on Exhibit A attached copy of Certificate of Free Sale is Kids Eye Health Chewable Tablet, needs clarification.</li> <li>• Accelerated and long term stabilities data of three (03) batches is required according to requirement of Zone IV A.</li> <li>• Mention specification of each ingredient.</li> </ul>
559.	<b>GNCBrightenCapsule</b> EachCapsulecontains:	<p>Deferred with <b>final opportunity</b> for the provision of following deficiencies:</p> <ul style="list-style-type: none"> <li>• Brand Name mentioned on Form 5 is GNC Brighten Capsule and brand name given on COA is Skin lightening Pil Vegetable Hard-shell capsule, needs clarification.</li> <li>• Accelerated and long term stabilities data of three (03) batches is required according to requirement of Zone IV A.</li> <li>• Valid and Notarized free sale certificate attested by the regulatory body in the country of origin and countersigned by the Embassy of Pakistan in the country of origin</li> <li>• Mention specification of each ingredient.</li> </ul>
560.	<b>GNC PNStressSupportCaplets</b>	<p>Deferred with <b>final opportunity</b> for the provision of following deficiencies:</p> <ul style="list-style-type: none"> <li>• Brand Name mentioned on Form 5 is GNC PN Stress Support Caplets and brand name given on Exhibit A attached copy of Certificate of Free Sale is PN Stress Support Caplets, needs clarification.</li> <li>• Monograph of Magnolia Bark Extract and Phellodendron Bark Extract are required.</li> <li>• Accelerated and long term stabilities data of three (03) batches is required according to requirement of Zone IV A.</li> <li>• Mention specification of each ingredient.</li> </ul>

561.	<b>GNC Inositol 500 Tablet</b>	Deferred with <b>final opportunity</b> for the provision of following deficiencies: <ul style="list-style-type: none"> <li>• Brand Name mentioned on Form 5 is GNC Inositol 500 Tablet</li> <li>• and brand name given on Exhibit A attached copy of Certificate of Free Sale is Inositol 500 Tablet, needs clarification.</li> <li>• Accelerated and long term stabilities data of three (03) batches is required according to requirement of Zone IV A.</li> <li>• Mention specification of each ingredient.</li> </ul>
562.	<b>GNC (INTL) AMP GOLD Thermo Tablet</b>	Deferred with <b>final opportunity</b> for the provision of following deficiencies: <ul style="list-style-type: none"> <li>• Brand Name mentioned on Form 5 is GNC (INTL) AMP GOLD Thermo Tablet and brand name given on Exhibit A attached copy of Certificate of Free Sale is INTL AMP GOLD Thermo Tablet, needs clarification.</li> <li>• Accelerated and long term stabilities data of three (03) batches is required according to requirement of Zone IV A.</li> <li>• Mention specification of each ingredient.</li> </ul>
<b>M/s Mcpharm International, 721, J-II, Johar Town Lahore - Pakistan is agent of M/s Aniva International S.A., 3 Kifissias Av., 15123 Maroussi Athens, Greece (Principal Manufacturer) M/s Lifeplan Products Ltd., Elizabethan Way, Lutterworth, Leicestershire LE17 4ND, United Kingdom (E.No.00432)</b>		
1.	<b>Lifeplan - Eye C</b>	Deferred with <b>final opportunity</b> for mentioning of specification of each active ingredient.

<b>M/s Brand Station, 89 A2, Wapda Town Extension, Lahore agent of M/s Sen Tarim Ve Sanayi A.S, Bugdayli Mah. Ta stepe Mevkii, Bandirma Organize, Sanayi Bolgesi, 4. Cadde No. 5, Gonen/Balikesir, Turkey (E.No.01147)</b>		
63.	<b>Nutri Liver Tonic</b> Each Liter contains: Vitamin B1.....3.5,00mg Vitamin B2.....1.000mg Vitamin B6.....3.5,00mg Vitamin B12.....15mg Vitamin C.....5.000mg Niacin.....25.000mg Calcium Pan...5.000mg D-Biotin...100mg Sorbitol....50.000mg Propylene Glycol....200.000mg Potassium Sorbate....500mg	Deferred with <b>final opportunity</b> for the provision of following deficiencies: <ul style="list-style-type: none"> <li>• Brand name needs to be changed.</li> <li>• Mention specification of each ingredient.</li> </ul>
<b>M/s Pak Care International Company, Al-Qadir Garden 203 RB Manawala, Faisalabad - Pakistan agent of M/s Reva Tarim Kimya San. Vet Tic. Ltd. STI, Tatlicak MAH Vatan Sanayi Sitesi Kavaf Sokak No :43-45-47-49-51 Karatay, Konya - Turkey (Veterinary) (E.No.00527)</b>		
64.	<b>Liver Active</b>	
<b>M/s GlaxoSmithKline Consumer Healthcare Pakistan Limited, 35- Dockyard Road, West Wharf Road, Karachi agent of M/s Pfizer Consumer Manufacturing, Italy, S.r.L, Via Nettuno 90, 04011, Aprilia, Italy (E.No.01312)</b>		
1.	<b>Centrum Adult Tablet</b>	Since the matter is referred to the Authority, therefore EEC decided to defer the application till the decision/direction of the Authority.

2.	<b>CentrumAdultTablet</b>	Since the matter is referred to the Authority, therefore EEC decided to defer the application till the decision/ direction of the Authority.
<b>M/sQASInternational,locatedattheaddressOppositeKingMall,NearWAPDATown,G.TRoad,Gujranwalaisa nagentofM/sSUPER'SDIANA,S.L.,CTRA.C-17,KM17,08150ParetsdelValles–Spain(E.No.00866)</b>		
3.	<b>ImpakOralSolution(Vet)</b>	Deferred with <b>final opportunity</b> for the provision of following deficiencies: <ul style="list-style-type: none"> <li>• Original and Notorized fee sale certificate issued by the regulatory body and countersigned by the Embassy of Pakistan is not provided by the firm.</li> <li>• Mention specification of each ingredient.</li> <li>•</li> </ul>
<b>M/s Add Leven Pharma (SMC-Pvt.) Ltd., SuiteNo.6, FirstFloor, Paramount Plaza,G-15 Markaz, Islamabad, asan agent of M/sValueMed Pharma S.r.l located at Via28 Luglio ,211, 47893 Borgo Maggiore, Rep. San Marino, Italy (Principal Manufacturer: M/s Erbe S.r.l located at Via Del Laghetto, n110, Badia Polesine (Rovigo), Italy(E.No.00982)</b>		
4.	<b>BestBerryTablet</b>	EEC decided to defer the application for further deliberations on common molecule i.e. saccharomyces boulardii.
5.	<b>Memory Tablet</b>	Deferred for change of brand name.
6.	<b>Prostaparen Tablet</b>	Deferred to seek clarification actual amount of selenium delivered by 0.55mg of sodium selenite being used in formulation.
7.	<b>Lipid Low Tablet</b>	The applied formulation contains Berberis dry extract which is a toxic ingredient hence prohibited under SRO 412(I)/2014.
8.	<b>NutriJoint Tablet</b>	Deferred for mentioning of salt of magnesium.  Explain the comparative advantage of using Shark Cartilage also co-related it with clinical parameters.  Mention specification of each ingredient.  Also provide Halal certificate of product.
9.	<b>Entero Junior Oral AMP</b>	Mention individual strength of probiotic specie being used in the formulation.  Mention specification of each ingredient.
10.	<b>Probiotics &amp; Vitamins Oral AMP</b>	Mention individual strength of probiotic specie being used in the formulation.  Mention specification of each ingredient.
11.	Gynepink Remedy Pessaries	The applied dosage form i.e. Pessaries is not defined as Alternative Medicine and Health Products Dosage Form in Guidelines approved for Manufacturer/Importer of “Food Supplement” or “Dietary Supplement” or “Health supplement” or Nutraceuticals issued in compliance with paragraph 50 of the judgment dated 26th February, 2018 passed by the Hon’ble High Court of Sindh, Karachi in Constitution Petition No. D-4387 of 2014 and other connected petitions
<b>M/sAmanTraders,11/1D,PeopleColonyNo.1,Faisalabad agent of M/s PEKANA Natur heilmittel Gmb HR aiffeisenstrasse15,88353 Kisslegg, Germany (E.No.0030)</b>		
563.	Graphites(Alc96%)Potency Graphites.3x.30,200,1M,10M, 50M,CM	Deferred with <b>final opportunity</b> for the provision of following deficiencies: <ul style="list-style-type: none"> <li>provide Long term and accelerated stability studies data as per the requirement of Zone IV A.</li> <li>Graphite potency below 6x cannot be enlisted.</li> <li>Mention specification of each ingredient.</li> </ul>
564.	Ipecacuanha(Alc96%)Potency Ipecacuanha3x,3C.30X,200X, 200C,1M,10M,50M,CM	Deferred with <b>final opportunity</b> for the provision of following deficiencies: <ul style="list-style-type: none"> <li>Provide Long term and accelerated stability studies data as per the requirement of Zone IV A.</li> <li>Mention specification of each ingredient.</li> </ul>



565.	Sepia(Alc96%)Potency Sepia3x.30,200,1M,10M,50M, CM	Deferred with <b>final opportunity</b> for the provision of following deficiencies: provide Long term and accelerated stability studies data as per the requirement of Zone IV A.  Mention specification of each ingredient.
566.	Silicea(Alc96%)Potency Silicea3x.30,200,1M,10M,50 M,CM	Deferred with <b>final opportunity</b> for the provision of following deficiencies: provide Long term and accelerated stability studies data as per the requirement of Zone IV A.  Mention specification of each ingredient.
567.	Sulphur(Alc96%)Potency Sulphur3x.30,200,1M,10M,50 M,CM	Deferred with <b>final opportunity</b> for the provision of following deficiencies: provide Long term and accelerated stability studies data as per the requirement of Zone IV A.  Mention specification of each ingredient.
568.	TeucriumMarumverum(Alc96 )Potency Teucrium3x.30,200,1M,10M,5 0M,CM	Deferred with <b>final opportunity</b> for the provision of following deficiencies: provide Long term and accelerated stability studies data as per the requirement of Zone IV A.  Mention specification of each ingredient.
569.	Ignatia(Alc96%)Potency IgnatiaAmara3x.30,200,1M,10 M,50M,CM	Deferred with <b>final opportunity</b> for the provision of following deficiencies: provide Long term and accelerated stability studies data as per the requirement of Zone IV A.  Mention specification of each ingredient.
570.	KaliBichromaticum1(Alc96%)P otency KaliBichromaticum3x.30,200,1 M,10M,50M,CM	Deferred with <b>final opportunity</b> for the provision of following deficiencies: provide Long term and accelerated stability studies data as per the requirement of Zone IV A.  Mention specification of each ingredient.
571.	KaliPhosphoricum(Alc96%)Po tency KaliPhosphoricum3x.30,200,1 M,10M,50M,CM	Deferred with <b>final opportunity</b> for the provision of following deficiencies: provide Long term and accelerated stability studies data as per the requirement of Zone IV A.  Mention specification of each ingredient.
572.	Lycopodium(Alc96%)Potency Lycopodium3x.30,200,1M,10 M,50M,CM	Deferred with <b>final opportunity</b> for the provision of following deficiencies: provide Long term and accelerated stability studies data as per the requirement of Zone IV A.  Mention specification of each ingredient.
573.	MercuriusSolubHahnemanni( Alc96%)Potency MercuriusSolubHahnemanni3x .30,200,1M,10M,50M,CM	Deferred with <b>final opportunity</b> for the provision of following deficiencies: provide Long term and accelerated stability studies data as per the requirement of Zone IV A. Mercurius Solub Hahnemanni potency below 6x cannot be enlisted.  Mention specification of each ingredient.
574.	Magnesium Phosphoricum (Alc 96%) Potency MagneisumPhosphoricum 3x.30,200,1M,10M,50M,CM	Deferred with <b>final opportunity</b> for the provision of following deficiencies: provide Long term and accelerated stability studies data as per the requirement of Zone IV A.  Mention specification of each ingredient.
575.	NatriumMuriaticum (Alc 96%) Potency NatriumMuriaticum 3x.30,200,1M,10M,50M,CM	Deferred with <b>final opportunity</b> for the provision of following deficiencies: provide Long term and accelerated stability studies data as per the requirement of Zone IV A.

		Mention specification of each ingredient.
576.	MercuriusSublimatCorrosiv (Alc 96%) Potency MercuriusSublimatCorrosiv 3x,30,200,1M,10M,50M,CM	Deferred with <b>final opportunity</b> for the provision of following deficiencies: provide Long term and accelerated stability studies data as per the requirement of Zone IV A. MercuriusSublimatCorrosiv (Alc 96%) potency below 6x cannot be enlisted.  Mention specification of each ingredient.
577.	RhusToxicodendron (Alc 96%) Potency RhusToxicodendron 3x, 3C.30X,200X, 200C,1M,10M,50M,CM	Deferred with <b>final opportunity</b> for the provision of following deficiencies: provide Long term and accelerated stability studies data as per the requirement of Zone IV A.  Mention specification of each ingredient.
578.	Calcium Flouratum (Alc 96%) Potency CalcareoFluorica 3x,30,200,1M,10M,50M,CM	Deferred with <b>final opportunity</b> for the provision of following deficiencies: provide Long term and accelerated stability studies data as per the requirement of Zone IV A.  Mention specification of each ingredient.
579.	Bryonia (Alc 96%) Potency Bryonia 3x, 3C.30X,200X, 200C,1M,10M,50M,CM	Deferred with <b>final opportunity</b> for the provision of following deficiencies: provide Long term and accelerated stability studies data as per the requirement of Zone IV A.  Mention specification of each ingredient.
580.	Calcium Phosphoricum (Alc 96%) Potency CalcareoPhosphoricum 3x, 3x,30,200,1M,10M,50M,CM	Deferred with <b>final opportunity</b> for the provision of following deficiencies: provide Long term and accelerated stability studies data as per the requirement of Zone IV A.  Mention specification of each ingredient.
581.	HeparSulfuris (Alc 96%) Potency HeparSulfuris 3x, 3C.30X,200X, 200C,1M,10M,50M,CM	Deferred with <b>final opportunity</b> for the provision of following deficiencies: provide Long term and accelerated stability studies data as per the requirement of Zone IV A.  Mention specification of each ingredient.
582.	Cantharis (Alc 96%) Potency Cantharis 3x, 3C.30X,200X, 200C,1M,10M,50M,CM	Deferred with <b>final opportunity</b> for the provision of following deficiencies: provide Long term and accelerated stability studies data as per the requirement of Zone IV A.  Mention specification of each ingredient.
583.	Chamomilla (Alc 96%) Potency Chamomilla 3x, 3x,30,200,1M,10M,50M,CM	Deferred with <b>final opportunity</b> for the provision of following deficiencies: provide Long term and accelerated stability studies data as per the requirement of Zone IV A.  Mention specification of each ingredient.
584.	CarboVegetabilis (Alc 96%) Potency CarboVegetabilis 3x, 3C.30X,200X, 200C,1M,10M,50M,CM	Deferred with <b>final opportunity</b> for the provision of following deficiencies: provide Long term and accelerated stability studies data as per the requirement of Zone IV A.  Mention specification of each ingredient.
585.	Gelsemium (Alc 96%) Potency Gelsemium 3x, 3C.30X,200X, 200C,1M,10M,50M,CM	Deferred with <b>final opportunity</b> for the provision of following deficiencies: provide Long term and accelerated stability studies data as per the requirement of Zone IV A.  Mention specification of each ingredient.
586.	CrotalusHor (Alc 96%) Potency CrotalusHorr 3x,30,200,1M,10M,50M,CM	Deferred with <b>final opportunity</b> for the provision of following deficiencies: provide Long term and accelerated stability studies data as per the requirement of Zone IV A.

		Mention specification of each ingredient.
587.	Conium Maculatum (Alc 96%) Potency Conium Maculatum 3x.30,200,1M,10M,50M,CM	Deferred with <b>final opportunity</b> for the provision of following deficiencies: provide Long term and accelerated stability studies data as per the requirement of Zone IV A.  Mention specification of each ingredient.
588.	China (Alc 96%) Potency China 3x, 3C.30X,200X, 200C,1M,10M,50M,CM	Deferred with <b>final opportunity</b> for the provision of following deficiencies: provide Long term and accelerated stability studies data as per the requirement of Zone IV A.  Mention specification of each ingredient.
589.	CausticumHahnemanni (Alc 96%) Potency CausticumHahnemanni 3x, 3C.30X,200X, 200C,1M,10M,50M,CM	Deferred with <b>final opportunity</b> for the provision of following deficiencies: provide Long term and accelerated stability studies data as per the requirement of Zone IV A.  Mention specification of each ingredient.
590.	Iodium = Jodum (Alc 96%) Potency Iodium 3x.30,200,1M,10M,50M,CM	Deferred with <b>final opportunity</b> for the provision of following deficiencies: provide Long term and accelerated stability studies data as per the requirement of Zone IV A. Iodium = Jodum (Alc 96%) Potency below 6x cannot be enlisted.  Mention specification of each ingredient.
591.	Selenium (Alc 96%) Potency Selenium 3C.30X,200X, 200C,1M,10M,50M,CM	Deferred with <b>final opportunity</b> for the provision of following deficiencies: provide Long term and accelerated stability studies data as per the requirement of Zone IV A.  Mention specification of each ingredient.
592.	Thuja (Alc 96%) Potency Thuja 3C.30X,200X, 200C,1M,10M,50M,CM	Deferred with <b>final opportunity</b> for the provision of following deficiencies: provide Long term and accelerated stability studies data as per the requirement of Zone IV A.  Mention specification of each ingredient.
593.	AcidumHydrofluori (Alc 96%) Potency AcidumNitricum 3x.30,200,1M,10M,50M,CM	Deferred with <b>final opportunity</b> for the provision of following deficiencies: provide Long term and accelerated stability studies data as per the requirement of Zone IV A.  Mention specification of each ingredient.
594.	Belladonna (Alc 96%) Potency Belladonna 3C.30X,200X, 200C,1M,10M,50M,CM	Deferred with <b>final opportunity</b> for the provision of following deficiencies: provide Long term and accelerated stability studies data as per the requirement of Zone IV A.  Mention specification of each ingredient.
595.	Barium Carbonicum (Alc 96%) Potency BaricumCarbonicum 3C.30X,200X, 200C,1M,10M,50M,CM	Deferred with <b>final opportunity</b> for the provision of following deficiencies: provide Long term and accelerated stability studies data as per the requirement of Zone IV A.  Mention specification of each ingredient.
596.	Arsenicum Album (Alc 96%) Potency Arsenicum Album 3C.30X,200X, 200C,1M,10M,50M,CM	Deferred with <b>final opportunity</b> for the provision of following deficiencies: provide Long term and accelerated stability studies data as per the requirement of Zone IV A.  Mention specification of each ingredient.
597.	Arnica Montana (Alc 96%) Potency Arnica Montana 3C.30X,200X, 200C,1M,10M,50M,CM	Deferred with <b>final opportunity</b> for the provision of following deficiencies: provide Long term and accelerated stability studies data as per the requirement of Zone IV A.  Mention specification of each ingredient.

598.	AntimoniumCrudum (Alc 96%) Potency AntimoniumCrudum 3x.30,200,1M,10M,50M,CM	Deferred with <b>final opportunity</b> for the provision of following deficiencies: provide Long term and accelerated stability studies data as per the requirement of Zone IV A. AntimoniumCrudum (Alc 96%) Potency below 6x cannot be enlisted.  Mention specification of each ingredient.
599.	AcidumPhosphoricum (Alc 96%) Potency AcidumPhosphoricum3x.30,200,1M,10M,50M,CM	Deferred with <b>final opportunity</b> for the provision of following deficiencies: provide Long term and accelerated stability studies data as per the requirement of Zone IV A.  Mention specification of each ingredient.
600.	Borax (Alc 96%) Potency Borax 3x.30,200,1M,10M,50M,CM	Deferred with <b>final opportunity</b> for the provision of following deficiencies: provide Long term and accelerated stability studies data as per the requirement of Zone IV A.  Mention specification of each ingredient.
<b>M/s. Synapse Chemicals (Pvt) Ltd., located at 298-H/3, Johar Town, Lahore is Agent of M/s. BioseIndustrie, 24 Avenue Georges Pompidou BP429, 15004Aurillac, France (E. No. 00057)</b>		
601.	Gynophilus Oral Route Capsule	Deferred with <b>final opportunity</b> for the provision of following deficiencies: Free sale certificate submitted is issued by Synadiet (French Food Supplements Association), France which is not a regulatory body in the country of origin.  Mention specification of each ingredient.
<b>M/s Muller &amp; Phipps Pakistan (Pvt) Ltd., Uzma Court, Main Clifton Road, Karachi-Pakistan agent of M/s Scientific Hospital Supplies International (SHS) Limited, 100 Wavertree Boulevard, Wavertree Technology Park, Liverpool, L7 9PT, England (E. No. 00479)</b>		
602.	<b>PKU Nutri 1 Energy Powder</b>	Deferred with <b>final opportunity</b> for the provision of following deficiencies: Original notarized/ attested Free sale certificate issued by Regulatory Authority in the country of origin. Long term and accelerated stability studies data as per requirement of Zone IV A. Mention salt of each elemental ingredient. Mention specification of each ingredient.
<b>M/s Muller &amp; Phipps Pakistan Pvt. Ltd, located at Uzma Court, Main Clifton Road, P.O Box 3880, Karachi agent of M/s PT Sugizindo, Jl, Pahalwan Km., 1,6 Karang Asem Barat Sub-district Citeurep District Bogor Regency, West Java Province, Indonesia (E. No. 01309)</b>		
603.	Pepticate Powder	Deferred with <b>final opportunity</b> for the provision of following deficiencies: Provide Long term and accelerated stability studies data as per requirement of Zone IV A. Mention salt of each elemental ingredient.  Mention specification of each ingredient.
<b>M/s ASN Healthcare (Pvt.) Ltd, located at Suit No.405, Wind Song Place, Block 7/8, K.C.H.S. Union, Shahr-e-Faisal, Karachi agent of M/s Henan Muxiang Veterinary Pharmaceutical Co. Ltd, No. 15 Konggang Wu Road Xinzhen Comprehensive Bonded Zone, Zhengzhou, China (E. No. 01136)</b>		
604.	<b>MS-Hepato Solution</b>	Deferred with <b>final opportunity</b> for the provision of following deficiencies: Provide Original notarized/ attested Free sale certificate issued by Regulatory Authority in the country of origin. The Free Sale certificate submitted is issued by China Chamber of International Commerce, which is not regulatory body in country of Origin. Justify use of sorbitol as active ingredient.  Mention specification of each ingredient.

<b>M/s Hi-Tech Pharmaceuticals, 1-C Shadman Chowk, Jail road, Lahore agent M/s X-Vet Sorthmannweg 20, 22529, Hamburg, Germany (Principal Manufacturer: M/s Miavit GmbH, Robert-Bosch-Strasse 3, 49632 Essen – Germany) (E. No. 01172)</b>		
605.	<b>Aromax Liquid</b>	Deferred with <b>final opportunity</b> for the provision of following deficiencies: provide Long term Stability studies data as per requirement of Zone IV A  Mention specification of each ingredient.
<b>M/s Uranus Biotech (Private) Limited, located at the address Office No. 112, 1st Floor, Arooj Arcade, F-10 Markaz, Islamabad agent of M/s Taiji Group Chongqing Fuling Pharmaceutical Co., Ltd., No. 1, Taiji Avenue/Fuling District, Chongqing City, China (E. No. 00966)</b>		
606.	<b>Dan Shen Oral Liquid</b>	Deferred with <b>final opportunity</b> for the provision of following deficiencies: Pack Size not given. Original Free Sale Certificate notarized and counter signed by the embassy of Pakistan in country of origin not provided. Long term and accelerated stability studies data as per the requirements of Zone IV A not provided.  Mention specification of each ingredient.
607.	<b>Tongtian Oral Liquid</b>	Deferred with <b>final opportunity</b> for the provision of following deficiencies: Pack Size not given. Original Free Sale Certificate notarized and counter signed by the embassy of Pakistan in country of origin not provided. Long term and accelerated stability studies data as per the requirements of Zone IV A not provided. Clarify which type of Tea beign used  Mention specification of each ingredient.
<b>M/s Service Line Private Limited, 21-A, Block-K, Gulberg-III Lahore-Pakistan being agent of M/s Lemasor GmbH, Bergstrasse 19, 6634 Puttlingen, GERMANY (E. No. 00137)</b>		
608.	Service Line's Abelmoschus (EHPI) Potencies 30,200,1M Alcohol content 85%	Deferred with <b>final opportunity</b> for the provision of following deficiencies: Provide Long term stability studies data as per the requirements of Zone IV A not provided. The firm vide deposit slip number 8195169 submitted Rs, 179000 for the enlistment of therapertic goods on 29-09-2014. However, no bifurcation of said fee was provided. Further more the same challan does not bear endorsement stamp of Statistical officer of DRAP.
609.	Service Line's Abies Canadensis (EHPI) Potencies 30,200,1M Alcohol content 85%	Deferred with <b>final opportunity</b> for the provision of following deficiencies:  Provide Long term stability studies data as per the requirements of Zone IV A not provided. The firm vide deposit slip number 8195169 submitted Rs, 179000 for the enlistment of therapertic goods on 29-09-2014. However, no bifurcation of said fee was provided. Further more the same challan does not bear endorsement stamp of Statistical officer of DRAP.
610.	Service Line's Abrotanum (EHPI) Potencies 30,200,1M Alcohol content 85%	Deferred with <b>final opportunity</b> for the provision of following deficiencies:  Provide Long term stability studies data as per the requirements of Zone IV A not provided. The firm vide deposit slip number 8195169 submitted Rs, 179000 for the enlistment of therapertic goods on 29-09-2014. However, no bifurcation of said fee was provided. Further more the same challan does not bear endorsement stamp of Statistical officer of DRAP.
611.	Service Line's Acalypha Indica (EHPI) Potencies 30,200,1M Alcohol content 85%	Deferred with <b>final opportunity</b> for the provision of following deficiencies:

		Provide Long term stability studies data as per the requirements of Zone IV A not provided. The firm vide deposit slip number 8195169 submitted Rs, 179000 for the enlistment of therapeutic goods on 29-09-2014. However, no bifurcation of said fee was provided. Further more the same challan does not bear endorsement stamp of Statistical officer of DRAP.
612.	Service Line's Acidum Aceticum (EHPI) Potencies 30,200,1M Alcohol content 85%	Deferred with <b>final opportunity</b> for the provision of following deficiencies:  Provide Long term stability studies data as per the requirements of Zone IV A not provided. The firm vide deposit slip number 8195169 submitted Rs, 179000 for the enlistment of therapeutic goods on 29-09-2014. However, no bifurcation of said fee was provided. Further more the same challan does not bear endorsement stamp of Statistical officer of DRAP.
613.	Service Line's Acidum Phosphoricum (EHPI) Potencies 30,200,1M Alcohol content 85%	Deferred with <b>final opportunity</b> for the provision of following deficiencies:  Provide Long term stability studies data as per the requirements of Zone IV A not provided. The firm vide deposit slip number 8195169 submitted Rs, 179000 for the enlistment of therapeutic goods on 29-09-2014. However, no bifurcation of said fee was provided. Further more the same challan does not bear endorsement stamp of Statistical officer of DRAP.
614.	Service Line's Actaea Spicata (EHPI) Potencies 30,200,1M Alcohol content 85%	Deferred with <b>final opportunity</b> for the provision of following deficiencies:  Provide Long term stability studies data as per the requirements of Zone IV A not provided. The firm vide deposit slip number 8195169 submitted Rs, 179000 for the enlistment of therapeutic goods on 29-09-2014. However, no bifurcation of said fee was provided. Further more the same challan does not bear endorsement stamp of Statistical officer of DRAP.
615.	Service Line's Adonis Vernalis (EHPI) Potencies 30,200,1M Alcohol content 85%	Deferred with <b>final opportunity</b> for the provision of following deficiencies:  Provide Long term stability studies data as per the requirements of Zone IV A not provided. The firm vide deposit slip number 8195169 submitted Rs, 179000 for the enlistment of therapeutic goods on 29-09-2014. However, no bifurcation of said fee was provided. Further more the same challan does not bear endorsement stamp of Statistical officer of DRAP.
616.	Service Line's Adrenalinum (EHPI) Potencies 30,200,1M Alcohol content 85%	Deferred with <b>final opportunity</b> for the provision of following deficiencies:  Long term stability studies data as per the requirements of Zone IV A not provided. The firm vide deposit slip number 8195169 submitted Rs, 179000 for the enlistment of therapeutic goods on 29-09-2014. However, no bifurcation of said fee was provided. Further more the same challan does not bear endorsement stamp of Statistical officer of DRAP.
617.	Service Line's Aesculus Hippocastanum (EHPI) Potencies 30,200,1M Alcohol content 85%	Deferred with <b>final opportunity</b> for the provision of following deficiencies:  Provide Long term stability studies data as per the requirements of Zone IV A not provided.



		The firm vide deposit slip number 8195169 submitted Rs, 179000 for the enlistment of therapeutic goods on 29-09-2014. However, no bifurcation of said fee was provided. Further more the same challan does not bear endorsement stamp of Statistical officer of DRAP.
618.	Service Line's Aethusa Cynapium (EHPI) Potencies 30,200,1M Alcohol content 85%	Deferred with <b>final opportunity</b> for the provision of following deficiencies:  Provide Long term stability studies data as per the requirements of Zone IV A not provided. The firm vide deposit slip number 8195169 submitted Rs, 179000 for the enlistment of therapeutic goods on 29-09-2014. However, no bifurcation of said fee was provided. Further more the same challan does not bear endorsement stamp of Statistical officer of DRAP.
619.	Service Line's Agaricus Muscarius (EHPI) Potencies 30,200,1M Alcohol content 85%	Deferred with <b>final opportunity</b> for the provision of following deficiencies:  Provide Long term stability studies data as per the requirements of Zone IV A not provided. The firm vide deposit slip number 8195169 submitted Rs, 179000 for the enlistment of therapeutic goods on 29-09-2014. However, no bifurcation of said fee was provided. Further more the same challan does not bear endorsement stamp of Statistical officer of DRAP.
620.	Service Line's Agraphis Nutans (EHPI) Potencies 30,200,1M Alcohol content 85%	Deferred with <b>final opportunity</b> for the provision of following deficiencies:  Provide Long term stability studies data as per the requirements of Zone IV A not provided. The firm vide deposit slip number 8195169 submitted Rs, 179000 for the enlistment of therapeutic goods on 29-09-2014. However, no bifurcation of said fee was provided. Further more the same challan does not bear endorsement stamp of Statistical officer of DRAP.
621.	Service Line's Ailanthus Glandulosus (EHPI) Potencies 30,200,1M Alcohol content 85%	Deferred with <b>final opportunity</b> for the provision of following deficiencies:  Provide Long term stability studies data as per the requirements of Zone IV A not provided. The firm vide deposit slip number 8195169 submitted Rs, 179000 for the enlistment of therapeutic goods on 29-09-2014. However, no bifurcation of said fee was provided. Further more the same challan does not bear endorsement stamp of Statistical officer of DRAP.
622.	Service Line's Aletris Farinosa (EHPI) Potencies 30,200,1M Alcohol content 85%	Deferred with <b>final opportunity</b> for the provision of following deficiencies:  Provide Long term stability studies data as per the requirements of Zone IV A not provided. The firm vide deposit slip number 8195169 submitted Rs, 179000 for the enlistment of therapeutic goods on 29-09-2014. However, no bifurcation of said fee was provided. Further more the same challan does not bear endorsement stamp of Statistical officer of DRAP.
623.	Service Line's Alfalfa (EHPI) Potencies 30,200,1M Alcohol content 85%	Deferred with <b>final opportunity</b> for the provision of following deficiencies:  Provide Long term stability studies data as per the requirements of Zone IV A not provided. The firm vide deposit slip number 8195169 submitted Rs, 179000 for the enlistment of therapeutic goods on 29-09-2014. However, no bifurcation of said fee was provided. Further more

		the same challan does not bear endorsement stamp of Statistical officer of DRAP.
624.	Service Line's Allium Cepa (EHPI) Potencies 30,200,1M Alcohol content 85%	Deferred with <b>final opportunity</b> for the provision of following deficiencies:  Provide Long term stability studies data as per the requirements of Zone IV A not provided. The firm vide deposit slip number 8195169 submitted Rs, 179000 for the enlistment of therapeutic goods on 29-09-2014. However, no bifurcation of said fee was provided. Further more the same challan does not bear endorsement stamp of Statistical officer of DRAP.
625.	Service Line's Allium Sativum (EHPI) Potencies 30,200,1M Alcohol content 85%	Deferred with <b>final opportunity</b> for the provision of following deficiencies:  Provide Long term stability studies data as per the requirements of Zone IV A not provided. The firm vide deposit slip number 8195169 submitted Rs, 179000 for the enlistment of therapeutic goods on 29-09-2014. However, no bifurcation of said fee was provided. Further more the same challan does not bear endorsement stamp of Statistical officer of DRAP.
626.	Service Line's Aloe Socotrina (EHPI) Potencies 30,200,1M Alcohol content 85%	Deferred with <b>final opportunity</b> for the provision of following deficiencies:  Provide Long term stability studies data as per the requirements of Zone IV A not provided. The firm vide deposit slip number 8195169 submitted Rs, 179000 for the enlistment of therapeutic goods on 29-09-2014. However, no bifurcation of said fee was provided. Further more the same challan does not bear endorsement stamp of Statistical officer of DRAP.
627.	Service Line's Alstonia Constricta (EHPI) Potencies 30,200,1M Alcohol content 85%	Deferred with <b>final opportunity</b> for the provision of following deficiencies:  Provide Long term stability studies data as per the requirements of Zone IV A not provided. The firm vide deposit slip number 8195169 submitted Rs, 179000 for the enlistment of therapeutic goods on 29-09-2014. However, no bifurcation of said fee was provided. Further more the same challan does not bear endorsement stamp of Statistical officer of DRAP.
628.	Service Line's Alumen (EHPI) Potencies 30,200,1M Alcohol content 85%	Deferred with <b>final opportunity</b> for the provision of following deficiencies:  Provide Long term stability studies data as per the requirements of Zone IV A not provided. The firm vide deposit slip number 8195169 submitted Rs, 179000 for the enlistment of therapeutic goods on 29-09-2014. However, no bifurcation of said fee was provided. Further more the same challan does not bear endorsement stamp of Statistical officer of DRAP.
629.	Service Line's Alumina (EHPI) Potencies 30,200,1M Alcohol content 85%	Deferred with <b>final opportunity</b> for the provision of following deficiencies:  Provide Long term stability studies data as per the requirements of Zone IV A not provided. The firm vide deposit slip number 8195169 submitted Rs, 179000 for the enlistment of therapeutic goods on 29-09-2014. However, no bifurcation of said fee was provided. Further more the same challan does not bear endorsement stamp of Statistical officer of DRAP.

630.	Service Line's Ambra Grisea (EHPI) Potencies 30,200,1M Alcohol content 85%	Deferred with <b>final opportunity</b> for the provision of following deficiencies:  Provide Long term stability studies data as per the requirements of Zone IV A not provided. The firm vide deposit slip number 8195169 submitted Rs, 179000 for the enlistment of therapeutic goods on 29-09-2014. However, no bifurcation of said fee was provided. Further more the same challan does not bear endorsement stamp of Statistical officer of DRAP.
631.	Service Line's Ammonium Bromatum (EHPI) Potencies 30,200,1M Alcohol content 85%	Deferred with <b>final opportunity</b> for the provision of following deficiencies:  Provide Long term stability studies data as per the requirements of Zone IV A not provided. The firm vide deposit slip number 8195169 submitted Rs, 179000 for the enlistment of therapeutic goods on 29-09-2014. However, no bifurcation of said fee was provided. Further more the same challan does not bear endorsement stamp of Statistical officer of DRAP.
632.	Service Line's Ammonium Phosphoricum (EHPI) Potencies 30,200,1M Alcohol content 85%	Deferred with <b>final opportunity</b> for the provision of following deficiencies:  Provide Long term stability studies data as per the requirements of Zone IV A not provided. The firm vide deposit slip number 8195169 submitted Rs, 179000 for the enlistment of therapeutic goods on 29-09-2014. However, no bifurcation of said fee was provided. Further more the same challan does not bear endorsement stamp of Statistical officer of DRAP.
633.	Service Line's Anacardium Occidentale (EHPI) Potencies 30,200,1M Alcohol content 85%	Deferred with <b>final opportunity</b> for the provision of following deficiencies:  Provide Long term stability studies data as per the requirements of Zone IV A not provided. The firm vide deposit slip number 8195169 submitted Rs, 179000 for the enlistment of therapeutic goods on 29-09-2014. However, no bifurcation of said fee was provided. Further more the same challan does not bear endorsement stamp of Statistical officer of DRAP.
634.	Service Line's Anagalis Arvensis (EHPI) Potencies 30,200,1M Alcohol content 85%	Deferred with <b>final opportunity</b> for the provision of following deficiencies:  Provide Long term stability studies data as per the requirements of Zone IV A not provided. The firm vide deposit slip number 8195169 submitted Rs, 179000 for the enlistment of therapeutic goods on 29-09-2014. However, no bifurcation of said fee was provided. Further more the same challan does not bear endorsement stamp of Statistical officer of DRAP.
635.	Service Line's Angustura (EHPI) Potencies 30,200,1M Alcohol content 85%	Deferred with <b>final opportunity</b> for the provision of following deficiencies:  Provide Long term stability studies data as per the requirements of Zone IV A not provided. The firm vide deposit slip number 8195169 submitted Rs, 179000 for the enlistment of therapeutic goods on 29-09-2014. However, no bifurcation of said fee was provided. Further more the same challan does not bear endorsement stamp of Statistical officer of DRAP.
636.	Service Line's Anthracokali (EHPI) Potencies 30,200,1M	Deferred with <b>final opportunity</b> for the provision of following deficiencies:

	Alcohol content 85%	Provide Long term stability studies data as per the requirements of Zone IV A not provided. The firm vide deposit slip number 8195169 submitted Rs, 179000 for the enlistment of therapeutic goods on 29-09-2014. However, no bifurcation of said fee was provided. Further more the same challan does not bear endorsement stamp of Statistical officer of DRAP.
637.	Service Line's Antimonium Arsenicosum (EHPI) Potencies 30,200,1M Alcohol content 85%	Deferred with <b>final opportunity</b> for the provision of following deficiencies:  Provide Long term stability studies data as per the requirements of Zone IV A not provided. The firm vide deposit slip number 8195169 submitted Rs, 179000 for the enlistment of therapeutic goods on 29-09-2014. However, no bifurcation of said fee was provided. Further more the same challan does not bear endorsement stamp of Statistical officer of DRAP.
638.	Service Line's Antipyrinum (EHPI) Potencies 30,200,1M Alcohol content 85%	Deferred with <b>final opportunity</b> for the provision of following deficiencies:  Provide Long term stability studies data as per the requirements of Zone IV A not provided. The firm vide deposit slip number 8195169 submitted Rs, 179000 for the enlistment of therapeutic goods on 29-09-2014. However, no bifurcation of said fee was provided. Further more the same challan does not bear endorsement stamp of Statistical officer of DRAP.
639.	Service Line's Aralia Racemosa (EHPI) Potencies 30,200,1M Alcohol content 85%	Deferred with <b>final opportunity</b> for the provision of following deficiencies: Provide Long term stability studies data as per the requirements of Zone IV A not provided. The firm vide deposit slip number 8195169 submitted Rs, 179000 for the enlistment of therapeutic goods on 29-09-2014. However, no bifurcation of said fee was provided. Further more the same challan does not bear endorsement stamp of Statistical officer of DRAP.
640.	Service Line's Aranea Diadema (EHPI) Potencies 30,200,1M Alcohol content 85%	Deferred with <b>final opportunity</b> for the provision of following deficiencies: Provide Long term stability studies data as per the requirements of Zone IV A not provided. The firm vide deposit slip number 8195169 submitted Rs, 179000 for the enlistment of therapeutic goods on 29-09-2014. However, no bifurcation of said fee was provided. Further more the same challan does not bear endorsement stamp of Statistical officer of DRAP.
641.	Service Line's Argentum Nitricum (EHPI) Potencies 30,200,1M Alcohol content 85%	Deferred with <b>final opportunity</b> for the provision of following deficiencies: Provide Long term stability studies data as per the requirements of Zone IV A not provided. The firm vide deposit slip number 8195169 submitted Rs, 179000 for the enlistment of therapeutic goods on 29-09-2014. However, no bifurcation of said fee was provided. Further more the same challan does not bear endorsement stamp of Statistical officer of DRAP.
642.	Service Line's Aristolochia (EHPI) Potencies 30,200,1M Alcohol content 85%	Deferred with <b>final opportunity</b> for the provision of following deficiencies: Provide Long term stability studies data as per the requirements of Zone IV A not provided. The firm vide deposit slip number 8195169 submitted Rs, 179000 for the enlistment of therapeutic goods on 29-09-2014. However, no bifurcation of said fee was provided. Further more the same challan does not bear endorsement stamp of Statistical officer of DRAP.

643.	Service Line's Arnica Montana (EHPI) Potencies 30,200,1M Alcohol content 85%	Deferred with <b>final opportunity</b> for the provision of following deficiencies: Provide Long term stability studies data as per the requirements of Zone IV A not provided. The firm vide deposit slip number 8195169 submitted Rs, 179000 for the enlistment of therapeutic goods on 29-09-2014. However, no bifurcation of said fee was provided. Further more the same challan does not bear endorsement stamp of Statistical officer of DRAP.
644.	Service Line's Arsenicum Bromatum (EHPI) Potencies 30,200,1M Alcohol content 85%	Deferred with <b>final opportunity</b> for the provision of following deficiencies: Provide Long term stability studies data as per the requirements of Zone IV A not provided. The firm vide deposit slip number 8195169 submitted Rs, 179000 for the enlistment of therapeutic goods on 29-09-2014. However, no bifurcation of said fee was provided. Further more the same challan does not bear endorsement stamp of Statistical officer of DRAP.
645.	Service Line's Arsenicum Lodatum (EHPI) Potencies 30,200,1M Alcohol content 85%	Deferred with <b>final opportunity</b> for the provision of following deficiencies: Provide Long term stability studies data as per the requirements of Zone IV A not provided. The firm vide deposit slip number 8195169 submitted Rs, 179000 for the enlistment of therapeutic goods on 29-09-2014. However, no bifurcation of said fee was provided. Further more the same challan does not bear endorsement stamp of Statistical officer of DRAP.
646.	Service Line's Arsenicum Sulfuratum Rubrum (EHPI) Potencies 30,200,1M Alcohol content 85%	Deferred with <b>final opportunity</b> for the provision of following deficiencies: Provide Long term stability studies data as per the requirements of Zone IV A not provided. The firm vide deposit slip number 8195169 submitted Rs, 179000 for the enlistment of therapeutic goods on 29-09-2014. However, no bifurcation of said fee was provided. Further more the same challan does not bear endorsement stamp of Statistical officer of DRAP.
<b>M/s Gee Vet International ,office. 11/12, first floor, Naz Medicine Market Namak Mandi, Peshawar- Pakistan agent of an M/s Inner Mongolia Huatain Pharmaceutical Co. Ltd., Economic Development Zone, Yuanbaoshan District Chi Fengcity, InnerMongolia, P.R. China (Veterinary)</b>		
12.	<b>Neo Acid Liquid</b>	Deferred for mentioning of specification of each ingredient.
13.	Control Viral Double Strength Liquid	Deferred to seek Justification/ clarification for using "APN" in the formulation.
14.	Multi Vet Liquid	Deferred to seek clarification for using Sodium Metabisulfite as active ingredient.
15.	Electro C Powder	Deferred for mentioning of specification of each ingredient.
16.	Lyso Immune Powder	Deferred for mentioning of salt of each elemental ingredient.  Mention specification of each ingredient.
<b>M/s Care &amp; Cure Farma &amp; Services, located at No. 1626, Block C, LDA Avenue - 1, Lahore agent of M/s Bentoli Agrinutrition Co., Ltd. 333 52-53 Moo 6, Tambon Bangpla Amphoe Bangphli, Samutprakarn 10540, Thailand (E. No. 01288)</b>		
17.	Microcell Powder	Deferred due to following reasons: Provided stability data is not as per the requirement of Zone IV A. Justify use of instant active yeast and yeast cell wall as active ingredient.  Mention specification of each ingredient.
18.	Flamotin Liquid	Deferred due to following reasons:

		<p>Provided stability data is not as per the requirement of Zone IV A.</p> <p>Justify use of instant ammonium hydroxide and surfactant as active ingredient.</p> <p>Mention specification of each ingredient.</p>
19.	Fixar S Powder	<p>Deferred due to following reasons:</p> <p>Provided stability data is not as per the requirement of Zone IV A.</p> <p>Justify/ clarify use of HSCAS as active ingredient.</p> <p>Mention specification of each ingredient.</p>
20.	Rumicell Powder	<p>Deferred due to following reasons:</p> <p>Provided stability data is not as per the requirement of Zone IV A.</p> <p>Justify use of instant active yeast as active ingredient.</p> <p>Mention specification of each ingredient.</p>
21.	Fixar Vivia Powder	<p>Deferred due to following reasons:</p> <p>Provided stability data is not as per the requirement of Zone IV A.</p> <p>Justify use of instant HSCAS and yeast cell wall as active ingredient.</p> <p>Mention specification of each ingredient.</p>
22.	Microcell Powder	<p>Deferred due to following reasons:</p> <p>Provided stability data is not as per the requirement of Zone IV A.</p> <p>Clarify / Justify use of instant Dried fermentation products and nutritive and Anti-caking agent as active ingredient.</p> <p>Mention specification of each ingredient.</p>
23.	Complemin 7+ powder	<p>Deferred due to following reasons:</p> <p>Provided stability data is not as per the requirement of Zone IV A.</p> <p>Mention salt of each elemental ingredient.</p> <p>Mention specification of each ingredient.</p>
24.	Pollstress Powder	<p>Deferred due to following reasons:</p> <p>Provided stability data is not as per the requirement of Zone IV A.</p> <p>Specify type of vitamin K being used in the formulation.</p> <p>Mention salt of each elemental ingredient.</p> <p>Mention strain(s) of Lactobacillus Speies alongwith indivial strength.</p> <p>Mention specification of each ingredient.</p>
<b>M/s Base6 (Pvt.) Ltd., located at the address E-216, Street No 6, Cavalry Ground, Lahore agent of M/s WN Pharmaceuticals Ltd., 2000 Brigantine Drive, Coquitlam BC Canada V3K 7B5 (Principal Manufacturer: M/s Factores Group of Nutritional Companies Inc., 1550 United Boulevard, Coquitlam, British Columbia, Canada) (E. No. 00316)</b>		
25.	<b>Webber Naturals Probiotic 30 Billion</b>	Deferred for Mentioning of specification of each ingredient.
<b>M/s Meezab Z International, located at the address, Near Bilal Mosque Fareeabad Jahanian District, Khanewal (E. No.01028)</b>		
26.	<b>Catching Plus Liquid</b>	<p>Deferred to seek clarification regarding what type of crude protein and crude ash being used in the formulation.</p> <p>Mention salt of phosphorus.</p> <p>Justify use of sugars as active ingredient also mention what type of sugars are being used.</p> <p>Mention specification of each ingredient.</p>
27.	<b>Electrolex Liquid</b>	<p>Justify the use of dextrose as active ingredient.</p> <p>Mention specification of each ingredient.</p>
28.	<b>Futuristic C Wsp</b>	The applied formulation contains viruses "Lytic Phages". Justify the applied formulatin/ ingredient as nutraceutical health product.



	Each 1gram Contains Lytic Phages 1x107 Pfu	Mention specification of each ingredient.
29.	<b>Futuristic S Wsp</b>	The applied formulation contains viruses "Lytic Phages". Justify the applied formulatin/ ingredient as nutraceutical health product.  Mention specification of each ingredient.
30.	<b>Immunat A Liquid</b>	Deferred for revision of strengths from percentage. Mention specification of each ingredient.  Mention specification of each ingredient.
31.	<b>Leximix Liquid</b>	Deferred for revision of strengths from percentage. Mention specification of each ingredient. Provide monograph of Cinnamaldehyde.  Mention specification of each ingredient.
32.	<b>Lexizyme Plus Powder</b>	Deferred to seek clarification is required regarding protease (proteolytic enzyme) since there are several proteolytic enzymes like bromelain, chymotrypsin, ficin, papain, serrapeptase, and trypsin. What type of Protease(s) beign used in the formulation? Mention specification of each ingredient.
33.	<b>Lexlyte Liquid</b>	Deferred for mentioning of salt selenium. Clarify / justify the use of Amino Nitrogen (10000ppm) ingredient to be used in nutraceutical health product.  Mention specification of each ingredient.
34.	<b>RENI PROTECT Liquid</b>	Deferred for seeking Clarification / justification for the use of Amino Nitrogen (10000ppm) and Nephromodulators as ingredient to be used in nutraceutical health product.  Mention specification of each ingredient.
<b>The Searle Company Limited, First Floor, N.I.C.L. Building, Abbasi Shaheed Road, Karachi-Pakistan agent of M/s HOCHDORF Swiss Nutrition Ltd., Siedereistrasse 9, 6281 Hochdorf, Switzerland (E. No. 00486)</b>		
35.	<b>NI-1</b>	<b>Deferred for mentioning of specifications of each ingredient.</b>
36.	<b>NI-FU</b>	<b>Deferred for mentioning of specifications of each ingredient.</b>
37.	<b>NI-AC</b>	<b>Deferred for mentioning of specifications of each ingredient.</b>
38.	<b>NURTUGROW</b>	<b>Deferred for mentioning of specifications of each ingredient.</b>
39.	<b>NURTUMIL-AR</b>	<b>Deferred for mentioning of specifications of each ingredient.</b>
<b>For Export Purpose Only)</b> <b>M/s Novamed Healthcare, 28Km Ferozpur Road, Lahore</b>		
1.	<b>NOGREY CAPSULE</b>	Deferred for verification of testing facility of minerals
<b>For Export Purpose Only)</b> <b>M/s Nutrasource International, Plot No. E-70/A, S.I.T.E, Phase-II, Super Highway, Ahsanabad, Karachi.</b>		
2.	<b>Iromin Syrup</b>	Deferred for final opportunity for submission of alternative brand names
3.	<b>Pregna Top Tablet</b>	Deferred for final opportunity for submission of alternative brand names along with verification of testing facility of minerals
<b>M/s Eon Pharmacy ,</b> <b>Plot No. A/150, Sector 11-E, New Karachi</b>		
4.	<b>Winfer-F Sachet</b>	Deferred for verification of testing facility of minerals
<b>M/s Bless Laboratories Pvt Ltd ,</b> <b>Factory No.179, 1.5-KM, Kattar Band Road, Off Multan Road, Thokar Niaz Baig, Lahore</b>		

For Export Purpose Only)		
M/s Novamed Healthcare, 28Km Ferozpur Road, Lahore		
5.	<b>Garent-C tablet</b>	Defererd with final opportunity for till the withdrawn of M/s Anza Pharma is decided by the EEC <b>The firm has submitted reply "The original Form-7 contains other products. Therefore copy of Form-7 Provided"</b>
6.	<b>Garent-C Syrup</b>	Defererd with final opportunity for till the withdrawn of M/s Anza Pharma is decided by the EEC <b>The firm has submitted reply "The original Form-7 contains other products. Therefore copy of Form-7 Provided"</b>
<b>M/s PharmEvo (Pvt) Ltd., (Nutraceutical Division), [Nutraceutical]</b> Plot A-29, North Western Industrial Zone, Port Qasim, Karachi		
7.	<b>Urievo capsules</b> Each 2 capsules contain; Pumpkin seed extract ....525 mg Willow herb extract ....300 mg Soy germ extract .....75 mg Vitamin D..... 20 µg Vitamin B <sub>12</sub> USP .....5 µg	Defererd with final opportunity for clarification of formulation
8.	<b>Evojoshanda Sachet</b> Each 4.5gm Sachet contains Pinus pinaster Extract 75 mg Echinacea purpurea Extract 450 mg Sambucus nigra Extract 30 mg Piper longum 105 mg	Defererd with final opportunity for clarification regarding contract manufacturing

9.	<b>Shevit tablet</b> Each tablet contains: Vitamin A USP....2000IU Vitamin C USP....50mg Vitamin D ....400IU Vitamin E USP....30IU Vitamin B1 USP....1.70mg Vitamin B2 USP ....2.00mg Niacin USP.....20.00mg Vitamin B6 USP....2.50mg Folic acid USP....800mcg Vitamin B12 USP...8 mcg Calcium ....200mg Magnesium USP....100mg Iron USP.....65mg Zinc USP....22.50 mg	Defererd with final opportunity for clarification regarding contract manufacturing
----	---	--

<b>M/s Paul Brooks Homeo Labs,</b> Plot No. A-69, S.I.T.E., Super Highway Phase-I, Karachi		
10.	<b>GASGON ANTACID SYRUP</b>	Defererd with final opportunity for submission of alternative brand name
11.	<b>FASTOGEL</b>	Defererd with final opportunity for submission of alternative brand name
12.	<b>PILEENO CAPSULES</b>	Defererd with final opportunity for clarification regrading applied formulation
13.	<b>MALEDO CAPSULES</b>	Defererd with final opportunity for for clarification regrading formulation and applied formulation and signed Form-3 is required
14.	<b>GINKGO STRESS RELIEF ORAL LIQUID</b>	Defererd with final opportunity for submission of alternative brand name
15.	<b>SPERMAX CAPSULES</b>	Defererd with final opportunity for change of brand name and <i>Svarnavanga, clarify its ingredients and testing method</i>
<b>M/s Schazoo Zaka (Pvt.) Ltd ,</b>		

Kalawala, Zaka-ur-Rehman Industrial Estate, Plot-1, 20km Lahore Jaranwala Road, District Sheikhpura		
16.	<b>Femvit Tablets</b>	Defererd with final opportunity for clarification since The firm is Herbal and the formulations contains mineral and vitamins
17.	<b>Instafer Sachet</b>	Defererd with final opportunity for clarification since The firm is Herbal and the formulations contains mineral and vitamins
18.	<b>Myova Sachet</b>	Defererd with final opportunity for clarification since The firm is Herbal and the formulations contains mineral and vitamins
19.	<b>Provig Tablets</b>	Defererd with final opportunity for clarification since The firm is Herbal and the formulations contains mineral and vitamins
20.	<b>Zefolic Tablets</b>	Defererd with final opportunity for Deferred for clarification since the formulation contains Glucosamine which is registered as drug
<b>M/s. Nutrabiobiotics, Nutritional Life Science,</b> Plot No. 89-K3, Industrial Estate, Hayatabad, Peshawar		
21.	<b>NUTRABIOTICS ANTACID SUSPENSION</b>	Defererd with final opportunity for provision of alternative brand names
22.	<b>PERFECTIVE CAPSULE</b>	Defererd with final opportunity for provision of alternative brand names
23.	<b>MYOSITOL SACHET</b>	Defererd with final opportunity for provision of alternative brand names
24.	<b>NUTRABIOTICS LAXATIVE SYRUP</b>	Defererd with final opportunity for provision of alternative brand names
<b>M/s Global Laboratories,</b> Plot No. 8, Street S-8, RCCI, Rawat		
25.	<b>Magpo-K Syrup</b>	Defererd with final opportunity for clarifcaition since the formulation and strength of Potassium citrate, which is registered as drug
26.	<b>Glomin Plus Tablet</b>	Defererd with final opportunity for provision of alternative brand names
<b>M/s New Shadman Dawakhana,</b> Chak No.80-10R, Peerowal, Tehsil & District Khanewa		
27.	<b>Shadman's Fibromas DS powder</b>	Defererd with final opportunity for confirmation of Probiotic oral powder section and clarification is required regarding source ,synthesis ,stability and use of Amino nitrogen in the formulation
28.	<b>Shadman's K.F Feed powder</b>	Defererd with final opportunity for clarification regarding applied formulation as firm uses Saccharomyces cerevisiae a yeast strain and availability of probiotic oral powder veterinary section
<b>M/s DUMCAP Healthcare,</b> Plot No.19, Near Rural Government Dispensary, Santh Pura, Wagha, G.T Road, Lahore		
29.	<b>DP 1 DROPS</b>	Defererd with final opportunity for Clarification is required as per Form 6 Approved section is Oral Liquid potentization section while firm applied Oral drops
30.	<b>DP 3 DROPS</b>	Defererd with final opportunity for Clarification is required as per Form 6 Approved section is Oral Liquid potentization section while firm applied Oral drops
31.	<b>DP 4 (DIASOLINE) DROPS</b>	Defererd with final opportunity for Clarification is required as per Form 6 Approved section is Oral Liquid potentization section while firm applied Oral drops
32.	<b>DP 5 DROPS</b>	Defererd with final opportunity for Clarification is required as per Form 6 Approved section is Oral Liquid potentization section while firm applied Oral drops
33.	<b>DP 13 DROPS</b>	Defererd with final opportunity for Clarification is required as per Form 6 Approved section is Oral Liquid potentization section while firm applied Oral drops
<b>M/s Mah-e-Noor Laboratories (Pvt.) Ltd.,</b> 7-km, Main Lahore Road, Near Mana More, Burewala		
34.	<b>MAH-E-NOOR'S ARQ SHIRIN</b>	Defererd with final for submission of alternative brand names

35.	<b>MAH-E-NOOR'S SHEENAL SYRUP</b>	Defererd with final for clarification regarding formulation as firm use nutraceutical ingredient in herbal formulation
36.	<b>VICSOL COUGH SYRUP</b>	Defererd with final for submission of alternative brand names
<b>M/s Blossom Labs,</b> 30km Badian Road, 1/2km Off Roda Bohgal Road, Lahore		
37.	<b>Gastocid Syrup</b>	Deferred with final opportunity for change of brand name
38.	<b>Heptolex Syrup</b>	Deferred with final opportunity for change of brand name
39.	<b>Ginza Bump baby Syrup</b>	Deferred with final opportunity for change of brand name
40.	<b>Hep-Heal Elixir</b>	Deferred with final opportunity for change of brand name
41.	<b>Ginza Blood Mass Syrup</b>	Deferred with final opportunity for change of brand name
42.	<b>Ginza safe Bone Syrup</b>	Deferred with final opportunity for change of brand name
<b>M/s. Nutrifactor Laboratories (Pvt) Ltd</b> Plot No 4-B, Value Addition City, Khurrianwala, Faisalabad		
43.	<b>VITAMAX SYRUP</b>	Defererd with final opportunity for submission of alternative brand names
44.	<b>VISIONEX SYRUP</b>	Defererd with final opportunity for submission of alternative brand names
45.	<b>BESTAVIT POWDER</b>	Defererd with final opportunity for submission of alternative brand names
<b>M/s Salbion Health Sciences,</b> 23km, Sheikhpura Road, Lahore		
46.	<b>PREVIT - M TABLET</b>	Rejeceted, since the firm failed to fullfil the deficiency despite lapse of ample time
<b>M/s Oasis Pharma,</b> 23-Km Raiwind Road, Lahore		
47.	<b>Hyrich Powder</b>	Rejeceted, since the firm failed to fullfil the deficiency despite lapse of ample time
48.	<b>Zecoplan Powder (as Magnovit)</b>	Rejeceted, since the firm failed to fullfil the deficiency despite lapse of ample time
49.	<b>Z mag Tablet</b>	Rejeceted, since the firm failed to fullfil the deficiency despite lapse of ample time
<b>M/s Arshzik,</b> 23 Km Near Al-Ghani CNG, G.T. Road, Rawat, Rawalpindi		
50.	<b>MilkoTech (Oral Liquid)</b>	Deferred with final opportunity for verification of testing facility of minerals
<b>M/s Bio-Med Pharma,</b> Plot No.DP-28/1, Sector 12 C, North Karachi Industrial Area, Karachi		
51.	<b>Comeg-Junior Syrup</b>	Defererd with final opportunity for submission of latrenative brand names
<b>M/s Sois Life Sciences,</b> Plot No. A-84, S.I.T.E., Phase-I, Super Highway, Karachi		
52.	<b>Softical Plus Tablet</b>	Defererd with final opportunity for submission of latrenative brand names
<b>M/s Glorious Laboratories,</b> Plot No. 238, Industrial Triangle, Kahuta Road, Islamabad		
53.	<b>Naphro Syrup</b>	Approved with general claim
<b>M/s Crystolite Pharamaceutical,</b> Plot #72, S-2, NIZ Rawat		
54.	<b>CHOLSET SYRUP</b>	Approved with general claim

<b>M/s Bless Laboratories,</b> Facotry no. 179, 1.5Km Kattar Band road, Off Multan road, Thokar Chowk, Lahore		
55.	<b>C Plus D Tablet</b>	Deferred for verification of testing facility of minerals
<b>M/s A.R. Nutraceutical Pharma (Pvt) Limited,</b> Plot No. F-4/C, S.I.T.E., Phase-II, Super Highway, Karachi		
56.	<b>Malexeed Sachet</b>	Deferred with final opportunity for submission of alternative brand names
57.	<b>Life-Carrient Sachet</b>	Deferred with final opportunity for submission of alternative brand names
58.	<b>Ostomove Syrup</b>	Deferred with final opportunity for submission of alternative brand names
59.	<b>Bycof Drop</b>	Deferred with final opportunity for submission of alternative brand names
60.	<b>Lungset Syrup</b>	Deferred with final opportunity for submission of alternative brand names
61.	<b>Prolite Syrup</b> Each	Deferred with final opportunity for submission of alternative brand names
<b>M/s PCP Healthcare,</b> 98-km , Multan Road, Akhtar Abad, Okara		
62.	<b>PCP's D-Cal Syrup</b>	Defererd for verification of testing facility for minerals
63.	<b>PCP's Vital-CM Sachet</b>	Deferred with final opportunity for verification of testing facility of amino acids
<b>M/s Oasis Pharma,</b> 23km Raiwind Road, Lahore		
64.	<b>Pregfol Tablet (Change of Name)</b>	Defered with final opportunity for verification of testing facility of minerals
65.	<b>Calmore D Syrup</b>	Defered with final opportunity for verification of testing facility of minerals
<b>M/s Alaq laboratories,</b> 5-Main Road, Amir Town, Harbanspura, Lahore		
66.	<b>Pulmocare Syrup</b>	Deferred with final opportunity for change of brand name
<b>M/s Royal Laboratories,</b> Plot no. 22-24, Farooq Industrial Estate, 20km Ferozpur Road, Lahore		
67.	<b>Triviz Tablet</b>	Defered with final opportunity for verification of testing facility of minerals
68.	<b>Bermax Tablet</b>	Defered with final opportunity for verification of testing facility of minerals
<b>M/s MSG Nutraceuticals,</b> Plot no. 34, S-1, RCCI Industrial Estate, Rawat, Islambad		
69.	<b><u>2-Fm Conception Tablet:</u></b>	Defered with final opportunity for verification of testing facility of minerals
70.	<b><u>Cartinext Tablet:</u></b>	Defered with final opportunity for verification of testing facility of minerals
71.	<b><u>Maarit M Tablet:</u></b>	Defered with final opportunity for verification of testing facility of minerals
<b>M/s Salbion health Sciences,</b> 23km, Sheikhpura Road, Lahore		
72.	<b>GYNO – 5 PLUS TABLET</b>	Deferred with final opportunity for verification of testing facility of minerals
73.	<b><u>VITROL TABLET</u></b>	Deferred with final opportunity for verification of testing facility of minerals
74.	<b><u>Q – WELL 10 TABLET</u></b>	Deferred with final opportunity for verification of testing facility of minerals
<b>M/s Bio life Enterprises</b> 14km, Adyala Road, Rawalpindi		

75.	<b>Bio Life's OSFORTE SYRUP</b>	Deferred with final opportunity for verification of testing facility of minerals
76.	<b>Bio Life's OSFORTE TABLET</b>	Deferred with final opportunity for verification of testing facility of minerals
77.	<b>Bio Life's CVD-3 TABLET</b>	Deferred with final opportunity for verification of testing facility of minerals
78.	<b>Bio Life's LIPRON TABLET</b>	Deferred with final opportunity for verification of testing facility of minerals
79.	<b>Bio Life's KOLFAR-D TABLET</b>	Deferred with final opportunity for verification of testing facility of minerals
80.	<b>Bio Life's XOBEX-Z TABLET</b>	Deferred with final opportunity for verification of testing facility of minerals
81.	<b>Bio Life's FOVIT SYRUP</b>	Deferred with final opportunity for verification of testing facility of minerals
82.	<b>Bio Life's GINXOL SYRUP</b>	Deferred with final opportunity for verification of testing facility of minerals
<b>M/s Asfar Healthcare,</b> Plot no. 34-A, Punjab small Industrial Area, Kasur		
83.	<b>Asfar's Heptasil Tablet</b>	Deferred with final opportunity for verification of testing facility of minerals
84.	<b>Asfar's Ovum Tablet</b>	Deferred with final opportunity for verification of testing facility of minerals
<b>M/s MSK Cosmo &amp; Nutraceuticals,</b> 5-KM, Lahore Road, Near Sialkot Bypass, Gujranwala.		
85.	<b><u>KAL PLUS SYRUP</u></b>	Deferred with final opportunity for change of brand name
<b>M/s Paul Brooks Homoeo Labs,</b> Plot No. A-69, S.I.T.E., Super Highway Phase-I, Karachi		
86.	<b>FERROTON FORTE CAPSULES</b>	Deferred with final opportunity for change of brand name
87.	<b>CALCIWIN CHILDREN DROPS</b>	Deferred with final opportunity for change of brand name
88.	<b>LEUCOGEN SYRUP</b>	Deferred with final opportunity for change of brand name
89.	<b>SAW PROSTA TABLETS</b>	Deferred with final opportunity for change of brand name
90.	<b>LEUCOGEN SACHET</b>	Deferred with final opportunity for change of brand name
<b>M/s Calgan Phyto Pharma,</b> Plot No. 2, Green Park Road, Near Band Road Grid Station, Lahore		
91.	<b>UNICAL-D EFFERVESCENT TABLET</b>	
<b>For Export Purpose Only</b> <b>M/s Nutrevo Healthcare,</b> Khewat No. 438, Khatauni No.452, Khasra No. 819, 14 – Km Adyala Road, Rawalpindi (E. No.01124) <b>Brand name</b>		
92.	<b>Lactolac Milk Powder</b>	Deferred with final opportunity for clarification of formulation as per 100g provisions of COAs, Undertakings and change of brand name
<b>M/s Human Health Pharma,</b> Plot No. 76, A5, Sector 12C, North Karachi Industrial Area, Karachi, (E. No. 00968)		
93.	<b>Ormig Pro Sachet For Export Purpose Only</b>	Deferred with final opportunity for clarification regarding formulation



<b>M/s Marhaba Laboratories (Pvt.) Ltd.,</b> 142 Main Quaid-e-Azam Industrial Estate Lahore (E. No. 00730)		
94.	<b>MARHABA JAWARISH SHAHI AMBRI</b>	Defererd with final opportunity for
95.	<b>MARHABA URINOL CAPSULE</b>	Defererd with final opportunity for
96.	<b>MARHABA URIFLOW CAPSULE</b>	Defererd with final opportunity for
97.	<b>MARHABA SURANJEENA CAPSULE</b>	Defererd with final opportunity for clarification of Styrax benzoin in unani formulation
98.	<b>MARHABA TYPHIL SYRUP</b>	Defererd with final opportunity for clarification of zinc compound in unani formulation
99.	<b>MARHABA JOSHANDA (compound Zinc)</b>	Defererd with final opportunity for clarification of zinc compound in unani formulation
100.	<b>MARHABA FLUNIL DROPS</b>	Defererd with final opportunity for clarification of zinc compound in unani formulation
101.	<b>MARHABA GOSHOON OIL</b>	Defererd with final opportunity for clarification of copper sulphate inm unani formulation
<b>M/s SOIS Life Sciences (Pvt) Ltd</b> Plot No. G-77, S.I.T.E, Super Highway, Phase – II, Karachi (E. No. 01304)		
102.	<b>No Block Drop</b>	Defererd with final opportunity for clarification regarding applied formulation and dosage form and justification of formulation as health product
103.	<b>Selvex Liquid</b>	Defererd with final opportunity for clarification regarding applied formulation and dosage form
104.	<b>Cufbees Nasal Drop</b>	Defererd with final opportunity for clarification regarding applied formulation and dosage form and justification of formulation as health product
105.	<b>Vivo Nasal Drops</b>	Defererd with final opportunity for applied formulation and dosage form and justification of formulation as health product
<b>M/s. Blossom Laboratories (Pvt.) Ltd.,</b> 30-KM, Badian Road, ½ K.M Off Roda Bohgal Road, Lahore Cant. (E. No.00181)		
106.	Blossom's Colic Syrup Each	Deferred with final opportunity for submission of latrenative brand names
107.	Hepalex Syrup	Deferred with final opportunity for submission of latrenative brand names
108.	Nervo Plus Syrup Each 10ml	Deferred with final opportunity for submission of latrenative brand names
109.	Sepia officinalis (EHPI) Mother Tincture = Q	Deferred with final opportunity for sarcode testing of sepia is required
110.	Condurango (EHPI) Mother Tincture = Q	Deferred with final opportunity for Homeopathic monograph of Condurango is required
111.	Cantharis (EHPI) 3c, 6c, 12c, 30c, 200c, 1m, 10m, 100m, 3x, 6x, 30x, 200x	Deferred with final opportunity for sarcode testing of Cantharis is required
112.	Calcarea renalis (EHPI)	Deferred with final opportunity for Homeopathic monograph of renalis calcarean is required

	3c, 6c, 12c, 30c, 200c, 1m, 10m, 100m, 3x, 6x, 30x, 200x	
113.	Cantharis (EHPI) 3c, 6c, 12c, 30c, 200c, 1m, 10m, 100m, 3x, 6x, 30x, 200x	Deferred with final opportunity for sarcode testing of cantharis is required
114.	Cholesterinum (EHPI) 3c, 6c, 12c, 30c, 200c, 1m, 10m, 100m, 3x, 6x, 30x, 200x	Deferred with final opportunity for Homeopathic monograph of Cholesterine is required
115.	Lac defloratum (EHPI) 3c, 6c, 12c, 30c, 200c, 1m, 10m, 100m, 3x, 6x, 30x, 200x	Deferred with final opportunity for sarcode testing of Lac defloratum is required
116.	Formica rufa (EHPI) 3c, 6c, 12c, 30c, 200c, 1m, 10m, 100m, 3x, 6x, 30x, 200x	Deferred with final opportunity for sarcode testing of Formica rufa is required
117.	Sepia officinalis (EHPI) 3c, 6c, 12c, 30c, 200c, 1m, 10m, 100m, 3x, 6x, 30x, 200x	Deferred with final opportunity for sarcode testing of sepia is required
118.	Serum anguillae (EHPI) 3c, 6c, 12c, 30c, 200c, 1m, 10m, 100m, 3x, 6x, 30x, 200x	Deferred with final opportunity for sarcode testing of Eel serum is required
119.	Coccus Cacti Potency (EHPI) 3c, 6c, 12c, 30c, 200c, 1m, 10m, 100m, 3x, 6x, 30x, 200x	Deferred with final opportunity for sarcode testing of Coccus Cacti is required
120.	Coughsolax Syrup Each 10ml	Deferred with final opportunity for submission of latrenative brand names
121.	Hemolex Syrup	Deferred with final opportunity for submission of latrenative brand names
122.	Hepagold Syrup Each 10ml	Deferred with final opportunity for submission of latrenative brand names
123.	<b>Ulcelex Syrup</b>	Deferred with final opportunity for submission of latrenative brand names
124.	Super Fresh Blood Syrup	Deferred with final opportunity for submission of latrenative brand names
125.	Hepa Max Syrup	Deferred with final opportunity for submission of latrenative brand names
126.	<b>Gasto-P Syrup</b>	Deferred with final opportunity for submission of latrenative brand names
127.	<b>Be-Fit Powder</b> Each 10g	Deferred with final opportunity for
128.	Self Guard Tablet Each tablet	Deferred with final opportunity for
129.	Alfalfa+Ginseng Syrup	Deferred with final opportunity for
130.	<b>B-Cool Tablet</b>	Deferred with final opportunity for submission of latrenative brand names
131.	<b>B-Vision Tablet</b>	Deferred with final opportunity for submission of latrenative brand names
132.	<b>Histalex Syrup</b>	Deferred with final opportunity for submission of latrenative brand names
133.	<b>Uro Stop Syrup</b>	Deferred with final opportunity for submission of latrenative brand names
134.	<b>Blood Off Tablet</b>	Deferred with final opportunity for submission of latrenative brand names
135.	<b>Face Care Tablet</b>	Deferred with final opportunity for submission of latrenative brand names
136.	<b>Matti Chor Tablet</b>	Deferred with final opportunity for submission of latrenative brand names
137.	<b>Smoke Stop Tablet</b>	Deferred with final opportunity for submission of latrenative brand names

138.	<b>Weight Plus Tablet</b>	Deferred with final opportunity for submission of latrenative brand names
139.	<b>Pilzee Tablet</b>	Deferred with final opportunity for submission of latrenative brand names
140.	<b>Piles One Capsule</b>	Deferred with final opportunity for submission of latrenative brand names
141.	<b>Cigarette ChhorTablet</b>	Deferred with final opportunity for submission of latrenative brand names
142.	<b>Neurozion Syrup</b>	Deferred with final opportunity for submission of latrenative brand names
143.	<b>Ashoka Cordial Syrup</b>	Deferred with final opportunity for submission of latrenative brand names
144.	<b>Bed Wetting Syrup</b>	Deferred with final opportunity for submission of latrenative brand names
145.	<b>Coughlex Syrup</b>	Deferred with final opportunity for submission of latrenative brand names
146.	<b>Feverlex Syrup</b>	Deferred with final opportunity for submission of latrenative brand names
147.	<b>Gynolex Syrup</b>	Deferred with final opportunity for submission of latrenative brand names
148.	<b>Luzogen Syrup</b>	
149.	<b>Mega Mass Syrup</b>	Deferred with final opportunity for submission of latrenative brand names
150.	<b>Thandak Syrup</b>	Deferred with final opportunity for submission of latrenative brand names
151.	<b>Ginkolex Tablet</b>	Deferred with final opportunity for submission of latrenative brand names
152.	<b>Leco Care Tablet</b> 6x(EHPI)....0.02ml	Deferred with final opportunity for submission of latrenative brand names
153.	<b>Piles Shoot Syrup Paeonia 6x</b>	Deferred with final opportunity for submission of latrenative brand names
<b>M/s D.M.A Homeo Lab,</b> 19..Km, Ferozepure Road, Lahore (E. No.01009)		
154.	<b>DMA'S HEIGHT COMPOUND DROPS</b>	Deferred with final opportunity for sarcode testing(TSE,BSE,Ecoli)is required or evidence that source is free from TSE,BSE and Ecoli
<b>M/s. Dr. Zia Homoeopathic Pharma DZHP,</b> Plot No. 18, Sector - 14 Korangi Industrial Area, Karachi (E. No.00176)		
155.	<b>Histaminum (Potencies)</b>	Deferred with final opportunity Homeopathic monograph of Histamine is required
156.	<b>Hydrophobinum (Potencies)</b>	Deferred with final opportunity for Homeopathic monograph of Lyssin is required
157.	<b>Insulinum (Potencies)</b>	Deferred with final opportunity for sarcode testing of source material is required
158.	<b>Pituitary gland (Potencies)</b>	Deferred with final opportunity for sarcode testing of source material is required
159.	<b>Adrenalinum (Potencies)</b>	Deferred with final opportunity for sarcode testing of source material is required
160.	<b>Sepia Officinalis Ø (Mother tincture)</b>	Deferred with final opportunity for sarcode testing of source material is required
161.	<b>Bufo Rana Ø (Mother tincture)</b>	Deferred with final opportunity for sarcode testing of source material is required
<b>M/s. Islamabad Pharmacy,</b> Behind Qadir Gas Way 1, G.T. Road Wah District, Rawalpindi (E. No.00270)		
162.	<b>Islamabad Pharmacy's Robina pseu potencies</b> Robina pseudacacia (EHPI) <b>Potencies: 30C, 100C, 200C, 1M</b>	Deferred with final opportunity for sarcode testing of Yellow locust is required

163.	<b>Islamabad Pharmacy's Sepia potencies</b> Sepia (EHPI)	Deferred with final opportunity for sarcode testing of Inky juice of cuttlefish is required
164.	<b>GR Gum paint Drops</b>	Deferred for final opportunity Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
<b>M/s. Kamal Laboratories</b> Sukho, District Rawalpindi (E. No.0020)		
165.	<b>KL-71 DROPS</b>	Deferred with final opportunity clarification regarding facility ,source ,production, and storage of x ray formation is required Homeopathic monograph of X rays is required The applied formulation contains radioactive substance X rays
166.	<b>KL-77 DROPS</b>	Deferred with final opportunity clarification regarding the formulation
167.	<b>KL-78 DROPS</b>	Deferred with final opportunity for clarification regarding facility ,source ,production, and storage of Radium formation is required Homeopathic monograph of X rays is required The applied formulation contains radioactive substance radium
168.	<b>Acetone</b>	Deferred with final opportunity for Homeopathic monograph of <u>Acetone</u> is required
169.	<b>Achromycin</b>	Deferred with final opportunity for Homeopathic monograph of Tetracycline hydrochloride is required
170.	<b>X Ray</b>	Deferred with final opportunity for The applied formulation contains Radioactive substance X rays
171.	<b>Albucid</b>	Deferred with final opportunity for Homeopathic monograph of Albucid is required
172.	<b>Alloxin</b>	Deferred with final opportunity The applied formulation contains <b>toxic glucose analogue, which selectively destroys insulin-producing cells in the pancreas (that is, beta cells) when administered</b> Homeopathic monograph of Alloxin
173.	<b>Aminophyllin</b>	Deferred with final opportunity for Justification regarding stability of aminophylline in oral solution form is required Homeopathic monograph of Aminophyllin is required
174.	<b>Araldite</b>	Deferred with final opportunity for Homeopathic monograph of Araldite (synthetic adhesive) is highly toxic when taken orally, Justification is required for its use as orally
175.	<b>Asbestos</b>	Deferred with final opportunity for Homeopathic monograph of Asbestos is required Asbestos is highly poisonous and cause Lung cancer , Justification is required for its use as orally Asbestos is banned item By EPA,(NIOSH) due to its air born particle hazards
176.	<b>Aureomycin</b>	Deferred with final opportunity for Homeopathic monograph of <u>Aureomycin</u> is required
177.	<b>Benadryl</b>	Deferred with final opportunity for The firm applied product with brand name/market name Benadryl

		contains Diphenhydramine and Homeopathic monograph is required
178.	<b>Busubhan</b>	Deferred with final opportunity for Homeopathic monograph of <u><b>Busubhan</b></u> is required
179.	<b>Butazolidin</b>	Deferred with final opportunity for Homeopathic monograph of <u><b>Butazolidin</b></u> is required
180.	<b>Chloramine-T</b>	Deferred with final opportunity for Homeopathic monograph of <u><b>Chloramine-T</b></u> is required
181.	<b>Chloramphenical</b>	Deferred with final opportunity for Homeopathic monograph of <u><b>Chloramphenical</b></u> is required
182.	<b>Chloroform</b>	Deferred with final opportunity for The applied formulation contains chloroform which is highly toxic when taken orally as due to its respiratory and cardiac arrest
183.	<b>Chlorothiazide</b>	Deferred with final opportunity for Homeopathic monograph of <u><b>Chlorothiazide</b></u> is required
184.	<b>Chlorpomazine Hydrochloride</b>	Deferred with final opportunity for Homeopathic monograph of <u><b>Chlorpomazine-Hydrochloride</b></u> is required furthermore its antipsychotic drug
185.	<b>Chlortetracycline Hydrochloride</b>	Deferred with final opportunity for Homeopathic monograph of <u><b>Chlortetracycline Hydrochlorid</b></u> is required
186.	<b>Cobal Rays</b>	Deferred with final opportunity for Homeopathic monograph of <u><b>Cobalt rays</b></u> is required The facility for source ,formation, handling ,production of cobalt rays is required
187.	<b>Cortine</b>	Deferred with final opportunity for Homeopathic monograph of <u><b>Deoxyocortone acetate</b></u> is required The applied formulation contains steroidal preparation of Deoxyocortone acetate as sterile facility is required
188.	<b>Cresol</b>	Deferred with final opportunity for Homeopathic monograph of <u><b>Cresol</b></u> is required
189.	<b>Dapsone</b>	Deferred with final opportunity for Homeopathic monograph of <u><b>Dapsone</b></u> is required
190.	<b>Dichloro Diphenyl Trichloroethane</b>	Deferred with final opportunity for The applied formulation contains Insecticides DDT( <u><b>Dichloro Diphenyl Trichloroethane</b></u> ) which is higly poisinious when taken orally
191.	<b>Durabolin</b>	Deferred with final opportunity for The applied formulation contains anabolic steroids ( Nandrolone cyclohexylpropionate

192.	<b>Electricity</b>	Deferred with final opportunity for Justify the role of electricity in homeopathic use along with Homeopathic monograph
193.	<b>Emetin Hydrochloride</b>	Deferred with final opportunity for Homeopathic monograph of Emetin Hydrochloride is required
194.	<b>Endoxan</b>	Deferred with final opportunity for The applied formulation contains Cyclophosphamide which is immunosuppressant drug
195.	<b>Ergotina</b>	Deferred with final opportunity for Homeopathic monograph of Ergotina is required
196.	<b>Erythromycin</b>	Deferred with final opportunity for Homeopathic monograph of Erythromycin is required
197.	<b>Ether</b>	Deferred with final opportunity for Homeopathic monograph of Ether is required Furthermore diethyl ether is highly flammable
198.	<b>Flagyl</b>	Deferred with final opportunity for The firm applied product with brand name Flagyl Homeopathic monograph of Metronidazol is required
199.	<b>Formalin</b>	Deferred with final opportunity for The applied formulation contains Formalin which is highly poisonous when taken orally
200.	<b>Gamma</b>	Deferred with final opportunity for The applied formulation contains Gamma rays which is radioactive substance
201.	<b>Chlortetracycline Hydrochloride</b>	Deferred with final opportunity for Homeopathic monograph of Chlortetracycline Hydrochloride is required
202.	<b>KL-64 DROPS</b>	Deferred with final opportunity for justification and clarification of formulation
203.	<b>Amygdale</b>	Deferred with final opportunity for monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
204.	<b>Aorte</b>	Deferred with final opportunity for monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
205.	<b>Artere Carotide</b>	Deferred with final opportunity for monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
206.	<b>Artere</b>	Deferred with final opportunity for monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
207.	<b>Ovarinum</b>	Deferred with final opportunity for monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
208.	<b>Bulbinum</b>	Deferred with final opportunity for monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
209.	<b>Cardine</b>	Deferred with final opportunity for monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
210.	<b>Cartilago</b>	Deferred with final opportunity for monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli



211.	<b>Cerebellum</b>	Deferred with final opportunity for monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
212.	<b>Cerebrinum</b>	Deferred with final opportunity for monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
213.	<b>Coccyx</b>	Deferred with final opportunity for monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
214.	<b>Colon (Muqueuse du)</b>	Deferred with final opportunity for monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
215.	<b>Corps Jaune</b>	Deferred with final opportunity for monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
216.	<b>Cortex Surrenal</b>	Deferred with final opportunity for monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
217.	<b>Disci Cervicales</b>	Deferred with final opportunity for monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
218.	<b>Disci Lumbales</b>	Deferred with final opportunity for monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
219.	<b>Epiphyse</b>	Deferred with final opportunity for monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
220.	<b>Estomac</b>	Deferred with final opportunity for Herbal monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
221.	<b>Ganglions Lymphatiques</b>	Deferred with final opportunity for monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
222.	<b>Gencives</b>	Deferred with final opportunity for monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
223.	<b>Glandes Mammaires</b>	Deferred with final opportunity for monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
224.	<b>Glandes Surrenales</b>	Deferred with final opportunity for monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
225.	<b>Parotidinum</b>	Deferred with final opportunity for monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
226.	<b>Hypophysine LA</b>	Deferred with final opportunity for monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
227.	<b>Pancreine</b>	Deferred with final opportunity for monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
228.	<b>Hypophysine</b>	Deferred with final opportunity for monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
229.	<b>Pancreine</b>	Deferred with final opportunity for monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
230.	<b>Intestine Gros</b>	Deferred with final opportunity for monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
231.	<b>Langue</b>	Deferred with final opportunity for monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli

232.	<b>Larynx</b>	Deferred with final opportunity for monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
233.	<b>Ligaments</b>	Deferred with final opportunity for monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
234.	<b>Mamelline</b>	Deferred with final opportunity for monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
235.	<b>Medulline</b>	Deferred with final opportunity for monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
236.	<b>Meduloss</b>	Deferred with final opportunity for monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
237.	<b>Muqueuse Endo</b>	Deferred with final opportunity for monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
238.	<b>Muqueuse Gastrique</b>	Deferred with final opportunity for monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
239.	<b>Orchitinum</b>	Deferred with final opportunity for monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
240.	<b>Muqueuse Intestinale</b>	Deferred with final opportunity for monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
241.	<b>Muqueuse Laryngee</b>	Deferred with final opportunity for monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
242.	<b>Muqueuse Linguale</b>	Deferred with final opportunity for monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
243.	<b>Muqueuse Sinusale</b>	Deferred with final opportunity for monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
244.	<b>Muqueuse Stomacale</b>	Deferred with final opportunity for monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
245.	<b>Muqueuse Uterine</b>	Deferred with final opportunity for monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
246.	<b>Muscle Lisse</b>	Deferred with final opportunity for monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
247.	<b>Muscle Oculaires</b>	Deferred with final opportunity for monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
248.	<b>Nerfs Moteur</b>	Deferred with final opportunity for monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
249.	<b>Nerfs Occipital</b>	Deferred with final opportunity for monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
250.	<b>Nerfs Optique</b>	Deferred with final opportunity for monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
251.	<b>Nerfs Parasympathique</b>	Deferred with final opportunity for monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
252.	<b>Nerfs</b>	Deferred with final opportunity for monograph along with Sarcode testing/evidence that source is free from TSE,BSE and Ecoli
253.	<b>FERRIN CAPSULES</b>	Deferred with final opportunity Homeopathic monograph of Folic acid, Vitamin B12 are required Sarcode testing/evidence that source is free from TSE,BSE and Ecoli

<b>M/s Mansoor Homoeo Pharma,</b> <b>LS-35, St-10/A, Block No.16, F.B. Area, Karachi (E. No.00419)</b>		
254.	<b>C5 GASTRONIN Drops</b>	<ul style="list-style-type: none"> <li>Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
255.	<b>C7 NEURALGION Drops</b>	<ul style="list-style-type: none"> <li>Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
256.	<b>C8 SINUTON Drops</b>	<ul style="list-style-type: none"> <li>Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
257.	<b>C9 RHEUMATON Drops</b>	<ul style="list-style-type: none"> <li>Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
258.	<b>NEFRO COMPLEX Drops</b>	<ul style="list-style-type: none"> <li>Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
259.	<b>CARDUUS COMPLEX Drops</b>	<ul style="list-style-type: none"> <li>Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
260.	<b>HAIR COMPLEX Drops</b>	<ul style="list-style-type: none"> <li>Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
261.	<b>MHP ... 1 GERD Drops</b>	<ul style="list-style-type: none"> <li>Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
262.	<b>MHP ... 2 RUMACARB Drops</b>	<ul style="list-style-type: none"> <li>Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
263.	<b>MHP ... 3 DETRULITH Drops</b>	<ul style="list-style-type: none"> <li>Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
264.	<b>MHP ... 4 HEMORECT Drops</b>	<ul style="list-style-type: none"> <li>Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
265.	<b>MHP ... 5 DERMECH Drops</b>	<ul style="list-style-type: none"> <li>Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
266.	<b>MHP ... 6 HEPAMAG Drops</b>	<ul style="list-style-type: none"> <li>Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>

267.	<b>MHP ... 7 LEUCOHYDE Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
268.	<b>MHP ... 8 ANXINAP Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
269.	<b>MHP ... 9 VOMEZ Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
270.	<b>MHP ... 10 WORMGARD Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
271.	<b>MHP ... 11 SINUX Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
272.	<b>MHP ... 12 DYROSOL Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
273.	<b>MHP ... 13 DIALOX Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
274.	<b>MHP ... 14 CALADEX Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
275.	<b>MHP ... 15 PYROX Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
276.	<b>MHP ... 16 URIX Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
277.	<b>MHP ... 17 ACNE FACE TONE Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
278.	<b>MHP ... 18 CERVINEX Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
279.	<b>MHP ... 19 PROSTOMALE Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
280.	<b>MHP ... 20 DENGNAL Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed</li> </ul>

		combination in local market for last 10 years(sales invoices including distribution record).
281.	<b>MHP ... 21 ASTHAM Drops</b>	• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
282.	<b>MHP ... 22 GOLD DROPS Drops</b>	• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
283.	<b>MHP ... 23 MENSTRAL Drops</b>	• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
284.	<b>MHP ... 24 BRAIN TONIC Drops</b>	• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
285.	<b>MHP ... 25 SMART Drops</b>	• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
286.	<b>MHP ... 27 VITILEC Drops</b>	• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
287.	<b>MHP ... 28 INFISORE Drops</b>	• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
288.	<b>MHP ... 29 LAXORECT Drops</b>	• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
289.	<b>MHP ... 30 GINGI Drops</b>	• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
290.	<b>MHP ... 31 MIGRA Drops</b>	• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
291.	<b>MHP ... 32 ENURIT Drops</b>	• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
292.	<b>MHP ... 33 HBP Drops</b>	• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
293.	<b>MHP ... 34 ANOREXIA Drops</b>	• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).

294.	<b>MHP ... 35 HL...TALL Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
295.	<b>MHP ... 36 EAR...EZ Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
296.	<b>MHP ... 37 EYEZOL Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
297.	<b>MHP ... 38 NERVOL Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
298.	<b>MHP ... 39 HOL...FIX Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
299.	<b>MHP ... 40 HAIR CARE Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
300.	<b>MHP ... 41 TRAUMIX Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
301.	<b>MHP ... 42 MOUTH SORE Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
302.	<b>MHP...43 STIMULATION TONIC Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
303.	<b>MHP ... 44 ALBUTOX Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
304.	<b>MHP ... 45 GINSENG BOOST Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
305.	<b>MHP ... 46 GALTOX Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
306.	<b>MHP ... 47 EPILEPSOL Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>



307.	<b>MHP ... 48 FALIJEX Drops</b>	• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
308.	<b>MHP ... 49 TONSINIL Drops</b>	• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
309.	<b>MHP ... 50 THYROXINIL Drops</b>	• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
310.	<b>MHP ... 51 VERTILEX Drops</b>	• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
311.	<b>MHP ... 52 MORBINIL Drops</b>	• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
312.	<b>MHP ... 53 TUMEDIC Drops</b>	• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
313.	<b>MHP ... 54 HERNIZIP Drops</b>	• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
314.	<b>MHP ... 55 SCIATILAX Drops</b>	• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
315.	<b>MHP ... 56 SHAPEUP Drops</b>	• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
316.	<b>MHP ... 57 PAPILOMA Drops</b>	• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
317.	<b>MHP ... 58 NICOTOX Drops</b>	• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
318.	<b>MHP ... 59 FUNGUS Drpos</b>	• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
319.	<b>MHP ... 60 HORMODEC Drops</b>	• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
320.	<b>MHP ... 61 VARICELLA Drops</b>	• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed

		combination in local market for last 10 years(sales invoices including distribution record).
321.	<b>MHP ... 62 URTISOL Drops</b>	• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
322.	<b>MHP ...63 PARKINSOL Drops</b>	• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
323.	<b>HEART COMPLEX Drops</b>	• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
324.	<b>ALFALFA TONIC Syrup</b>	• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
325.	<b>ASHOKA Syrup</b>	• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
326.	<b>BRYCOVIT Syrup</b>	• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
327.	<b>GERD Syrup</b>	• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
328.	<b>HAPAMAG Syrup</b>	• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
329.	<b>HERSTEL Syrup</b>	• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
330.	<b>LAXI Syrup</b>	• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
331.	<b>PANTOUX Syrup</b>	• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
332.	<b>RENECAL Syrup</b>	• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
333.	<b>VOMEZ Syrup</b>	• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).

334.	<b>ACIDIN-C Syrup</b>	<ul style="list-style-type: none"> <li>Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
335.	<b>GINKGO BILOBA TONIC Syrup</b>	<ul style="list-style-type: none"> <li>Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
336.	<b>JAM E RAHAT Syrup</b>	<ul style="list-style-type: none"> <li>Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
337.	<b>MHP FEVER SYRUP Syrup</b>	<ul style="list-style-type: none"> <li>Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
338.	<b>MHP GASTRIC SYRUP Syrup</b>	<ul style="list-style-type: none"> <li>Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
339.	<b>MHP COUGH SYRUP Syrup</b>	<ul style="list-style-type: none"> <li>Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
340.	<b>MHP DIARRHEA SYRUP Syrup</b>	<ul style="list-style-type: none"> <li>Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
341.	<b>MHP TONSITRIX SYRUP Syrup</b>	<ul style="list-style-type: none"> <li>Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
342.	<b>FIBROLEC MALT Syrup</b>	<ul style="list-style-type: none"> <li>Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
343.	<b>INFACURE COLIC DROPS Drops</b>	<ul style="list-style-type: none"> <li>Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
344.	<b>MULLEIN EAR DROPS Drops</b>	<ul style="list-style-type: none"> <li>Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
345.	<b>PEDITRON GRIPE WATER Syrup</b>	<ul style="list-style-type: none"> <li>Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
346.	<b>PLANTAGO DENTAL REMEDY Drops</b>	<ul style="list-style-type: none"> <li>Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>

347.	<b>SINUX NASAL SPRAY Spray</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
348.	<b>SHARBAT E FAULAD Syrup</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
349.	<b>DYROSOL Syrup</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
350.	<b>Diaracin Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
351.	<b>Brenol Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
352.	<b>Venrol Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
353.	<b>Verminal Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
354.	<b>Sleepnex Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
355.	<b>Semone Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
356.	<b>Baby Tonic Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
357.	<b>Yohimbitone Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
358.	<b>Diagoline Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
359.	<b>Eyetis Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
360.	<b>Rheumacin Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed</li> </ul>

		combination in local market for last 10 years(sales invoices including distribution record).
361.	<b>Mensee Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
362.	<b>Lactocin Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
363.	<b>Pleuragin Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
364.	<b>Easy Birth Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
365.	<b>Respicin Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
366.	<b>Episinium Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
367.	<b>Strumeel Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
368.	<b>Tonsilex Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
369.	<b>PILES FAR Powder</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
370.	<b>Scialgin Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
371.	<b>Preshole Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
372.	<b>Redcor Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
373.	<b>Reno Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>

374.	<b>Sinuse Drops</b>	<ul style="list-style-type: none"> <li>Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
375.	<b>Pilex Drops</b>	<ul style="list-style-type: none"> <li>Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
376.	<b>Alfasy Drops</b>	<ul style="list-style-type: none"> <li>Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
377.	<b>Paralysin Drops</b>	<ul style="list-style-type: none"> <li>Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
378.	<b>Veratrum Drops</b>	<ul style="list-style-type: none"> <li>Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
379.	<b>Vertigone Drops</b>	<ul style="list-style-type: none"> <li>Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
380.	<b>Baresin Drops</b>	<ul style="list-style-type: none"> <li>Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
381.	<b>Geritax Drops</b>	<ul style="list-style-type: none"> <li>Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
382.	<b>Ulcerine Drops</b>	<ul style="list-style-type: none"> <li>Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
383.	<b>Steron Drops</b>	<ul style="list-style-type: none"> <li>Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
384.	<b>Nervita Drops</b>	<ul style="list-style-type: none"> <li>Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
385.	<b>Antifebrol Drops</b>	<ul style="list-style-type: none"> <li>Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
386.	<b>Barsal Drops</b>	<ul style="list-style-type: none"> <li>Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>



387.	<b>Womenlex Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
388.	<b>Headexine Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
389.	<b>Menstone Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
390.	<b>Kalsolene Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
391.	<b>B...Tax Lotion</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
392.	<b>Rheumalex Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
393.	<b>Arteria Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
394.	<b>Calculin Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
395.	<b>Uritone Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
396.	<b>Epigo Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
397.	<b>Vomitis Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
398.	<b>Mouthogin Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
399.	<b>Jenitone Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
400.	<b>Heptone Drops</b>	<ul style="list-style-type: none"> <li>• Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed</li> </ul>

		combination in local market for last 10 years(sales invoices including distribution record).
401.	<b>Gripsin Drops</b>	<ul style="list-style-type: none"> <li>Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
402.	<b>Hernex Drops</b>	<ul style="list-style-type: none"> <li>Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
403.	<b>Cardina Drops</b>	<ul style="list-style-type: none"> <li>Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
404.	<b>Tansol Drops</b>	<ul style="list-style-type: none"> <li>Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
405.	<b>Rheumata Drops</b>	<ul style="list-style-type: none"> <li>Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
406.	<b>Cancerolene Drops</b>	<ul style="list-style-type: none"> <li>Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
407.	<b>Francy Drops</b>	<ul style="list-style-type: none"> <li>Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
408.	<b>Lekreen Drops</b>	<ul style="list-style-type: none"> <li>Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
409.	<b>Deafol Drops</b>	<ul style="list-style-type: none"> <li>Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
410.	<b>Enura Drops</b>	<ul style="list-style-type: none"> <li>Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).</li> </ul>
411.	<b>Blut Drops</b>	Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
412.	<b>Psorineel Drops</b>	Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
413.	<b>Kidsal Drops</b>	Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).

414.	<b>Spermatorrhin Drops</b>	Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
415.	<b>Gelsemium Drops</b>	Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
416.	<b>Jaitol Drops</b>	Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
417.	<b>Intestinal Drops</b>	Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
418.	<b>Stomolene Drops</b>	Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
419.	<b>Skinex Drops</b>	Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
420.	<b>Shifanole Drops</b>	Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
421.	<b>Baimisal Drops</b>	Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
422.	<b>Colicin Drops</b>	Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
423.	<b>Facit Drops</b>	Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
424.	<b>Gastru Drops</b>	Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
425.	<b>Pelone Drops</b>	Defererd with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
<b>M/s Mektum Homoeo Pharma, Karachi</b>		
426.	Gynofex Syrup	Deferred with final opportunity for submission of soft copy of the formulation as per checklist of form 3
427.	Mek-Safi Syrup	Deferred with final opportunity for submission of soft copy of the formulation as per checklist of form 3
<b>M/s MS Laboratories (Homoeo Division), St.No.28, Nisar Colony Industrial Area, Samanabad, Faisalabad (E. No.00551)</b>		

428.	Antipyrinum Q	Deferred with final opportunity for Homeopathic monograph of Phenazone is required
429.	Apis Mellifica Q	Deferred with final opportunity for for evidence of sarcoce testing (TSE BSE Ecoli) free is required
430.	Cantharis Vesicatoria Q	Deferred with final opportunity for sarcode testing of TSE,BSE is required
431.	Cola Q	Deferred with final opportunity for Homeopathic monograph of cola is required
432.	Fel Tauri Q(EHPI)	Deferred with final opportunity for for sarcode testing (TSE,BSE is required )
433.	Formica Rufa Q	Deferred with final opportunity for for sarcode testing (TSE,BSE is required )
434.	Naphthalinum Q=ICH	Deferred with final opportunity for Homeopathic monograph of Naphthalinum is required
435.	Sepia Q	Deferred with final opportunity for sarcode testing(TSE,BSE ) is required
<b>M/s Pak German Pharma,</b> Plot No. 39-A, R-3 Industrial Estate, Gadoon Amzai, Swabi (E. No.00723)		
436.	<b>Stone Crasher syrup</b>	Deferred with final opportunity for submission of alternative brand name
437.	<b>Testa ovarum drops</b>	Deferred for final opportunity for sarcode testing of product is required
438.	<b>Kali Phos drops</b>	Approved with general claim
439.	<b>Berberis drops</b>	Approved with general claim
440.	<b>Abdamee tablet</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
441.	<b>Agnus Plus tablet</b>	Deferred for sarcode testing of product is required
442.	<b>Calcarea Plus tablet</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
443.	<b>UP Calcium tablet</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
444.	<b>Luteum Tin capsule</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
445.	<b>Leucorrhoea Folaad capsule</b>	Deferred for sarcode testing of product is required
446.	<b>Acid Phos capsule</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
447.	<b>Morgan capsule</b>	Deferred for sarcode testing of product is required
448.	<b>B.H capsule</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).

449.	<b>Shifa e Naswa Drops (External use)</b>	Deferred for sarcode testing of product is required
450.	<b>Ferrum Drops</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
451.	<b>Gastrozyme Syrup</b>	Deferred for sarcode testing of product is required
452.	<b>Ashoka Syrup</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
453.	<b>Night capsule</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
454.	<b>Tonsil Drops</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
455.	<b>Nux Drops</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
456.	<b>Calciron Syrup</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
457.	<b>Fertile Capsule</b>	Deferred for sarcode testing of product is required
458.	<b>Ova agnus Tablet</b>	Deferred for sarcode testing of product is required
459.	<b>No abortion Syrup</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
460.	<b>Bed wetting Drops</b>	Deferred for sarcode testing of product is required
461.	<b>Appetite Drops</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
462.	<b>Freckles acne Drops</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
463.	<b>Collins Drops</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
464.	<b>Kidney Drops</b>	Deferred for sarcode testing of product is required
<b>M/s. Paul Brooks Homoeo Labs,</b> Plot No. A-69, S.I.T.E., Super Highway Phase-I, Karachi (E. No.0088)		

465.	<b>Rulcid Syrup</b>	Defererd with final opportunity for submission of required documents as per checklist of form 3 and submission whether their product is disposed of or otherwise
466.	<b>Antifat Plus Capsule</b>	Defererd with final opportunity for submission of required documents as per checklist of form 3 and submission whether their product is disposed of or otherwise
467.	<b>Ginseng 1x Tablet</b>	Defererd with final opportunity for submission of required documents as per checklist of form 3 and submission whether their product is disposed of or otherwise
468.	<b>Itcho Cream</b>	Defererd with final opportunity for submission of required documents as per checklist of form 3 and submission whether their product is disposed of or otherwise
469.	<b>Kracko Cream</b>	Defererd with final opportunity for submission of required documents as per checklist of form 3 and submission whether their product is disposed of or otherwise
470.	<b>Vitigo Ointment</b>	Defererd with final opportunity for submission of required documents as per checklist of form 3 and submission whether their product is disposed of or otherwise
471.	<b>Gandhakeen Cream</b>	Defererd with final opportunity for submission of required documents as per checklist of form 3 and submission whether their product is disposed of or otherwise
472.	<b>V.Care Cream</b>	Defererd with final opportunity for submission of required documents as per checklist of form 3 and submission whether their product is disposed of or otherwise
473.	<b>Nozema Ointment</b>	Defererd with final opportunity for submission of required documents as per checklist of form 3 and submission whether their product is disposed of or otherwise
474.	<b>Markonil Cream</b>	Defererd with final opportunity for submission of required documents as per checklist of form 3 and submission whether their product is disposed of or otherwise
475.	<b>Arsenicum Album 30C Tablet</b>	Defererd with final opportunity for submission of required documents as per checklist of form 3 and submission whether their product is disposed of or otherwise
476.	<b>Caricon Capsule</b>	Defererd with final opportunity for submission of required documents as per checklist of form 3 and submission whether their product is disposed of or otherwise
477.	<b>Immune Elderbarry Tablet</b>	Defererd with final opportunity for submission of required documents as per checklist of form 3 and submission whether their product is disposed of or otherwise
478.	<b>Kali Plex Drops</b>	Defererd with final opportunity for submission of required documents as per checklist of form 3 and submission whether their product is disposed of or otherwise
479.	<b>Malca Drops</b>	Defererd with final opportunity for submission of required documents as per checklist of form 3 and submission whether their product is disposed of or otherwise
480.	<b>Podina Syrup</b>	Defererd with final opportunity for submission of required documents as per checklist of form 3 and submission whether their product is disposed of or otherwise
481.	<b>Vital C Syrup</b>	Defererd with final opportunity for submission of required documents as per checklist of form 3 and submission whether their product is disposed of or otherwise
482.	<b>Colic Drop</b>	Defererd with final opportunity for submission of required documents as per checklist of form 3 and submission whether their product is disposed of or otherwise
483.	<b>Anti Krack Cream</b>	Defererd with final opportunity for submission of required documents as per checklist of form 3 and submission whether their product is disposed of or otherwise
484.	<b>Gasgon Syrup</b>	Defererd with final opportunity for submission of required documents as per checklist of form 3 and submission whether their product is disposed of or otherwise
485.	<b>Coffic Syrup</b>	Defererd with final opportunity for submission of required documents as per checklist of form 3 and submission whether their product is disposed of or otherwise
486.	<b>Fasto Gel</b>	Defererd with final opportunity for submission of required documents as per checklist of form 3 and submission whether their product is disposed of or otherwise



487.	<b>Pileeno Ointment</b>	Defererd with final opportunity for sunmission of required documents as per checklist of form 3 and submission whether their product is disposed of or otherwise
488.	<b>Pileeno Capsule</b>	Defererd with final opportunity for sunmission of required documents as per checklist of form 3 and submission whether their product is disposed of or otherwise
489.	<b>Leuconil Capsule</b>	Defererd with final opportunity for sunmission of required documents as per checklist of form 3 and submission whether their product is disposed of or otherwise
490.	<b>Maledo Capsule</b>	Defererd with final opportunity for sunmission of required documents as per checklist of form 3 and submission whether their product is disposed of or otherwise
491.	<b>Ginkgo Stress Relief Oral Liquid</b>	Defererd with final opportunity for sunmission of required documents as per checklist of form 3 and submission whether their product is disposed of or otherwise
492.	<b>Spermax Capsule</b>	Defererd with final opportunity for sunmission of required documents as per checklist of form 3 and submission whether their product is disposed of or otherwise
<b>M/s Roots Pharma (Pvt) Ltd., Plot No.602, Sunder Industrial Estate, Lahore (E. No.00553)</b>		
493.	<b>Roots STONIL Drops</b>	Defererd for sarcode testing of product is required
494.	<b>Roots MSL VITA M SYRUP</b>	Defererd for sarcode testing of product is required
495.	<b>Roots MSL MediPlex Syrup</b>	Defererd for sarcode testing of product is required
496.	<b>Roots Cough Max Syrup</b>	Deferred with final opportunity for submission of latrenative brand name
497.	<b>Roots GASTRO MAX Syrup</b>	Defererd for sarcode testing of product is required
<b>M/s Rose Homeo Research Laboratories, Plot No. 75-78, Small Industrial Estate, Sheikhabad, Takhtbhi Road, Charsadda (E. No.00932)</b>		
498.	<b>Gun Powder</b>	Deferred with final opportunity for specification of applied product is required clarification regarding handling source, storage and safety profile of gun powder is required
499.	<b>Hekla Lava</b>	Deferred with final opportunity for specification of applied product is required clarification regarding handling source, storage and safety profile of Hekla lava is required
500.	<b>Insulin Dilution</b>	Deferred with final opportunity for sarcode testing (TSE,BSE and Ecoli) is required
501.	<b>Murex Purpurea</b>	Homeopathic Medicine to be used as per published homeopathic pharmacopeia or meteria medica
502.	<b>NAPHTHALINUM</b>	Homeopathic Medicine to be used as per published homeopathic pharmacopeia or meteria medica
503.	<b>Prostate Gland Dilution</b>	Deferred for sarcode testing of finished product is required
504.	<b>Paraffinum Dilution</b>	Deferred for specification of applied product is required
505.	<b>Malaria Officinalis Dilution</b>	Deferred for specification of applied product is required

506.	Happy Move 20ml drops	Deferred with final opportunity for submission of 10 years data of sales and distribution of applied combination product
507.	Ginkgo-G 120ml 250 ml Syrup	Deferred with final opportunity for submission of 10 years data of sales and distribution of applied combination product
508.	Artemet 20ml Drops	Deferred with final opportunity for submission of 10 years data of sales and distribution of applied combination product
509.	Pilomorm 20ml drops	Deferred with final opportunity for submission of 10 years data of sales and distribution of applied combination product
510.	Ferrum Hony 120ml syrup	Deferred with final opportunity for submission of 10 years data of sales and distribution of applied combination product
511.	Bell-O-Nion 20ml drops	Deferred with final opportunity for submission of 10 years data of sales and distribution of applied combination product
512.	Parkinsonism 20ml drops	deferred with final opportunity for submission of 10 years data of sales and distribution of applied combination product
<b>M/s Sadiq Pharma (Pvt) Ltd.,</b> Moza Kotli Rawalpindi Road, Jand (E. No.00499)		
513.	<b>Rani Khet Cure 1X Liquid</b>	Deferred with final opportunity for strength of active ingrdeints in the formulation is required
514.	<b>Colcogest Fort 1X Liquid</b>	Deferred with final opportunity for strength of active ingrdeints in the formulation is required
515.	<b>High Gest 30X Powder</b>	Deferred with final opportunity for strength of active ingrdeints in the formulation is required
516.	<b>OTC 1X Liquid</b>	Deferred with final opportunity for strength of active ingrdeints in the formulation is required
517.	<b>Magic OTC 3x Liquid</b>	Deferred with final opportunity for strength of active ingrdeints in the formulation is required
518.	<b>Arnica Gold 30 Liquid</b>	
<b>M/s Sante Graine de Vie Pharma (Pvt) Ltd.,</b> Plot No. 1-A, Engineering Zone, Value Addition City Khurrianwala, Faisalabad (E. No.00806)		
519.	<b>PUR TONSIL Tab.</b>	Deferred with final opportunity for change of brand name
520.	<b>PPUR VISION TABLET</b>	Deferred with final opportunity for change of brand name
521.	<b>HAIR VITA TABLET</b>	Deferred with final opportunity for change of brand name
522.	<b>CONT. DEPRESSIVE TABLET</b>	Deferred with final opportunity for change of brand name
523.	<b>PUR DYSMENORR Tablet</b>	Deferred with final opportunity for change of brand name
524.	<b>CONT. ALLERGIN Tab.</b>	Deferred with final opportunity for change of brand name
525.	<b>BRONCHCARE SYRUP</b>	Defererd with final opportunity for change of brand name
<b>M/s Sonexo Homoeo</b> <b>15 Lakhodher Industrial Zone, Turkey Road, Lahore (E. No.00758)</b>		
526.	Sonexo's Robina Pseud	Deferred with final opportunity for sarcode testing (TSE,BSe,Ecoli) is required
527.	Sonexo's Sepia	Deferred with final opportunity for sarcode testing (TSE,BSe,Ecoli) is required
<b>M/s TS Laboratories, [Homeopathic Human]</b> 5-Km Makkuana Bypass, Khurianwala, Faisalabad-Pakistan (E. No. 00640)		
528.	<b>TS CRATAEGUS POTENCY</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product

529.	<b>TS CARBO VEGETABILIS POTENCY</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product
530.	<b>TS CIMICIFUGA RACEMOSA POTENCY</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product
531.	<b>TS SABINA POTENCY</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product
532.	<b>TS SARSAPARILLA POTENCY</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product
533.	<b>TS POLYGALA SENEGA POTENCY</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product
534.	<b>TS SEPIA POTENCY</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product
535.	<b>TS CINA POTENCY</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product
536.	<b>TS SYZYGIIUM CUMINII POTENCY</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product
537.	<b>TS STERCULIA POTENCY</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product
538.	<b>TS SOLIDAGO VIRGAUREA POTENCY</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product
539.	<b>TS COLLINSONIA POTENCY</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product
540.	<b>TS COLOCYNTHIS POTENCY</b> )	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product
541.	<b>TS CONVALLARIA POTENCY</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product
542.	<b>TS THYMOL Q</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product
543.	<b>TS SABADILLA POTENCY</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product
544.	<b>TS COLCHICUM POTENCY</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product
545.	<b>TS CAMPHOR POTENCY</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product
546.	<b>TS NUX VOMICA POTENCY</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product
547.	<b>TS ALSTONIA SCHOLARS POTENCY</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product
548.	<b>TS EUCALYPTUS GLOBULUS Q</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product
549.	<b>TS GENTIANA LUTEA Q</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product
550.	<b>TS HELIANTHUS ANNUS Q</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product

551.	<b>TS HYDRASTIS CANADENSIS Q</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product
552.	<b>TS WITHANIA SOMNIFERA POTENCY</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product
553.	<b>TS TARAXACUM POTENCY</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product
554.	<b>TS ORNITHOGALUM UMBELLATUM POTENCY</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product
555.	<b>TS THUJA POTENCY</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product
556.	<b>TS PULSATILLA POTENCY</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product
557.	<b>TS ARSENICUM ALBUM POTENCY</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product
558.	<b>TS ACIDUM BENZOICUM Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
559.	<b>TS MENTHA PIPERATA Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
560.	<b>TS CHIONANTHUS VERGINICA Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
561.	<b>TS SELENIUM POTENCY</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
562.	<b>TS TERMINALIA ARJUNA POTENCY</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
563.	<b>TS VALERIANA OFFICINALIS...Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
564.	<b>TS ZINGIBER OFFICINALE Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
565.	<b>TS GOSSYPIUM HERBACEUM Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
566.	<b>TS ALLIUM CEPA Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
567.	<b>TS SARACA INDICA Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section

568.	<b>TS CHAMOMILLA Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
569.	<b>TS CHELIDONIUM MAJUS Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
570.	<b>TS MORINGA OLIFERA Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
571.	<b>TS PAEONIA OFFICINALIS Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
572.	<b>TS PIPER NIGRUM Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
573.	<b>TS RICINUS COMMUNIS Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
574.	<b>TS AMMI VISNAGA POTENCY</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product
575.	<b>TS ARGENTUM NITRICUM POTENCY</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product
576.	<b>TS PASSIFLORA POTENCY</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product
577.	<b>TS ABIES NIGRA POTENCY</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product
578.	<b>TS RAUWOLFIA SERPENTIN POTENCY</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product
579.	<b>TS CINNAMONUM POTENCY</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product
580.	<b>TS RHUS TOXICODENDRON POTENCY</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product
581.	<b>TS RUMEX CRISPUS POTENCY</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product
582.	<b>TS BERBERIS VULGARIS POTENCY</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product
583.	<b>TS BRYONIA ALBA POTENCY</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product

584.	<b>TS BELLADONA POTENCY</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product
585.	<b>TS OPIUM POTENCY</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product
586.	<b>TS ROBINA PSELLDACACIA POTENCY</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product
587.	<b>TS RUTA GRAVEOLENS POTENCY</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product
588.	<b>TS SANGUINARIA CANADENSIS POTENCY</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product
589.	<b>TS SPONGIA TOSTA POTENCY</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product
590.	<b>TS STAPHYSAGRIA POTENCY</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product
591.	<b>TS PHYSOSTIGMA VENENOSUM Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
592.	<b>TS RAPHANUS SATIVUS Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
593.	<b>TS NUPHER LUTEUM Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
594.	<b>TS ORIGANUM MAJORANA Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
595.	<b>TS PAREIRA BRAVA Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
596.	<b>TS CAPSICUM ANNUM Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
597.	<b>TS BAPTISIA TINCTORIA Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
598.	<b>TS BERBERIS AQUIFOLIUM Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
599.	<b>TS CALENDULA OFFICINALIS Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
600.	<b>TS CARUM CARVI Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section



601.	<b>TS SENECIO AUREUS Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
602.	<b>TS SLAIX NIGRA Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
603.	<b>TS RUBIA TINCTORIA Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
604.	<b>TS SCUTELLARIA LATERIFLORA Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
605.	<b>TS SABAL SERRULATA Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
606.	<b>TS FRAXINUS AMERICANA Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
607.	<b>TS GINKGO BILOBA Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
608.	<b>TS FILIX MAS Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
609.	<b>TS EUPATORIUM PERFOLIATUM Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
610.	<b>TS EPIGAEA REPENS Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
611.	<b>TS APIS MELLIFICA Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
612.	<b>TS BADIAGA Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
613.	<b>TS BACOPA MONNIERI Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
614.	<b>TS AZADIRACHTA INDICA Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
615.	<b>TS ASAFOETIDA Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
616.	<b>TS CASCARA SAGRADA Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section

617.	<b>TS COCCULUS INDICUS Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
618.	<b>TS CHELONE GLABRA Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
619.	<b>TS CEANOTHUS AMERICANUS Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
620.	<b>TS CAULOPHYLLUM THALICTROIDES Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
621.	<b>TS AGNUS CASTUS Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
622.	<b>TS ALETRIS FARINOSA Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
623.	<b>TS AMBRA GRISEA Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
624.	<b>TS ANGUSTURA VERA Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
625.	<b>TS ABSINTHIUM Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
626.	<b>TS GLYCYRRHIZA GLABRA Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
627.	<b>TS GINSENG Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
628.	<b>TS GUAIACUM Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
629.	<b>TS HEDERA HELIX Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
630.	<b>TS NASTURTIUM AQUATICUM Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section

631.	<b>TS SOLANUM NIGRUM Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
632.	<b>TS SYMPHYTUM OFFICINALE Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
633.	<b>TS URTICA URENS Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
634.	<b>TS YOHIMBINUM Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
635.	<b>TS THLASPI BURSA PASTORIS Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
636.	<b>TS COCCUS CACTI Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
637.	<b>TS DULCAMARA Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
638.	<b>TS CROCUS SATIVUS Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
639.	<b>TS CORIANDRUM SATIVUM Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
640.	<b>TS COFFEA CRUDA Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
641.	<b>TS THYMOL POTENCY</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
642.	<b>TS VALERIANA OFFICINALIS POTENCY</b>	Deferred with final opportunity for for the Clarification is required regarding the potencies /Serial Dilution of applied product
643.	<b>TS ZINGIBER OFFICANALE POTENCY</b>	Deferred with final opportunity for for the Clarification is required regarding the potencies /Serial Dilution of applied product
644.	<b>TS GOSSYPIUM HERBACEUM POTENCY</b>	Deferred with final opportunity for for the Clarification is required regarding the potencies /Serial Dilution of applied product
645.	<b>TS VIBURNUM OPULUS POTENCY</b>	Deferred with final opportunity for for the Clarification is required regarding the potencies /Serial Dilution of applied product
646.	<b>TS MENTHA PIPERATA POTENCY</b>	Deferred with final opportunity for for the Clarification is required regarding the potencies /Serial Dilution of applied product

647.	<b>TS MORINGA OLIFERA POTENCY</b>	Deferred with final opportunity for for the Clarification is required regarding the potencies /Serial Dilution of applied product
648.	<b>TS PAEONIA OFFICINALIS POTENCY</b>	Deferred with final opportunity for for the Clarification is required regarding the potencies /Serial Dilution of applied product
649.	<b>TS PIPER NIGRUM POTENCY</b>	Deferred with final opportunity for for the Clarification is required regarding the potencies /Serial Dilution of applied product
650.	<b>TS RICINUS COMMUNIS POTENCY</b>	Deferred with final opportunity for for the Clarification is required regarding the potencies /Serial Dilution of applied product
651.	<b>TS DROSERA ROTUNDIFOLIA POTENCY</b>	Deferred with final opportunity for for the Clarification is required regarding the potencies /Serial Dilution of applied product
652.	<b>TS SOLANUM DULCAMARA POTENCY</b>	Deferred with final opportunity for for the Clarification is required regarding the potencies /Serial Dilution of applied product
653.	<b>TS ECHINACEA ANGUSTIFOLIA POTENCY</b>	Deferred with final opportunity for for the Clarification is required regarding the potencies /Serial Dilution of applied product
654.	<b>TS EUPHRASIA OFFICINALIS POTENCY</b>	Deferred with final opportunity for for the Clarification is required regarding the potencies /Serial Dilution of applied product
655.	<b>TS FUCUS VES POTENCY</b>	Deferred with final opportunity for for the Clarification is required regarding the potencies /Serial Dilution of applied product
656.	<b>TS ACIDUM BENZOICUM POTENCY</b>	Deferred with final opportunity for for the Clarification is required regarding the potencies /Serial Dilution of applied product
657.	<b>TS ALLIUM CEPA POTENCY</b>	Deferred with final opportunity for for the Clarification is required regarding the potencies /Serial Dilution of applied product
658.	<b>TS ASHOKA POTENCY</b>	Deferred with final opportunity for for the Clarification is required regarding the potencies /Serial Dilution of applied product
659.	<b>TS CHAMOMILLA POTENCY</b>	Deferred with final opportunity for for the Clarification is required regarding the potencies /Serial Dilution of applied product
660.	<b>TS CHELIDONIUM MAJUS POTENCY</b>	Deferred with final opportunity for for the Clarification is required regarding the potencies /Serial Dilution of applied product
661.	<b>TS CHIONANTHUS VERGINICAL POTENCY</b>	Deferred with final opportunity for for the Clarification is required regarding the potencies /Serial Dilution of applied product
662.	<b>TS EUCALYPTUS GLOBULUS POTENCY</b>	Deferred with final opportunity for for the Clarification is required regarding the potencies /Serial Dilution of applied product

663.	<b>TS GENTIANA LUTEA POTENCY</b>	Deferred with final opportunity for for the Clarification is required regarding the potencies /Serial Dilution of applied product
664.	<b>TS HELIANTHUS ANNUS POTENCY</b>	Deferred with final opportunity for for the Clarification is required regarding the potencies /Serial Dilution of applied product
665.	<b>TS HYDRASTIS CANADENSIS POTENCY</b>	Deferred with final opportunity for for the Clarification is required regarding the potencies /Serial Dilution of applied product
666.	<b>TS ROBINIA PSELLDACACIA Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
667.	<b>TS RUTA GRAVEOLENS Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
668.	<b>TS SANGUINARIA CANADENSIS Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
669.	<b>TS SPONGIA TOSTA Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
670.	<b>TS STAPHYSAGRIA Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
671.	<b>TS CINCHONA CHINA Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
672.	<b>TS CROTON TIGLIUM Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
673.	<b>TS DAMIANA Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
674.	<b>TS DIGITALIS PURPUREA Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
675.	<b>TS DIOSCOREA VILLOSA Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
676.	<b>TS COLOCHICUM Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
677.	<b>TS COLLINSONIA CANDENSIS Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
678.	<b>TS COLOCYNTHIS Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section

679.	<b>TS CONVALLARIA Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
680.	<b>TS CRATAEGUS OXYACANTYHA Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
681.	<b>TS TEUCRIUM MARUM POTENCY</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product
682.	<b>TS USNEA BARBATA POTENCY</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product
683.	<b>TS VERATRUM ALBUM POTENCY</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product
684.	<b>TS VERATRUM VIRIDE POTENCY</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product
685.	<b>TS TRIBULUS TERRESTRIS POTENCY</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product
686.	<b>TS CHIMAPHILA UMBELLATA POTENCY</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product
687.	<b>TS CARDUUS MARIANUS POTENCY</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product
688.	<b>TS CAULOPHYLLUM THALICTROIDES POTENCY</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product
689.	<b>TS ACIDUM PHOSPHORICUM POTENCY</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product
690.	<b>TS AESCULUS HIPPOCASTANUM POTENCY</b>	Deferred with final opportunity for the Clarification is required regarding the potencies /Serial Dilution of applied product
691.	<b>TS ACIDUM PHOSPHORICUM Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
692.	<b>TS AESCULUS HIPPOCASTANUM Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
693.	<b>TS CARDUUS MARIANUS Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section



694.	<b>TS CAULOPHYLLUM THALICTROIDES Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
695.	<b>TS CHIMAPHILA UMBELLATA Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
696.	<b>TS GELSEMIUM SEMPERVIRENS Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
697.	<b>TS GUAIAVUM OFFICINALE Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
698.	<b>TS HAMAMELIS VIRGINICA Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
699.	<b>TS PLANTAGO MAJOR Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
700.	<b>TS PODOPHYLLUM PELTATUM Q</b>	Deferred with final opportunity for the Clarification is required regarding the dosage form of applied product along with availability of section
701.	<b>TS CINCHONA CHINA POTENCY</b>	Deferred with final opportunity for Clarification is required regarding the potencies /Serial Dilution of applied product
702.	<b>TS CROTON TIGLUM POTENCY</b>	Deferred with final opportunity for Clarification is required regarding the potencies /Serial Dilution of applied product
703.	<b>TS DAMIANA POTENCY</b>	Deferred with final opportunity for Clarification is required regarding the potencies /Serial Dilution of applied product
704.	<b>TS DIGITALIS PURPUREA POTENCY</b>	Deferred with final opportunity for Clarification is required regarding the potencies /Serial Dilution of applied product
705.	<b>TS DIOSCORIA VILLOSA POTENCY</b>	Deferred with final opportunity for Clarification is required regarding the potencies /Serial Dilution of applied product
706.	<b>TS BELLADONA Q</b>	Deferred with final opportunity for Clarification is required regarding the dosage form of applied product along with availability of section
707.	<b>TS BERBERIS VULGARIS Q</b>	Deferred with final opportunity for Clarification is required regarding the dosage form of applied product along with availability of section
708.	<b>TS BRYONIA ALBA Q</b>	Deferred with final opportunity for Clarification is required regarding the dosage form of applied product along with availability of section
709.	<b>TS OPIUM Q</b>	Deferred with final opportunity for Clarification is required regarding the dosage form of applied product along with availability of section
710.	<b>TS ORNITHOGALUM Q</b>	Deferred with final opportunity for Clarification is required regarding the dosage form of applied product along with availability of section

711.	<b>TS ANACARDIUM Q</b>	Deferred with final opportunity for Clarification is required regarding the dosage form of applied product along with availability of section
712.	<b>TS ARNICA MONTANA Q</b>	Deferred with final opportunity for Clarification is required regarding the dosage form of applied product along with availability of section
713.	<b>TS ARTEMISIA VULGARIS Q</b>	Deferred with final opportunity for Clarification is required regarding the dosage form of applied product along with availability of section
714.	<b>TS AVENA SATIVA Q</b>	Deferred with final opportunity for Clarification is required regarding the dosage form of applied product along with availability of section
715.	<b>TS ABIES NIGRA Q</b>	Deferred with final opportunity for Clarification is required regarding the dosage form of applied product along with availability of section
716.	<b>TS TRIBULUS TERRESTRIS Q</b>	Deferred with final opportunity for Clarification is required regarding the dosage form of applied product along with availability of section
717.	<b>TS TEUCRIUM MARUM Q</b>	Deferred with final opportunity for Clarification is required regarding the dosage form of applied product along with availability of section
718.	<b>TS USNEA BARBATA Q</b>	Deferred with final opportunity for Clarification is required regarding the dosage form of applied product along with availability of section
719.	<b>TS VERATRUM ALBUM Q</b>	Deferred with final opportunity for Clarification is required regarding the dosage form of applied product along with availability of section
720.	<b>TS VERATRUM VIRIDE Q</b>	Deferred with final opportunity for Clarification is required regarding the dosage form of applied product along with availability of section
721.	<b>TS VIBURNUM OPULUS Q</b>	Deferred with final opportunity for Clarification is required regarding the dosage form of applied product along with availability of section
722.	<b>TS PASSIFLORA INCARNATA Q</b>	Deferred with final opportunity for Clarification is required regarding the dosage form of applied product along with availability of section
723.	<b>TS PULSATILLA Q</b>	Deferred with final opportunity for Clarification is required regarding the dosage form of applied product along with availability of section
724.	<b>TS RAWOLFIA SERPENTINA Q</b>	Deferred with final opportunity for Clarification is required regarding the dosage form of applied product along with availability of section
725.	<b>TS RHUS TOXICODENDRON Q</b>	Deferred with final opportunity for Clarification is required regarding the dosage form of applied product along with availability of section
726.	<b>TS RUMEX CRISPUS Q</b>	Deferred with final opportunity for Clarification is required regarding the dosage form of applied product along with availability of section
727.	<b>TS ABROTANUM Q</b>	Deferred with final opportunity for Clarification is required regarding the dosage form of applied product along with availability of section
728.	<b>TS ACONITUM Q</b>	Deferred with final opportunity for Clarification is required regarding the dosage form of applied product along with availability of section
729.	<b>TS AETHUSA CYNAPIUM Q</b>	Deferred with final opportunity for Clarification is required regarding the dosage form of applied product along with availability of section
730.	<b>TS ALFALFA Q</b>	Deferred with final opportunity for Clarification is required regarding the dosage form of applied product along with availability of section
731.	<b>TS ALLIUM SATIVUM Q</b>	Deferred with final opportunity for Clarification is required regarding the dosage form of applied product along with availability of section

732.	<b>TS GELSEMIUM SEMPERVIRENS POTENCY</b>	Deferred with final opportunity for Clarification is required regarding the potencies /Serial Dilution of applied product
733.	<b>TS GUAIACUM OFFICINALE POTENCY</b>	Deferred with final opportunity for Clarification is required regarding the potencies /Serial Dilution of applied product
734.	<b>TS HAMAMELIS VIRGINICA POTENCY</b>	Deferred with final opportunity for Clarification is required regarding the potencies /Serial Dilution of applied product
735.	<b>TS PLANTOGO MAJOR POTENCY</b>	Deferred with final opportunity for Clarification is required regarding the potencies /Serial Dilution of applied product
736.	<b>TS PODOPHYLLUM PELTATUM POTENCY</b>	Deferred with final opportunity for Clarification is required regarding the potencies /Serial Dilution of applied product
737.	<b>TS CAMPHOR OFFICINALIS Q</b>	Deferred with final opportunity for Clarification is required regarding the dosage form of applied product along with availability of section
738.	<b>TS CARBO VEGETABILIS Q</b>	Deferred with final opportunity for Clarification is required regarding the dosage form of applied product along with availability of section
739.	<b>TS CIMICIFUGA RACEMOSA Q</b>	Deferred with final opportunity for Clarification is required regarding the dosage form of applied product along with availability of section
740.	<b>TS CINA Q</b>	Deferred with final opportunity for Clarification is required regarding the dosage form of applied product along with availability of section
741.	<b>TS CINNAMONUM ZYLONICUM Q</b>	Deferred with final opportunity for Clarification is required regarding the dosage form of applied product along with availability of section
742.	<b>TS ARSENICUM ALBUM Q</b>	Deferred with final opportunity for Clarification is required regarding the dosage form of applied product along with availability of section
743.	<b>TS ASHWAGANDHA Q</b>	Deferred with final opportunity for Clarification is required regarding the dosage form of applied product along with availability of section
744.	<b>TS SEPIA Q</b>	Deferred with final opportunity for Clarification is required regarding the dosage form of applied product along with availability of section
745.	<b>TS STERCULIA Q</b>	Deferred with final opportunity for Clarification is required regarding the dosage form of applied product along with availability of section
746.	<b>TS SELENIUM Q</b>	Deferred with final opportunity for Clarification is required regarding the dosage form of applied product along with availability of section
747.	<b>TS DROSERA ROTUNDIFOLIA Q</b>	Deferred with final opportunity for Clarification is required regarding the dosage form of applied product along with availability of section
748.	<b>TS DULCAMARA Q</b>	Deferred with final opportunity for Clarification is required regarding the dosage form of applied product along with availability of section

749.	<b>TS ECHINACEA ANGUSTIFOLIA Q</b>	Deferred with final opportunity for Clarification is required regarding the dosage form of applied product along with availability of section
750.	<b>TS EUPHRASIA OFFICINALIS Q</b>	Deferred with final opportunity for Clarification is required regarding the dosage form of applied product along with availability of section
751.	<b>TS FUCUS VISICULOSUS Q</b>	Deferred with final opportunity for Clarification is required regarding the dosage form of applied product along with availability of section
752.	<b>TS SUGER CONTROL SYRUP</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
753.	<b>TS BRAIN TONIC SYRUP</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
754.	<b>TS BABY VIT SYRUP</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
755.	<b>TS THANDAK SYRUP</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
756.	<b>TS PAIN OFF SYRUP</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
757.	<b>TS HBP SYRUP</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
758.	<b>TS COUGH DRY POWDER</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
759.	<b>TS VITA PLUS DRY POWDER</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
760.	<b>TS CALCIUM PLUS DRY POWDER</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).

761.	<b>TS NISA HAIR OIL</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
762.	<b>TS GYNO REX SYRUP</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
763.	<b>TS MUSAFI KHOON SYRUP</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
764.	<b>TS BLOOD SYRUP</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
765.	<b>TS COLIREX SYRUP</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
766.	<b>TS VOMINAL SYRUP</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
767.	<b>TS DAMIANA PLUS SYRUP</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
768.	<b>TS VITA PLUS SYRUP</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
769.	<b>TS DROP 7</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
770.	<b>TS DROP 8</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
771.	<b>TS DROP 9</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
772.	<b>TS DROP 10</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).

773.	<b>TS DROP 11</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
774.	<b>TS DROP 12</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
775.	<b>TS DROP 13</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
776.	<b>TS DROP 14</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
777.	<b>TS DROP 15</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
778.	<b>TS DROP 16</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
779.	<b>TS DROP 17</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
780.	<b>TS DROP 18</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
781.	<b>TS DROP 19</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
782.	<b>TS DROP 21</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
783.	<b>TS DROP 22</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).



784.	<b>TS DROP 23</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
785.	<b>TS THUJA Q</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
786.	<b>TS TOFEN LOTION</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
787.	<b>TS D-TOX TABLET</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
788.	<b>TS LICON -T TABLET</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
789.	<b>TS P-NIL TABLET</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
790.	<b>TS C-CEPA TABLET</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
791.	<b>TS SACFEN LOTION</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
792.	<b>TS SAFOOF MAGHALAZ KHAS JWAHRDAR</b>	Deferred with final opportunity for Evidence are provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).
<b>M/s Zam Zam Homoeo Pharma, Multan</b>		
793.	<b>ZM#1 GASTRIC Drops</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
794.	<b>ZM#2 URIC FLOW Drops</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
795.	<b>ZM#3 ALLER...Z Drops</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
796.	<b>ZM#4 H.B.P. Drops</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination

		in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
797.	<b>ZM#5 ACNO...Z Drops</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
798.	<b>ZM#6 UTRINOL Drops</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
799.	<b>ZM#7 KIDNAL Drops</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
800.	<b>ZM#8 CHELLICARD Drops</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
801.	<b>ZM#9 ZLYSIS Drops</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
802.	<b>ZM#10 SPERMA PHOS Drops</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
803.	<b>ZM#11 PILOZAM Drops</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
804.	<b>ZM#12 ARTHO...Z Drops</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
805.	<b>ZM#13 SINO...Z Drops</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
806.	<b>ZM#14 EASY FEEL Drops</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
807.	<b>ZM#15 SULPHUR COMPOUND Drops</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).

		Brand name needs to be changed
808.	<b>ZM#16 MENORRHOEA Drops</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
809.	<b>ZM#17 BED WETTING Drops</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
810.	<b>ZM#18 INFEC...Z Drops</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
811.	<b>ZM#19 BARBELLA Drops</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
812.	<b>ZM#20 SALIX COMPOUND Drops</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
813.	<b>ALFA DS SYRUP</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
814.	<b>ALFA+GINSENG SYRUP S.F</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
815.	<b>ALETRIS+ASHOKA SYRUP</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
816.	<b>APPETONE SYRUP</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
817.	<b>AVENA + SYRUP</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
818.	<b>B.COLIC SYRUP</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed

819.	<b>BELLACEF SYRUP</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
820.	<b>CAL...Z SYRUP</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
821.	<b>CAPTAIN BABY TONIC SYRUP</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
822.	<b>CATT...Z SYRUP</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
823.	<b>CHELLICARD SYRUP</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
824.	<b>DAMIANA+GINSENG S.F</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
825.	<b>DERMO...Z SYRUP</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
826.	<b>FEMO...Z SYRUP</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
827.	<b>FERRO-Z SYRUP</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
828.	<b>FLU...Z SYRUP</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
829.	<b>GASTO VIT SYRUP</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
830.	<b>GASTO...Z SYRUP</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination

		in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
831.	<b>GENSO FORTE SYRUP:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
832.	<b>HEPA...Z ELIXIR:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
833.	<b>KIDNO...Z SYRUP:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
834.	<b>KUF...Z SYRUP:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
835.	<b>KURCHI COMPOUND SYRUP:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
836.	<b>Mensocard SYRUP:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
837.	<b>PEPPO...Z SYRUP:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
838.	<b>POWER...Z SYRUP:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
839.	<b>RUMEX SYRUP:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
840.	<b>SLIM...Z SYRUP:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
841.	<b>TONSI COUGH SYRUP:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).

		Brand name needs to be changed
842.	<b>VITA GLOBIN SYRUP:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
843.	<b>VITA...Z SYRUP:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
844.	<b>VOMITO...Z SYRUP:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
845.	<b>WARMO...Z SYRUP:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
846.	<b>ALOE SONIA ELIXIR:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
847.	<b>BERBE CAN ELIXIR:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
848.	<b>KUF RELIEF SYRUP:</b> EHPI(2266)	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
849.	<b>COUGH GONE SYRUP:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
850.	<b>ZAMZAM PLACEBO SYRUP:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
851.	<b>ZAMZAM DISKETTES/ ZAMZAM ICING SUGAR</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
852.	<b>ZAMZAM BLANKETTES/ ZAMZAM MILK OF SUGAR</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed



853.	<b>DENTO...Z LOTION:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
854.	<b>MOUTH CURE LOTION:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
855.	<b>OTALLEIN LOTION:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
856.	<b>KRACK...Z OINTMENT:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
857.	<b>ZAMZAM BALM:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
858.	<b>Pain Gone Lotion:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
859.	<b>Pain...Z Lotion:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
860.	<b>SCABO...Z Lotion:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
861.	<b>ZAMZAM KHARISH Lotion:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
862.	<b>B.P NORMAL DROPS:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
863.	<b>CALCO...Z DROPS:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
864.	<b>COCA...Z DROPS:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination

		in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
865.	<b>INFERTO...Z DROPS:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
866.	<b>RAPHNUS + DROPS:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
867.	<b>RESCUE Oral Spray:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
868.	<b>SEPTI CURE DROPS:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
869.	<b>SPERMO...Z DROPS:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
870.	<b>KIDNEY WASH DROPS:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
871.	<b>MENOGIN TABLET:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
872.	<b>FEMOGIN TABLET:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
873.	<b>ANTIFEVER TABLET:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
874.	<b>ANTIPYREEN TABLET:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
875.	<b>AVEGIN TABLET:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record).

		Brand name needs to be changed
876.	<b>BLEEDING CURE TABLET:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
877.	<b>CHOLE...Z TABLET:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
878.	<b>DYRO...Z TABLET:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
879.	<b>FERRO...Z TABLET:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
880.	<b>FLU...Z TABLET:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
881.	<b>GASTO...Z TABLET:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
882.	<b>HAYOCYNTH COMPOUND TABLET:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
883.	<b>HEPTO...Z TABLET:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
884.	<b>HISTA...Z TABLET:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
885.	<b>HYPER...Z TABLET:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
886.	<b>KUF...Z TABLET:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed

887.	<b>L.B.P TABLET:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
888.	<b>LECI...CAL...D TABLET:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
889.	<b>LECOCIN TABLET:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
890.	<b>MENSOGEN TABLET:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
891.	<b>PILOZAM TABLET:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
892.	<b>SALIX PLUS TABLET:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
893.	<b>SPERMA PHOS TABLET:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
894.	<b>SULPHOGEN TABLET:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
895.	<b>TONSO...Z TABLET:</b> ...0.8% v/w EHPI(926)	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
896.	<b>TYPHOGEN TABLET:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
897.	<b>ULSOOGEN TABLET:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
898.	<b>URIC FLOW TABLET:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination

		in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
899.	<b>ZAMODOL TABLET:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
900.	<b>Z...DRY TABLET:</b>	Deferred with final opportunity for Evidence are not provided in support of the claim of availability of the proposed combination in local market for last 10 years(sales invoices including distribution record). Brand name needs to be changed
<b>Adcok Pharmaceutical (Pvt) Ltd, Lahore</b>		
901.	Chelifer Tablet	Defererd for Submission and verification of CAPA and alternative brand names
902.	Rinon Tablet	Defererd for Submission and verification of CAPA and alternative brand names
903.	Calcify Tablet	Defererd for Submission and verification of CAPA and alternative brand names
904.	Sacran Sachet	Defererd for Submission and verification of CAPA and alternative brand names
905.	Calcif-D Tablet	Defererd for verification of CAPA
906.	Lifolac Powder	Defererd for Submission and verification of CAPA and alternative brand names
907.	Sacran Syrup	Defererd for Submission and verification of CAPA and alternative brand names
908.	On Life Tablet	Defererd for Submission and verification of CAPA and alternative brand names
909.	Cranblex Syrup	Defererd for verification of CAPA
910.	Gomeg Drop	Defererd for Submission and verification of CAPA and alternative brand names
911.	Neo Choline Tablet	
912.	Koffsafe Drops	Defererd for verification of CAPA
913.	Magtin Tablet	Defererd for Submission and verification of CAPA and alternative brand names
914.	Rexbion Tablet	Defererd for Submission and verification of CAPA and alternative brand names
915.	Trisafe Syrup	Defererd for Submission and verification of CAPA and alternative brand names
916.	Maxfair Tablet	Defererd for Submission and verification of CAPA and alternative brand names
917.	Proneed Sachet	Defererd for Submission and verification of CAPA and alternative brand names
918.	Q-Lime Tablet	Defererd for verification of CAPA
919.	Testron Tablet	Defererd for Submission and verification of CAPA and alternative brand names
920.	Ultra D Tablet	Defererd for Submission and verification of CAPA and alternative brand names
921.	Magtin Tablet	Defererd for verification of CAPA
922.	Activer Tablet	Defererd for verification of CAPA
923.	Laze-D Tablet	Defererd for verification of CAPA
924.	Ripro Drops	Defererd for Submission and verification of CAPA and alternative brand names
925.	Cal-X Syrup	Defererd for Submission and verification of CAPA and alternative brand names
926.	Cof-Nix Syrup	Defererd for Submission and verification of CAPA and alternative brand names
927.	<b>Cosatin Tablet Alaq Laboratories, Lahore</b>	Deferred with final opportunity for submission of soft copy of formulation as per requirement of form 3
928.	Pretize Syrup	Deferred with final opportunity for submission of soft copy of formulation as per requirement of form 3

929.	Nt.Kuff Drops	Deferred with final opportunity for submission of soft copy of formulation as per requirement of form 3
930.	Chondroitin Plus Tablet	Deferred with final opportunity for submission of soft copy of formulation as per requirement of form 3
931.	Berry Mic Sachet	Deferred with final opportunity for submission of soft copy of formulation as per requirement of form 3
932.	E Tone Syrup	Deferred with final opportunity for submission of soft copy of formulation as per requirement of form 3
<b>M/s Allomed Curatives, Islamabad</b>		
933.	Minto Guard Liquid	Deferred with final opportunity for submission of required documents as per check list of form 3 and submission on undertaking that wheather instant product is disposed of or otherwise
934.	Happy Chick Liquid	Deferred with final opportunity for submission of altrenative brand name
935.	Immuno Fit Liquid	Deferred with final opportunity for submission of required documents as per check list of form 3 and submission on undertaking that wheather instant product is disposed of or otherwise
936.	Liveron Liquid	Deferred with final opportunity for submission of altrenative brand name
937.	Multi Vito Max Liquid	Deferred with final opportunity for submission of altrenative brand name
938.	Adek Fit Liquid	Deferred with final opportunity for submission of altrenative brand name
939.	Super Temp Cure Oral Liquid	Deferred with final opportunity for submission of altrenative brand name
940.	Meat Up Powder	Deferred with final opportunity for submission of altrenative brand name
941.	Milk Up Powder	Deferred with final opportunity for submission of altrenative brand name
942.	Tempanil Liquid	Deferred with final opportunity for submission of altrenative brand name
943.	Bio Lizo Vit Powder	Deferred with final opportunity for submission of altrenative brand name
944.	Parwaz Plus Powder	Deferred with final opportunity for submission of required documents as per check list of form 3 and submission on undertaking that wheather instant product is disposed of or otherwise
945.	Triple 5 Oral Solution	Deferred with final opportunity for submission of required documents as per check list of form 3 and submission on undertaking that wheather instant product is disposed of or otherwise
946.	Colic Star Liquid	Deferred with final opportunity for submission of required documents as per check list of form 3 and submission on undertaking that wheather instant product is disposed of or otherwise
947.	Pak Akseer Jair Nafas Powder	Deferred with final opportunity for submission of altrenative brand name
948.	Bone Phosphate Powder	Deferred with final opportunity for submission of required documents as per check list of form 3 and submission on undertaking that wheather instant product is disposed of or otherwise
949.	B-Cure Minerals Powder	Deferred with final opportunity for submission of altrenative brand name
<b>Anza Pharma, Lahore</b>		
950.	Garent-C Syrup	
951.	Garent-C Tablet	
952.	Garent-D Drop	
953.	Kidsol Sachet	
954.	Mc New Sachet	
955.	Qufo Tablet	
956.	Qx-Forte Tablet	Deferred with final opportunity for submission of required documents as per check list of form 3 and submission on undertaking that wheather instant product is disposed of or otherwise



957.	Calmoon Tablet	Deferred with final opportunity for submission of required documents as per check list of form 3 and submission on undertaking that wheather instant product is disposed of or otherwise
958.	H-D Oral Drops	Deferred with final opportunity for submission of required documents as per check list of form 3 and submission on undertaking that wheather instant product is disposed of or otherwise
959.	Instacal-D Tablet	
960.	Tonisan Syrup	Deferred with final opportunity for submission of required documents as per check list of form 3 and submission on undertaking that wheather instant product is disposed of or otherwise
961.	Noni Grow Syrup	
962.	Noni Grow Drops	
<b>M/s Arber Pharma, Lahore</b>		
963.	<b>Glosence Tablet</b>	
964.	<b>Glosence Syrup</b>	
965.	<b>Super-Cal Syrup</b>	
966.	<b>Super-Cal Tablet</b>	
967.	<b>Osteo-5 Tablet</b>	
968.	<b>Bio-Mv Syrup</b>	
969.	<b>Bio-Mv Tablet</b>	
970.	<b>Mecolax Tablet</b>	
971.	<b>Ct Max Tablet</b>	
972.	<b>Ct Max Syrup</b>	
973.	<b>Noor Colic Drops</b>	
974.	<b>Cuf-Go Syrup</b>	
975.	<b>Bio-Kuff Syrup</b>	
976.	<b>Scio-Cid Syrup</b>	
977.	<b>Enuf Supplement</b> Magnesium Oxide (BP) ..... 90mg (Equivalent to elemental Magnesium 54mg) Potassium iodide (BP) .....0.35mg Zinc Sulfate (USP) .....0.37mg	
978.	<b>Glomom Supplement</b>	
979.	<b>Nutri-M Supplement</b>	
980.	<b>Suppli-M Supplement</b>	
981.	<b>Wellpro Supplement</b>	
982.	<b>Ovasital Sachet</b>	
983.	<b>Ad-Plus Drops</b>	
984.	<b>Spirglo Tablet</b>	
<b>M/s Arzik Laboratories, Faisalabad</b>		

985.	Co-Q10 Vits Tablet	Deferred with final opportunity for submission of required documents as per check list of form 3 and submission on undertaking that wheather instant product is disposed of or otherwise
986.	Bone Plus-Z Tablet	Deferred with final opportunity for submission of required documents as per check list of form 3 and submission on undertaking that wheather instant product is disposed of or otherwise
987.	Multi-Vit Tablet	Deferred with final opportunity for submission of required documents as per check list of form 3 and submission on undertaking that wheather instant product is disposed of or otherwise
<b>M/s Aurum Health Care, Lahore</b>		
988.	Fertimap Tablet	Deferred with final opportunity for submission of required documents as per check list of form 3 and submission on undertaking that wheather instant product is disposed of or otherwise
989.	Aritmove Tablet	Deferred with final opportunity for submission of required documents as per check list of form 3 and submission on undertaking that wheather instant product is disposed of or otherwise
990.	Deon 200Iu Tablet	Deferred with final opportunity for submission of required documents as per check list of form 3 and submission on undertaking that wheather instant product is disposed of or otherwise
991.	Flobac Tablet	Deferred with final opportunity for submission of required documents as per check list of form 3 and submission on undertaking that wheather instant product is disposed of or otherwise
992.	Calmax-D Tablet	
993.	Eatio Syrup	
994.	Pepice Suspension	
995.	Ed-Cure Tablet	
996.	Sensory Oral Liquid	
997.	Natfol Tablet	Deferred with final opportunity for submission of required documents as per check list of form 3 and submission on undertaking that wheather instant product is disposed of or otherwise
<b>Bio Classic Pharma, Lahore</b>		
998.	Rb Plus Capsule	Deferred with final opportunity for submission of required documents as per check list of form 3 and submission on undertaking that wheather instant product is disposed of or otherwise
999.	Bioplex Capsule	Deferred with final opportunity for submission of required documents as per check list of form 3 and submission on undertaking that wheather instant product is disposed of or otherwise
<b>Bio Life Enterprises Nutraceuticals, Rawalpindi</b>		
1000.	<b>Bio Life's TALVIT TABLET</b>	Deferred with final opportunity for verification of testing facility for minerals
1001.	<b>Bio Life's CALI+ TABLET</b>	Deferred with final opportunity for verification of testing facility for minerals
1002.	<b>Bio Life's ALNEED TABLET</b>	Deferred with final opportunity for verification of testing facility for minerals
1003.	<b>Bio Life's VITONA TABLET</b>	Deferred with final opportunity for verification of testing facility for minerals
1004.	<b>Bio Life's MAGNUM-Z GOLD TABLET</b>	Deferred with final opportunity for verification of testing facility for minerals
1005.	<b>Bio Life's MAGNUM-Z SILVER TABLET</b>	Deferred with final opportunity for verification of testing facility for minerals

<b>Bio Serve Pharma, Karachi</b>		
1006.	Chem-Cal Tablet	Deferred with final opportunity for submission of required documents as per check list of form 3 and submission on undertaking that wheather instant product is disposed of or otherwise
1007.	Pedistar Ors	Deferred with final opportunity for submission of required documents as per check list of form 3 and submission on undertaking that wheather instant product is disposed of or otherwise
1008.	Pedicon Ors	Deferred with final opportunity for submission of required documents as per check list of form 3 and submission on undertaking that wheather instant product is disposed of or otherwise
<b>Blossom Lab, Pvt, Ltd, Lahore</b>		
1009.	Sharbat E Faulad Syrup	Deferred with final opportunity for submission of latervative brand name
1010.	Jam E Zindagi Syrup	Deferred with final opportunity for submission of latervative brand name
1011.	Gingko Biloba Syrup	<ul style="list-style-type: none"> <li>Deferred with final opportunity for submission of Form-3, brand name and contents undertakings are unsigned/unstamped.</li> <li>Fee receipt is missing.</li> </ul>
1012.	Pain Stop Syrup	Deferred with final opportunity for submission of latervative brand name
1013.	Damialex Plus Tablet	Deferred with final opportunity for submission of latervative brand name
1014.	Colic Tablet	Deferred with final opportunity for submission of latervative brand name
1015.	Tonsilex Tablet	Deferred with final opportunity for submission of latervative brand name
1016.	Dialex Tablet	Deferred with final opportunity for submission of latervative brand name
1017.	Asthalex Tablet	Deferred with final opportunity for submission of latervative brand name
1018.	Calcilex Syrup	Deferred with final opportunity for submission of latervative brand name
1019.	Gastro Ulcer Capsule	Deferred with final opportunity for submission of latervative brand name
<b>Calgan Phyto Pharma Pvt Ltd, Lahore</b>		
1020.	<b>ADTIVE DROPS</b>	
1021.	<b>KOFECT DROPS</b>	Deferred with final opportunity for submission of latervative brand name
1022.	<b>PRIMAL-DK DROPS</b>	Deferred with final opportunity for submission of latervative brand name
<b>Cidex Laboratories, Peshawar</b>		
1023.	Boncal-D Tablet	Deferred with final opportunity for submission of latervative brand name
1024.	Fibo-C Sachet	Deferred with final opportunity for submission of latervative brand name
1025.	Filbert Sharbat Podina Sharbat	Deferredwith final opportunity for submission Form 3, brand name and contents undertakings are unsigned, unstamped. Fee receipt is missing.
1026.	Folit-Q Tablet	Deferred with final opportunity for submission of latervative brand name
1027.	Hyomint Suspension	Deferred with final opportunity for submission of latervative brand name
1028.	Infra-Ad Tablet	Deferredwith final opportunity for submission Form 3, brand name and contents undertakings are unsigned, unstamped. Fee receipt is missing.
1029.	Infra Drop	Deferredwith final opportunity for submission Form 3, brand name and contents undertakings are unsigned, unstamped. Fee receipt is missing.

1030.	Migra Fort Tablet	Deferred with final opportunity for submission of latervative brand name
1031.	Nutracid Suspension	Deferred with final opportunity for submission of latervative brand name
1032.	Triloba Capsule	Deferred with final opportunity for submission of latervative brand name
<b>Cure Inn Phytoceuticals Pvt Ltd, Lahore</b>		
1033.	Fevical Tablet	Deferred with final opportunity for submission of required documents as per check list of form 3 and submisson on undertaking that wheather instant product is disposed of or otherwise
1034.	Parofis Syrup	Deferred with final opportunity for submission of required documents as per check list of form 3 and submisson on undertaking that wheather instant product is disposed of or otherwise
1035.	Fahcal Syrup	Deferred with final opportunity for submission of required documents as per check list of form 3 and submisson on undertaking that wheather instant product is disposed of or otherwise
1036.	Iq-Mega Syrup	Deferred with final opportunity for submission of required documents as per check list of form 3 and submisson on undertaking that wheather instant product is disposed of or otherwise
<b>Cynosure Pvt. Ltd., Multan</b>		
1037.	Oxim Tablet	Deferred with final opportunity for submission of latervative brand name
1038.	Vitfol Drops	Deferred with final opportunity for submission of latervative brand name
1039.	Uricran Sachet	Deferred with final opportunity for submission of latervative brand name
1040.	Myocid Suspension	Deferred with final opportunity for submission of latervative brand name
1041.	Holistic-D Drops	Deferred with final opportunity for submission of required documents as per check list of form 3 and submisson on undertaking that wheather instant product is disposed of or otherwise
1042.	Cynofer Syrup	Deferred with final opportunity for submission of required documents as per check list of form 3 and submisson on undertaking that wheather instant product is disposed of or otherwise
1043.	Calfi 8 Syrup	Deferred with final opportunity for submission of required documents as per check list of form 3 and submisson on undertaking that wheather instant product is disposed of or otherwise
1044.	Pectal Syrup	Deferred with final opportunity for submission of required documents as per check list of form 3 and submisson on undertaking that wheather instant product is disposed of or otherwise
1045.	Sily 8 Syrup	Deferred with final opportunity for submission of required documents as per check list of form 3 and submisson on undertaking that wheather instant product is disposed of or otherwise
1046.	Revicof Syrup	Deferred with final opportunity for submission of required documents as per check list of form 3 and submisson on undertaking that wheather instant product is disposed of or otherwise
1047.	Appetex Syrup	Defererd with final opportunity for submission of latrentaive brand names
<b>Crystolite Pharmaceuticals, Islamabad</b>		
1048.	Xefic 400Mcg Tablet	EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer

		<p>decision of the instant product application to check its status whether it has been disposed of or otherwise.</p> <p>Reply not received yet</p>
1049.	Xefic 800Mcg Tablet	<p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p> <p>Reply not received yet</p>
1050.	<b>URIBEX TABLETS</b>	Deferred for verification of testing facility
1051.	<b>Hairlet Capsule.</b>	<p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p> <p>Reply not received yet</p>
1052.	Vitovil Plus Capsule	<p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p> <p>Reply not received yet</p>
1053.	Vitabit Tablet	<p>EEC was apprised that division undertook a big task of company wise arrangement of applications in various designated racks. Since computerization of record of submitted applications and subsequent preparation of their FIFO list, the division has been evaluating and processing files. Hence, there are chances that some product applications were disposed of but still their names are available in the FIFO list. Accordingly, EEC appreciated the services of division of health and OTC and decided to defer decision of the instant product application to check its status whether it has been disposed of or otherwise.</p> <p>Reply not received yet</p>
<b>Dew Natural Pharma, Lahore</b>		
1054.	Stasmodine Syrup	Deferred with final opportunity for submission of latrenative brand name
1055.	Dew'S Toot Siah Syrup	Deferred with final opportunity for submission of latrenative brand name

1056.	Dew-Safi Syrup	Deferred with final opportunity for submission of latrenative brand name
1057.	Orange-C Syrup	Deferred with final opportunity for submission of latrenative brand name
1058.	Nurogin Syrup	Deferred with final opportunity for submission of latrenative brand name
1059.	Grow Fast Baby Tonic Suspension	Deferred with final opportunity for submission of latrenative brand name
1060.	Dew'S Minti Syrup	Deferred with final opportunity for submission of latrenative brand name
1061.	Globiton Syrup	Deferred with final opportunity for submission of latrenative brand name
1062.	Mintdew Syrup	Deferred with final opportunity for submission of latrenative brand name
1063.	A-Plus Aletris Cordial Syrup	Deferred with final opportunity for submission of latrenative brand name
1064.	Ivy Kuf Sooth Syrup	Deferred with final opportunity for submission of latrenative brand name
1065.	Feroton-S Syrup	Deferred with final opportunity for submission of latrenative brand name
1066.	Kanavit Syrup	Deferred with final opportunity for submission of latrenative brand name
1067.	Dew'S Mint Syrup (Sharbat Podina) Syrup	Deferred with final opportunity for submission of latrenative brand name
1068.	Hycid Antacid Syrup	Deferred with final opportunity for submission of latrenative brand name
1069.	Ginko-Min Syrup	Deferred with final opportunity for submission of latrenative brand name
1070.	Honey Dew'S Cough Syrup	Deferred with final opportunity for submission of latrenative brand name
1071.	Avescon Antacid Syrup	Deferred with final opportunity for submission of latrenative brand name
1072.	Polybin Syrup	Deferred with final opportunity for submission of latrenative brand name
1073.	Hemoclean Syrup	Deferred with final opportunity for submission of latrenative brand name
1074.	Dewcid Syrup	Deferred with final opportunity for submission of latrenative brand name
1075.	Polykuf Syrup	Deferred with final opportunity for submission of latrenative brand name
1076.	Lusar Cough Syrup	Deferred with final opportunity for submission of latrenative brand name
1077.	Luma Cough Syrup	Deferred with final opportunity for submission of latrenative brand name
1078.	Bonofit-D Suspension	Deferred with final opportunity for submission of latrenative brand name
1079.	A-Plus Reton Syrup	Deferred with final opportunity for submission of latrenative brand name
1080.	Honitus Syrup	Deferred with final opportunity for submission of latrenative brand name
1081.	Stasmodine Drops	Deferred with final opportunity for submission of latrenative brand name
1082.	Diarrh Syrup	Deferred with final opportunity for submission of latrenative brand name
1083.	Ginger-Mint Syrup	Deferred with final opportunity for submission of latrenative brand name
1084.	Orange Plex Syrup	Deferred with final opportunity for submission of latrenative brand name
1085.	<b>Arsal Natural Cough Syrup</b>	Deferred for verification of testing facility
1086.	<b>Cough Syrup Junior</b>	Deferred for verification of testing facility
1087.	<b>Baby Balm</b>	Deferred for verification of testing facility
1088.	<b>Arsal Balm</b>	Deferred for verification of testing facility
1089.	<b>Arofen Syrup</b>	Deferred for verification of testing facility



1090.	<b>Diarro Syrup</b>	Deferred for verification of testing facility
1091.	<b>Gasnol Syrup (Sugar free)</b>	Deferred for verification of testing facility
1092.	<b>Analgesic Cream</b>	Deferred for verification of testing facility
<b>Genetics Healthcare, Lahore</b>		
1093.	<b>Reforce Tablet</b>	<b>Deferred with final opportunity for clarification regarding applied formulation by using most active synthetic form of vitamin B1</b>
1094.	<b>Deplate 15mg Tablets</b>	<b>Deferred with final opportunity for clarification regarding strength of folat</b>
<b>GreenMan Pharmaceuticals, Rawalpindi</b>		
1095.	Lekol Capsule	Deferred for verification of testing facility
1096.	Promass Tablet	Deferred with final opportunity for submission of alternative brand name
1097.	Barium Meal Sachet	Deferred for verification of testing facility along with clarification regarding applied formulation as health product
1098.	<b>Optofyt Tablet</b>	Deferred for verification of testing facility
<b>Hi-Nutrition Pvt Ltd, Lahore</b>		
1099.	<b>C-1000 Mg Effervescent Tablet</b>	Deferred with final opportunity for submission of soft copy of formulation as per requirement of form 3
1100.	<b>C-500 Mg Effervescent Tablet</b>	Deferred with final opportunity for submission of soft copy of formulation as per requirement of form 3
1101.	<b>Zinc Boost Effervescent Tablet</b>	Deferred with final opportunity for submission of soft copy of formulation as per requirement of form 3
1102.	<b>Fe Boost Effervescent Tablet</b>	Deferred with final opportunity for submission of soft copy of formulation as per requirement of form 3
1103.	<b>Bella Liquid Collagen Syrup</b>	Deferred with final final opportunity for submission of required documents as per check list along with undertaking regarding the status of product whether disposed of or otherwise
1104.	<b>C+Zn Effervescent Tablet</b>	
<b>Hiranis Pharmaceuticals (Pvt) Limited, Karachi</b>		
1105.	Lokasol Toothpaste	Deferred with final final opportunity for submission of required documents as per check list along with undertaking regarding the status of product whether disposed of or otherwise
1106.	Lokasol Oral Paste Liquid	Deferred with final final opportunity for submission of required documents as per check list along with undertaking regarding the status of product whether disposed of or otherwise
<b>Incepta Pharma, Taxila</b>		
1107.	<b>Incepta's Wrinklex Sachet</b>	Deferred for verification of testing facility of minerals
1108.	<b>Incepta's Glutaglow Capsules</b>	Deferred for verification of testing facility
1109.	<b>Incepta's Myofert Sachet</b>	Deferred for verification of testing facility
1110.	<b>Incepta's Trufiber Sachet</b>	Deferred for verification of testing facility
1111.	<b>Incepta's Activa Capsules</b>	Deferred for verification of testing facility
1112.	<b>Incepta's Fiberaid Sachet</b>	Deferred for verification of testing facility
<b>Izfaar Nutraceutical Industries, Lahore</b>		
1113.	<b>Mastito (Vet) Liquid</b>	Deferred for provision of method of testing of finished product is required

1114.	Gyno-Far Tablet	Deferred with final final opportunity for submission of soft copy of formulation as per requirement of form 3
1115.	Higlob Liquid	Deferred with final final opportunity for submission of soft copy of formulation as per requirement of form 3
1116.	Ferofar Liquid	Deferred with final final opportunity for submission of soft copy of formulation as per requirement of form 3
<b>Leads Impex Pharma, Lahore</b>		
1117.	M-Fol B Tablet	Deferred with final final opportunity for submission of required documents as per check list along with undertaking regarding the status of product wheather disposed of or otherwise
1118.	Giga-Q Tablet	Deferred with final final opportunity for submission of required documents as per check list along with undertaking regarding the status of product wheather disposed of or otherwise
<b>Legacy Pharmaceuticals, Peshawar</b>		
1119.	Apricare 500Mg Capsule	Deferred with final opportunity for submission of alternative brand names
1120.	Cal Poppy 500Mg Capsule	Deferred with final final opportunity for submission of required documents as per check list along with undertaking regarding the status of product wheather disposed of or otherwise
1121.	Dibcare 10Mg Tablet	Deferred with final opportunity for submission of alternative brand names
1122.	Dibcare 25Mg Tablet	Deferred with final opportunity for submission of alternative brand names
1123.	Ez Rest Capsule	Deferred with final opportunity for submission of alternative brand names
1124.	Happy Mood 500Mg Capsule	Deferred with final opportunity for submission of alternative brand names
1125.	Lesschol 375Mg Tablet	Deferred with final opportunity for submission of alternative brand names
1126.	Lesschol 500Mg Tablet	Deferred with final opportunity for submission of alternative brand names
1127.	Livosmin 375Mg Capsule	Deferred with final opportunity for submission of alternative brand names
1128.	Livosmin Plus Capsule	Deferred with final opportunity for submission of alternative brand names
1129.	Magtim 1000Mg Tablet	Deferred with final final opportunity for submission of required documents as per check list along with undertaking regarding the status of product wheather disposed of or otherwise
1130.	Saw Pal 800Mg Capsule	Deferred with final opportunity for submission of alternative brand names
<b>M.R.G Laboratories, Karachi</b>		
1131.	Hecho Sachet	Deferred with final final opportunity for submission of required documents as per check list along with undertaking regarding the status of product wheather disposed of or otherwise
1132.	Celimixt Sachet	Deferred with final final opportunity for submission of required documents as per check list along with undertaking regarding the status of product wheather disposed of or otherwise
1133.	Culturela Sachet	Deferred with final opportunity for submission of alternative brand names
1134.	Ener-C Sachet	Deferred with final opportunity for submission of alternative brand names
<b>Mediformers Neutraceutical, Lahore</b>		
1135.	Neutroon Capsule	Deferred with final opportunity for submission of alternative brand names
<b>Medinoon Research Laboratories, Lahore</b>		
1136.	Naslus Suspension	Deferred with final final opportunity for submission of required documents as per check list along with undertaking regarding the status of product wheather disposed of or otherwise
1137.	Dravit-D Oral Drops	Deferred with final final opportunity for submission of required documents as per check list along with undertaking regarding the status of product wheather disposed of or otherwise
1138.	Nthiron Syrup	Deferred with final final opportunity for submission of required documents as per check list along with undertaking regarding the status of product wheather disposed of or otherwise
<b>Merit Pvt. Ltd., Lahore</b>		

1139.	Marit Ors Sachet	Deferred with final final opportunity for submission of required documents as per check list along with undertaking regarding the status of product wheather disposed of or otherwise
<b>MRG Laboratories, Karachi</b>		
1140.	Howatic Sachet	Deferred with final final opportunity for submission of required documents as per check list along with undertaking regarding the status of product wheather disposed of or otherwise
<b>MTI Medical, Lahore</b>		
1141.	Estosan Suspension	Deferred with final opportunity for submission of alternative brand names
1142.	Efron Syrup	Deferred with final final opportunity for submission of required documents as per check list along with undertaking regarding the status of product wheather disposed of or otherwise
1143.	Lifolac Syrup	Deferred with final final opportunity for submission of required documents as per check list along with undertaking regarding the status of product wheather disposed of or otherwise
1144.	Zocobin Syrup	Deferred with final opportunity for submission of alternative brand names
1145.	Cistimax Syrup	Deferred with final opportunity for submission of alternative brand names
1146.	Sampa Syrup	Deferred with final final opportunity for submission of required documents as per check list along with undertaking regarding the status of product wheather disposed of or otherwise
1147.	Complivit Syrup	Deferred with final final opportunity for submission of required documents as per check list along with undertaking regarding the status of product wheather disposed of or otherwise
<b>Nascon Pharmaceutical, Peshawar</b>		
1148.	Folic Acid Tablet	Deferred with final opportunity for submission of alternative brand names
1149.	Feuromin Tablet	Deferred with final opportunity for submission of alternative brand names
1150.	Panthomine-M	Deferred with final opportunity for submission of alternative brand names
1151.	Irocon Tablet	Deferred with final opportunity for submission of alternative brand names
1152.	Cal-D Fort Tablet	Deferred with final opportunity for submission of alternative brand names
1153.	Camzol-D Tablet	Deferred with final opportunity for submission of alternative brand names
1154.	Calcon-D Tablet	Deferred with final opportunity for submission of alternative brand names
1155.	Endomax Tablet	Deferred with final opportunity for submission of alternative brand names
1156.	Cidlock Sachet	Deferred with final opportunity for submission of alternative brand names
1157.	Uroflux Tablet	Deferred with final opportunity for submission of alternative brand names
1158.	Trihad Capsule	Deferred with final opportunity for submission of alternative brand names
1159.	Sleepwel Tablet	Deferred with final opportunity for submission of alternative brand names
1160.	Sleepwel Drops	Deferred with final opportunity for submission of alternative brand names
1161.	Ido Folic Acid Tablet	Deferred with final opportunity for submission of alternative brand names
1162.	Aormin-D Drops	Deferred with final opportunity for submission of alternative brand names
1163.	Lemo Cid Syrup	Deferred with final opportunity for submission of alternative brand names
1164.	Ginsol Syrup	Deferred with final opportunity for submission of alternative brand names
1165.	Podina Adrak Plus Calvange Syrup	Deferred with final opportunity for submission of alternative brand names
1166.	Megzora-D Drops	Deferred with final opportunity for submission of alternative brand names
<b>Nigehban, Karachi</b>		

1167.	Nourish & Flourish Whitening Face Wash	Deferred with final final opportunity for submission of required documents as per check list along with undertaking regarding the status of product wheather disposed of or otherwise
1168.	Foot Repair Cream	Deferred with final final opportunity for submission of required documents as per check list along with undertaking regarding the status of product wheather disposed of or otherwise
1169.	Nutra Shampoo	Deferred with final final opportunity for submission of required documents as per check list along with undertaking regarding the status of product wheather disposed of or otherwise
1170.	Nutra Conditioner	Deferred with final final opportunity for submission of required documents as per check list along with undertaking regarding the status of product wheather disposed of or otherwise
1171.	Nourish & Flourish Whitening Whitening Cream	Deferred with final final opportunity for submission of required documents as per check list along with undertaking regarding the status of product wheather disposed of or otherwise
1172.	Revitalise Moisturizing Cream	Deferred with final final opportunity for submission of required documents as per check list along with undertaking regarding the status of product wheather disposed of or otherwise
1173.	Nourish & Flourish Whitening Acne Face Wash	Deferred with final final opportunity for submission of required documents as per check list along with undertaking regarding the status of product wheather disposed of or otherwise
<b>Nutrabiobiotics Nutritional Life Sciences, Peshawar</b>		
1174.	Pre-Vomit Capsule	Deferred with final opportunity for submission of alternative brand names
1175.	Foliget Tablet	Deferred with final opportunity for submission of alternative brand names
1176.	E-Vita Tablet	Deferred with final opportunity for submission of alternative brand names
1177.	Genmax Capsule	Deferred with final opportunity for submission of alternative brand names
1178.	Agcal-D Tablet	Deferred with final opportunity for submission of alternative brand names
1179.	Ginsavin Tablet	Deferred with final opportunity for submission of alternative brand names
1180.	Getcall-D Sachet	Deferred with final opportunity for submission of alternative brand names
1181.	Flexi D Tablet	Deferred with final opportunity for submission of alternative brand names
1182.	Subtize Syrup	Deferred with final opportunity for submission of alternative brand names
1183.	Due Fee	Deferred with final opportunity for submission of alternative brand names
<b>Nutrifactor Laboratories (Pvt) Ltd, Faisalabad</b>		
1184.	Apifocus Syrup	Deferred with final final opportunity for submission of required documents as per check list along with undertaking regarding the status of product wheather disposed of or otherwise
1185.	Qfend Syrup	Deferred with final final opportunity for submission of required documents as per check list along with undertaking regarding the status of product wheather disposed of or otherwise
1186.	Nurozon Syrup	Deferred with final final opportunity for submission of required documents as per check list along with undertaking regarding the status of product wheather disposed of or otherwise
<b>Oasis Pharma, Lahore</b>		
1187.	<b>Maxyberry Sachet</b>	Deferred for verification of testing facility for minerals
1188.	Protec 1 Syrup	<b>Deferred for verification of testing facility for minerals</b>
<b>Opal Laboratories, Karachi</b>		
1189.	Cberry C Effervescent Sachet	Deferred with final final opportunity for submission of required documents as per check list along with undertaking regarding the status of product wheather disposed of or otherwise
1190.	Cberry C Plus Effervescent Sachet	Deferred with final final opportunity for submission of required documents as per check list along with undertaking regarding the status of product wheather disposed of or otherwise
1191.	Bc-Lyse Plus Syrup	<ul style="list-style-type: none"> <li>Deferred with final final opportunity for Brand name to be change.</li> </ul>

		<ul style="list-style-type: none"> <li>Formulation contains herbs with vitamins while the firm possess only nutraceutical facility</li> </ul>
<b>Paramount Healthcare, Islamabad</b>		
1192.	Maxofol Plus Tablet	Deferred with final opportunity for submission of alternative brand names
1193.	Irocrib 120Ml Syrup	Deferred with final opportunity for submission of alternative brand names
1194.	Irocrib 65Mg Tablet	Deferred with final opportunity for submission of alternative brand names
1195.	Myocure-D Sachet	Deferred with final opportunity for submission of alternative brand names
1196.	Myocure Tablet	Deferred with final opportunity for submission of alternative brand names
<b>Parina Pharma Pvt Ltd, Karachi</b>		
1197.	Iv-Zone Syrup	Deferred with final final opportunity for submission of required documents as per check list along with undertaking regarding the status of product wheather disposed of or otherwise
1198.	<b>Otizer Syrup</b>	deferred with final opportunity for submission of soft copy of formulation as per requirement of form 3
1199.	<b>Vitazone Syrup</b>	deferred with final opportunity for submission of soft copy of formulation as per requirement of form 3
1200.	<b>Ozocid Syrup</b>	deferred with final opportunity for submission of soft copy of formulation as per requirement of form 3
<b>Phytotia Laboratory, Peshawar</b>		
1201.	Folrex-F Tablet	Deferred with final opportunity for submission of alternative brand names
1202.	Folrex-L Tablet	Deferred with final opportunity for submission of alternative brand names
1203.	Iroomax Tablet	Deferred with final opportunity for submission of alternative brand names
<b>Regimen Nutraceuticals, Lahore</b>		
1204.	Eyzl Capsule	Deferred with final final opportunity for submission of required documents as per check list along with undertaking regarding the status of product wheather disposed of or otherwise
<b>RG Pharmaceutica (Pvt.) Ltd., Lahore</b>		
1205.	Refrid Sachet	Deferred with final final opportunity for submission of required documents as per check list along with undertaking regarding the status of product wheather disposed of or otherwise
1206.	Maxocid Sachet	Deferred with final opportunity for submission of alternative brand names
1207.	<b>Neend Syrup</b>	
1208.	Sistove Sachet	Deferred with final final opportunity for submission of required documents as per check list along with undertaking regarding the status of product wheather disposed of or otherwise
1209.	D-Congesta Drops	Deferred with final opportunity for submission of alternative brand names
1210.	Flumca Sachet	Deferred with final final opportunity for submission of required documents as per check list along with undertaking regarding the status of product wheather disposed of or otherwise
1211.	Easup Drops	Deferred with final opportunity for submission of alternative brand names
1212.	Glucoliq Sachet	Deferred with final final opportunity for submission of required documents as per check list along with undertaking regarding the status of product wheather disposed of or otherwise
1213.	Minfant Syrup	Deferred with final final opportunity for submission of required documents as per check list along with undertaking regarding the status of product wheather disposed of or otherwise
1214.	Osteosam Tablet	Deferred with final opportunity for submission of alternative brand names
1215.	Grobaby Drops	Deferred with final opportunity for submission of alternative brand names
1216.	Interact Sachet	Deferred with final opportunity for submission of alternative brand names
1217.	Colibid Drops	Deferred with final opportunity for submission of alternative brand names

1218.	Menorag Tablet	Deferred with final opportunity for submission of alternative brand names
1219.	Proantho Sachet	Deferred with final final opportunity for submission of required documents as per check list along with undertaking regarding the status of product wheather disposed of or otherwise
1220.	Neend Drops	Deferred with final opportunity for submission of alternative brand names
1221.	Stooler Drops	Deferred with final opportunity for submission of alternative brand names
1222.	Locyst Tablet	Deferred with final opportunity for submission of alternative brand names
1223.	Maxperm Sachet	Deferred with final opportunity for submission of alternative brand names
1224.	Optimune Syrup	Deferred with final opportunity for submission of alternative brand names
1225.	Diafol Tablet	Deferred with final opportunity for submission of alternative brand names
1226.	Acd Plus Drops	Deferred with final opportunity for submission of alternative brand names
1227.	Myfol Syrup	Deferred with final opportunity for submission of alternative brand names
1228.	Myfol Drops	Deferred with final opportunity for submission of alternative brand names
1229.	Myfol Tablet	Deferred with final opportunity for submission of alternative brand names
<b>Sancura Pharma, Karachi</b>		
1230.	Ovit-M Soft Gel Capsules	Deferred with final final opportunity for submission of required documents as per check list along with undertaking regarding the status of product wheather disposed of or otherwise
1231.	Orsup-D Tablets	Deferred with final final opportunity for submission of required documents as per check list along with undertaking regarding the status of product wheather disposed of or otherwise
1232.	Precon Tablet	Deferred with final final opportunity for submission of required documents as per check list along with undertaking regarding the status of product wheather disposed of or otherwise
1233.	Ultra-D Softgel Capsules	
1234.	Cardimox Softgel Capsule	
1235.	Redmax Tablet	Deferred with final final opportunity for submission of required documents as per check list along with undertaking regarding the status of product wheather disposed of or otherwise
1236.	Cransure Sachet	
1237.	Ivy Cof Syrup	
1238.	Cal Soft Gel Capsule	
1239.	Folimax Softgel Capsules	
1240.	Ris Cal Syrup	
1241.		
<b>Saviour Pharma, Lahore</b>		
1242.	Ss-Vit Tablet	Deferred with final final opportunity for submission of required documents as per check list along with undertaking regarding the status of product wheather disposed of or otherwise
<b>SHMZ Labs &amp; Pharmaceuticals, Lahore</b>		
1243.	SHMZ's CAL SUN TABLET	Defererd for verification of testing facility of minerals
1244.	SHMZ's MACUVIT ADVANCE TABLET	Defererd for verification of testing facility of minerals
1245.	SHMZ's UNICORN SYRUP	Defererd for verification of testing facility of minerals
<b>Sigma Life Pharmaceuticals, Rawalpindi</b>		
1246.	Osofit Syrup	Defererd for verification of testing facility of minerals



<b>Sois Life Sciences, Karachi</b>		
1247.	Calgi Forte Tablet	Deferred with final opportunity for submission of required documents as per checklist of form 3 along undertaking wheather product is disposed of or otherwise
<b>Steg laboratories, Sheikhpura</b>		
1248.	Retipal-A Softgel	Deferred with final opportunity for submission of required documents as per checklist of form 3 along undertaking wheather product is disposed of or otherwise
1249.	Elevit-E400 Softgel	Deferred with final opportunity for submission of required documents as per checklist of form 3 along undertaking wheather product is disposed of or otherwise
1250.	Elevit-E200 Softgel	Deferred with final opportunity for submission of required documents as per checklist of form 3 along undertaking wheather product is disposed of or otherwise
1251.	Cheervit Softgel	Deferred with final opportunity for submission of required documents as per checklist of form 3 along undertaking wheather product is disposed of or otherwise
1252.	Elevit-E600 Softgel	Deferred with final opportunity for submission of required documents as per checklist of form 3 along undertaking wheather product is disposed of or otherwise
<b>Tehseen Industries, Lahore</b>		
1253.	Cola Gin Tablet	Deferred with final opportunity for submission of laternative brand names
1254.	Cola Gin Sachet	Deferred with final opportunity for submission of laternative brand names
1255.	Bone Plus Tablet	Deferred with final opportunity for submission of laternative brand names
1256.	Bone Plus Syrup	Deferred with final opportunity for submission of laternative brand names
1257.	Vitagim Syrup	Deferred with final opportunity for submission of laternative brand names
1258.	Vitagim Tablet	Deferred with final opportunity for submission of laternative brand names
1259.	Leadofor Syrup	Deferred with final opportunity for submission of laternative brand names
1260.	Folic Plus	Deferred with final opportunity for submission of laternative brand names
<b>Verbana International, Islamabad</b>		
1261.	Blue Min P Powder	Deferred with final opportunity for submission of laternative brand names
1262.	T-Tox	Deferred with final opportunity for submission of laternative brand names
1263.	Dcp-Vet Powder	Deferred with final opportunity for submission of laternative brand names
1264.	Ab Entol Syrup	Deferred with final opportunity for submission of required documents as per checklist of form 3 along undertaking wheather product is disposed of or otherwise
1265.	T-Plcenta Off Sachet	Deferred with final opportunity for submission of laternative brand names
1266.	Immune Plus Liquid	Deferred with final opportunity for submission of laternative brand names
1267.	Bull Max Powder	Deferred with final opportunity for submission of laternative brand names
1268.	Respo-Vet Liquid	Deferred with final opportunity for submission of laternative brand names
1269.	Appetonic Liquid	Deferred with final opportunity for submission of required documents as per checklist of form 3 along undertaking wheather product is disposed of or otherwise
1270.	<b>Masti Cure Liquid</b>	
1271.	Dairy Gold Powder	Deferred with final opportunity for submission of laternative brand names
<b>Vida Laboratories, Karachi</b>		
1272.	Ornafin Syrup	Deferred with final opportunity for provision of submission of required docuemnts as per check list of form 3 along with undertaking that their product is disposed or otherwise
<b>Viegen Pharma, Lahore</b>		

1273.	Xtramen Tablet	Deferred with final opportunity for provision of soft copy of formulation as requirement of form 3
1274.	Ossetrol Tablet	Deferred with final opportunity for provision of soft copy of formulation as requirement of form 3
1275.	Peptol Suspension	Deferred with final opportunity for provision of soft copy of formulation as requirement of form 3
1276.	Tulac Syrup	Deferred with final opportunity for provision of soft copy of formulation as requirement of form 3
1277.	Livsure Syrup	Deferred with final opportunity for provision of soft copy of formulation as requirement of form 3
1278.	Mucare Syrup	Deferred with final opportunity for provision of soft copy of formulation as requirement of form 3
1279.	Ultra Co-Q10 Tablet	Deferred with final opportunity for provision of soft copy of formulation as requirement of form 3
1280.	Urined Sachet	Deferred with final opportunity for provision of soft copy of formulation as requirement of form 3
1281.	Vyfat Tablet	Deferred with final opportunity for provision of submission of required documents as per check list of form 3 along with undertaking that their product is disposed or otherwise
<b>Wilshire Laboratories Pvt Ltd, Lahore</b>		
1282.	<b>Calcimax TABLET</b>	Deferred for verification of testing facility of minerals
<b>Wilson's Healthcare, Islamabad</b>		
1283.	Serowil Tablet 60,000Iu Tablet	Deferred with final opportunity for submission of evidence of R and I receiving ,form 3,fee copy and undertaking regarding content and brand name and wheather product is disposed off or otherwise
1284.	Serowil Tablet 60,000Iu Tablet	Deferred with final opportunity for submission of evidence of R and I receiving ,form 3,fee copy and undertaking regarding content and brand name and wheather product is disposed off or otherwise
<b>Xecutive Pharma, Lahore</b>		
1285.	Ph Pro Tablet	Deferred with final opportunity for submission of alternative brand names
1286.	Multipro M Tablet	Deferred with final opportunity for submission of alternative brand names
1287.	Ad-Folvitic Tablet	Deferred with final opportunity for submission of alternative brand names
1288.	Lowcid Syrup	Deferred with final opportunity for submission of alternative brand names
1289.	A+ Farfly Syrup	Deferred with final opportunity for submission of alternative brand names
1290.	Spasmo Syrup	Deferred with final opportunity for submission of alternative brand names
1291.	Respivil Syrup	Deferred with final opportunity for submission of alternative brand names
1292.	Onefolin Tablet	Deferred with final opportunity for submission of alternative brand names
1293.	Apiget Syrup	Deferred with final opportunity for submission of alternative brand names
1294.	Perinef Tablet	Deferred with final opportunity for submission of alternative brand names
1295.	Osserise Tablet	Deferred with final opportunity for submission of alternative brand names
1296.	Diazik Tablet	Deferred with final opportunity for submission of alternative brand names
1297.	Citiflow Tablet	Deferred with final opportunity for submission of alternative brand names
1298.	Ardin Syrup	Deferred with final opportunity for submission of alternative brand names
1299.	Deone-3 Capsule <b>Zahi Nutraceutical Laboratories, Peshawar</b>	Deferred with final opportunity for submission of alternative brand names
1300.		Deferred with final opportunity for submission of alternative brand names
1301.	Ked-3 Drops	Deferred with final opportunity for submission of alternative brand names

1302.	Cren Mxx Maya Syrup	Defererd with final opportunity for submission of alternative brand names
1303.	Amlite Capsule	Defererd with final opportunity for submission of evidence of R and I receiving ,form 3,fee copy and undertaking regarding content and brand name
<b>M/s Dew Max Pharmaceuticals Pvt Ltd, Plot No 6, Street S-6, National Industrial Zone, RCCI, Rawat, holding Drug Manufacturing License No.000889 (Contract Givers), has submitted the application vide letter No. Nil, dated 11-02-2022, for provisional product enlistment on basis of contract manufacturing from M/s Damac Healthcare, located at Plot No. 5, Street No. N-1 E1, RCCI Industrial Estate, Rawat, (Enlistment No. 01233) (Contract Acceptor)</b>		
1304.	<b>Dew-Max's Dew-Flex</b>	Defererd with final opportunity for clarification regarding rationality of formulation along with role of ingredients
<b>M/s Macter International Limited, F-216, SITE, Karachi, holding Drug Manufacturing License No.000111, has submitted the application vide letter No. Nil, submitted on 10-08-2022, for permission of contract manufacturing from M/s Trends Pharmaceuticals (Nutraceuticals &amp; Cam Division), located at Plot 546/ 547, Sundar Industrial Estate, Lahore.</b>		
1305.	<b>IB-Mac Syrup</b>	Defererd with final opportunity for provision of exact species of Angelica along with scientific evidences that the said ingredient does not contain phototoxic furanocumarins.
<b>M/s Verbena (M-102)</b>		
1.	<b>CALCONIL LIQUID</b>	Defererd with final opportunity for verification of testing facility for minerals
2.	<b>FAGSAS MASTIFIG POWDER</b>	Defererd with final opportunity for verification of testing facility for minerals
3.	<b>FAGAS MINO TINO POWDER</b>	Defererd with final opportunity for verification of testing facility for minerals
4.	<b>MASTITIS REMOVER POWDER</b>	Defererd with final opportunity for verification of testing facility for minerals
5.	<b>GRATO ORAL LIQUID</b>	Defererd with final opportunity for verification of testing facility for minerals
<b>M/s Laraib Herbal Pharma, Plot no. 25-27, Main Dera Muhammadi Road, Near Bahawalpur Bypass Multan. (M-108)</b>		
6.	<b>Janam Ghutti (Syrup)</b>	Defererd with final opportunity for specification of active ingredinets are required
7.	<b>Arq Motapa Door</b>	Defererd with final opportunity for specification of active ingredinets are required
8.	<b>Baby Tonic (Syrup)</b>	Defererd with final opportunity for specification of active ingredinets are required
9.	<b>Akseer Niswan (Syrup)</b>	Defererd with final opportunity for specification of active ingredinets are required
<b>M/s Bion Life Sciences, Lahore (M-89)</b>		
10.	<b>Biowomen Capsule</b>	Defererd with final opportunity for specification of active ingredinets are required
<b>M/s Samco Laboratories, Kasur (M-108)</b>		
11.	<b>Samco Hi-Rise Tablet</b>	Defererd with final opportunity for verification of testing facility
12.	<b>Samco Dyso-D Syrup</b>	Defererd with final opportunity for use of china clay in the formulation
13.	<b>Samco Family Fit Syrup</b>	Defererd with final opportunity for change of brand name
14.	<b>Samco Fruit Bank Syrup</b>	Defererd with final opportunity for change of brand name
15.	<b>Samco Livton Syrup</b>	Defererd with final opportunity for verification of testing facility
<b>M/s Sigma Life Pharmaceuticals, Officie no. 3, 1<sup>st</sup> Floor Chand Plaza Peshawar Road, Rawalpindi (M-102)</b>		
16.	<b>Element Syrup</b>	Defererd with final opportunity for verification of testing facility for minerals
17.	<b>SHMZ's CALVIT-D TABLET</b>	Defererd with final opportunity for verification of testing facility for minerals

	Each Tablet Contains: Calcium Carbonate(BP)...1000mg Vitamin D3(BP).....400IU Manganese Sulfate(BP)... 1mg M/s SHMZ Labs & Pharmaceuticals (M-96)	
<b>M/s SHMZ Labs &amp; Pharmaceuticals (M-97)</b>		
<b>18.</b>	<b>SHMZ's MAXCOOL LOZENGES (ORANGE FLAVOR)</b>	Deferred with final opportunity for submission of latervative brand name
<b>M/s Medella Pharmaceuticals Pvt Ltd., Sundar Industrial Estate, Raiwind Road, Lahore (M-102)</b>		
<b>19.</b>	<b>Urinizer Syrup</b>	<b>Defererd with final opportunity for testing method of finished product is required</b>
<b>20.</b>	<b>Hi-Fenchlor</b>	<b>Defererd with final opportunity for testing method of finished product is required</b>
<b>21.</b>	<b>Femicure Syrup</b>	<b>Defererd with final opportunity for submission of latervative brand names</b>
<b>M/s Aurum Healthcare (M-99)</b>		
<b>22.</b>	<b>LIBRO-D TABLET</b>	Deferred with final opportunity for verification of testing facility for minerals
<b>23.</b>	<b>CALCIMUM TABLET</b>	Deferred with final opportunity for verification of testing facility for minerals
<b>24.</b>	<b>GROW AD DROPS</b>	Deferred with final opportunity for submission of alternative brand names
<b>25.</b>	<b>SUPER MULTI Tablet</b>	Deferred with final opportunity for verification of testing facility for minerals
<b>26.</b>	<b>Kid-MV Syrup</b>	<b>Defererd with final opportunity for submission of alternative brand names</b>
<b>27.</b>	<b>E-MAMA Tablet</b>	Deferred with final opportunity for verification of testing facility for minerals
<b>28.</b>	<b>ENERGY C 1000</b>	<b>Deferred with final opportunity for submission of alternative brand name</b>
<b>29.</b>	<b>MALEVIT TABLET</b>	Deferred with final opportunity for verification of testing facility for minerals
<b>30.</b>	<b>MILTO FAST</b>	Deferred with final opportunity for verification of testing facility for minerals
<b>31.</b>	<b>ZITGAS SUSPENSION</b>	
<b>M/s Arber Pharma located at the address Plot No. 626-Sunder Industrial Estate, Lahore</b>		
	<b>Cuf-GO syrup</b>	Deferred with final opportunity for change of brand name
	<b>Bio-Kuff syrup</b>	Deferred with final opportunity for change of brand name